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7Abstract
 
 Non-alcoholic fatty liver diseases (NAFLD) are associated with 
obesity and type II diabetes, which are rapidly increasing worldwide 
due to a fat rich diet and lack of exercise. Fatty liver is characterized 
by the accumulation of fat in the cytoplasm of hepatocytes derived 
from adipocytes, intestinal absorption or hepatic lipogenesis. Clinical 
data has shown that fatty livers are more susceptible to ischemia/
reperfusion (I/R) injury, leading to diminished liver function. Different 
hypothesis, such as impaired ATP synthesis, microcirculation, Kupffer 
cell dysfunction and increased leukocytical adhesion have been 
proposed for the increased susceptibility of fatty organs to ischemic 
injury. Fatty degeneration, which induces a series of alterations in 
mitochondria, renders these organelles intrinsically more susceptible to 
I/R injury. Impairment of oxidative phosphorylation and induction of the 
mitochondrial permeability transition (MPT) are critical determinants for 
mitochondrial dysfunction induced by prolonged periods of ischemia 
followed by reperfusion.
 Regarding this, and taking into account the increased incidence 
of this pathology, we aimed to protect fatty livers from I/R damage. 
Ischemic preconditioning (IPC) is a phenomenon in which brief periods 
of ischemia make tissues resistant to injury resulting from prolonged 
ischemia and reperfusion. Thus, it became crucial to define the 
functioning mechanisms of preconditioning (PC) to allow drug targeting 
in a pharmacological treatment in fatty livers, as a strategy to reduce 
I/R injury observed in transplantation and hepatic resections. 
 The first strategy presented demonstrates that selective blocking 
of A1Rs with DPCPX abolished the protection achieved by ischemic 
preconditioning, and A1R agonist CCPA reproduced the beneficial 
effects. This fact confirms the participation of this receptor in protection 
induced by IPC in lean livers. This involves preservation of OXPHOS 
efficiency and increase resistance to MPT onset.  Induction of the MPT 
by I/R leads to cell death by uncoupling oxidative phosphorylation, 
inducing mitochondrial swelling and collapsing mitochondrial 
membrane potential, thus blocking cellular ATP formation. IPC induces 
the increase of HSP70 that may further protect mitochondria and 
prevent the MPT, thus maintaining the ability to generate ATP and 
recover from I/R insult. We demonstrate that modulation of the MPT is 
80
achieved in preconditioning (ischemic and pharmacological) in a GSK-
3β-dependent manner, which is essential to achieve protection in I/R.
 GSK-3β inhibition prevents impairment of hepatic mitochondrial 
function and depletion of cellular ATP. Pharmacological preconditioning 
with indirubin-3’-oxime, an inhibitor of GSK-3β, in conditions of 
hepatic I/R, protects the liver by maintaining mitochondrial calcium 
homeostasis, thus preserving mitochondrial function and hepatic 
energetic balance. I/R induces translocation of GSK-3β from the 
cytosol to the mitochondria, increasing mitochondrial GSK-3β activity. 
Indirubin-3’-oxime preserves the level of inhibition of GSK-3β activity 
on mitochondria, by preserving the mitochondrial pool of phospho-
Ser9-GSK-3β, that is decreased in I/R.
 Although fatty livers exhibit an underlying state of mitochondrial 
dysfunction that enhances damage after I/R, treatment with indirubin-
3’-oxime was also able to preserve the efficiency of mitochondrial 
function and prevent I/R damage in fatty livers. We demonstrated that 
active GSK-3β (in I/R situation) promotes an enhancement of CypD 
phosphorylation, resulting in increased binding of CypD to the ANT, 
sensitizing mitochondria to calcium-induced MPT. Therefore, indirubin-
3’-oxime has great therapeutic potential in the clinical setting of hepatic 
ischemia/reperfusion, acting as pharmacological preconditioning in 
lean and fatty livers.
 The last protective strategy highlights the importance of MPT 
modulation against I/R injury in fatty livers, involving the preventive axis 
SIRT3-CypD-MPT. Obesity decreases the cellular NAD+/NADH ratio, 
thereby contributing to a decrease in SIRT3 activity, thus increasing 
the acetylation of mitochondrial proteins and decreasing mitochondrial 
efficiency. We demonstrated that the increase in CypD acetylation 
in I/R animals was accompanied by an inhibition of SIRT3 activity. 
Conversely, adding NAD+ to fatty livers prior to I/R significantly increases 
SIRT3 activity and decreases CypD acetylation, activity and binding 
to ANT, increasing the threshold to MPT induction. NAD+ modulates 
mitochondrial function and preserves oxidative phosphorylation, being 
protective against injury in a model of hepatic warm I/R in fatty livers.
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9 Resumo
 As doenças do fígado gordo não-alcoólicas (NAFLD) estão 
associadas à obesidade diabetes tipo II, estão a aumentar rapidamente 
em todo o mundo devido a uma dieta rica em gorduras e falta de 
exercício. Um fígado gordo é caracterizado pela acumulação de gordura 
no citoplasma de hepatócitos, derivada de adipócitos, da absorção 
intestinal ou da lipogénese hepática. Os dados clínicos mostram que os 
fígados gordos são mais suscetíveis à lesão por isquemia/reperfusão 
(I/R), levando à diminuição da função hepática. Diferentes hipóteses, tais 
como síntese de ATP debilitada, microcirculação alterada, disfunção das 
células de Kupffer e aumento da adesão leucocitária têm sido propostas 
para o aumento da susceptibilidade de órgãos gordos à lesão isquémica. 
Este tipo de degeneração causada pela acumulação de gordura, induz 
uma série de alterações na mitocôndria, tornando estes organelos mais 
suscetíveis à lesão por I/R. Diminuição da eficiência fosforilativa  e indução 
da transição de permeabilidade mitocondrial (MPT) são determinantes 
críticos para a disfunção mitocondrial induzida por períodos prolongados 
de isquémia seguidos de reperfusão.
 Tendo em conta o aumento da incidência desta patologia, o nosso 
objetivo é aumentar a resistência dos fígados gordos aos danos por I/R. 
Pré-condicionamento isquémico (IPC) é um fenómeno em que breves 
períodos de isquemia tornam os tecidos resistentes à lesão decorrente 
de isquemia e reperfusão prolongadas.
 Assim, tornou-se crucial definir os mecanismos subjacentes ao 
pré-condicionamento (PC) para permitir a identificação de alvos para 
drogas num tratamento farmacológico em fígados gordos como uma 
estratégia para reduzir a lesão por I/R observada no transplante e 
ressecções hepáticas.
 A  primeira estratégia apresentada demonstra que o bloqueio 
seletivo de A1Rs com DPCPX aboliu a proteção obtida pelo pré-
condicionamento isquémico, enquanto que um agonista de A1R, o CCPA, 
reproduziu os seus efeitos benéficos. Este fato confirma a participação 
deste receptor na proteção induzida pelo IPC em fígados magros. Isto 
envolve a preservação da eficiência fosforilativa e aumenta a resistência 
ao MPT.
 A indução da MPT por I/R leva a morte celular por desacoplamento 
da fosforilação oxidativa, induzindo entumescimento mitocondrial e o 
colapso do potencial de membrana mitocondrial, bloqueando assim a 
10
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formação de ATP. O IPC induz o aumento de HSP70 protegendo da indução 
do MPT, mantendo assim a capacidade para gerar ATP e recuperar do 
insulto por I/R. Demonstrámos que a modulação da MPT é alcançada 
em pré-condicionamento (isquémico e farmacológico) via modulação da 
GSK-3β.
 A  inibição de GSK-3β  previne a disfunção mitocondrial e depleção 
do ATP celular. Pré-condicionamento farmacológico com indirubina-3’-
oxima, um inibidor de GSK-3β, em condições de I/R hepática, protege 
o fígado através da manutenção da homeostase do cálcio mitocondrial, 
preservando assim a função mitocondrial e o equilíbrio energético hepático. 
A I/R induz a translocação de GSK-3β do citosol para a mitocondria, 
aumentando a actividade da GSK-3β mitocondrial. A indirubina-3’-oxima 
preserva o nível de inibição da actividade da GSK-3β nas mitocondrias, 
preservando o “pool” mitocondrial de fosfo-Ser9-GSK-3β, que diminuí em 
I/R.
 Embora os fígados gordos exibam um estado subjacente de 
disfunção mitocondrial que aumenta os danos depois de I/R, o tratamento 
com indirubina-3’-oxima também foi capaz de preservar a eficiência 
da função mitocondrial e prevenir os danos da I/R em fígados gordos. 
Demonstrámos que a GSK-3β ativa (em situação de I/R) promove um 
aumento da fosforilação da CypD, resultando num aumento da ligação 
entre CypD e ANT, sensibilizando as mitocondrias à MPT induzida pelo 
cálcio. Portanto, a indirubina-3’-oxima tem um grande potencial terapêutico 
no estado clínico de isquemia/reperfusão hepática, atuando como pré-
condicionamento farmacológico em fígados magros e gordos.
A última estratégia de proteção destaca a importância da modulação da 
MPT contra a lesão da I/R em fígados gordos, envolvendo o eixo preventivo 
SIRT3-CypD-MPT. A obesidade diminui a o conteudo de NAD+ disponivel, 
contribuindo assim para uma diminuição na actividade da SIRT3,o que 
aumenta a acetilação de proteínas mitocondriais e diminui a eficiência 
mitocondrial. Demonstrámos que o aumento da acetilação da CypD 
em animais em situação de I/R foi acompanhada por uma inibição da 
actividade da SIRT3. Por outro lado, a adição de NAD+ a fígados gordos 
antes da I/R aumenta significativamente a actividade da SIRT3 e diminui 
a acetilação, actividade e ligação entre a ANT e CypD, aumentando a 
restência ao MPT. O NAD+ modula a função mitocondrial e preserva a 
fosforilação oxidativa, sendo protectivo contra danos num modelo de I/R 
hepática, em fígados gordos.
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List of abbreviations: 
•OH, hydroxyl radicals 
A1R  adenosine receptors, subtype receptor 1
A2AR, A2A subtype receptor 
ADP, adenosine diphosphate; 
AICAR, 5-amino-4-imidazole carboxamideriboside 
AIF, apoptosis-inducing factor 
Akt, protein kinase B
ALT, alanine aminotransferase
AMP, adenosine monophosphate
AMPK, Adenosine Monophosphate- Activated Protein Kinase 
ANT, adenine nucleotide translocator
Apaf-1, apoptotic protease activating factor 1
ApoB, Apolipoprotein B 
AST, aspartate aminotransferase
ATP, adenosine triphosphate;
BAG-1, Bcl-2 associated athanogene
Bax, Bcl-2–associated X protein
Bak, Bcl-2 homologous antagonist /killer
Bcl-2, B cell lymphoma - 2
BPR, benzodiazepines peripheral receptor
BSA, bovine serum albumin
Ca2+, calcium 
CCPA, 2-chlloro-N6-cyclopentyladenosine 
CDD, choline-deficient diet 
CK, Creatine kinase 
CoQ, coenzyme Q
CyA, cyclosporin Ay
CypD, cyclophylin D
cyt c, cytochrome c
DAG, diacylglycerol 
DCCD , N, N’-dicyclohexylcarbodiimide
DIABLO, Direct IAP-binding protein with low PI 
DPCPX , 8-cyclopentyl-1,3-dipropulxanthine 
ECD, extended criteria donor 
EGTA, ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid
eNOS, nitric oxide synthase, endothelial form
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T ER, endoplasmic reticulum
ERK, extracellular signal-regulated kinase
ETC, electron transport chain 
FCCP; carbonylcyanide-p-trifluoromethoxyphenylhydrazon 
GSK-3β, glycogen synthase kinase 3β;
GTP, guanosine triphosphate
H2DCFDA , 2’,7’-dichlorodihydrofluorescein diacetate
H2O2, hydrogen peroxide 
HDL, high-density lipoprotein
HEPES , N-[2-hydroxyethyl]piperazine-N’--[2-ethanesulphonic acid]
HIF-1α, hypoxia inducible factor-1α 
HK, hexokinase 
HO-1, heme oxygenase-1 
HSP, heat shock proteins 
I/R, ischemia/reperfusion
IAPs, Inhibitor of Apoptosis Proteins 
ICAM-1, intercellular adhesion molecule-1
IF1, inhibitor F1 subunit 
IL, interleukin 
IL-1Ra, interleukin-1 receptor antagonist 
Ind, indirubin-3’-oxime;
iNOS, nitric oxide synthase, inducible form  
I/R, ischemia/reperfusion
IκB-α, inhibitor of kB-α 
KC, Kupffer cells 
LC3, microtubule - associated protein 1 light chain 3.
LDH, lactate dehydrogenase
MAPK ,mitogen-actived protein kinase 
mCa, mitochondrial Ca2  channels
MCU. mitochondrial Ca2+ uniporter 
MPO, myeloperoxidase 
MPT, mitochondrial permeability transition
mRyR, ryanodine receptor 
mtDNA, mitochondrial DNA 
NAD+ , nicotinamide adenine nucleotide, oxidized form 
NADH, nicotinamide adenine nucleotide, reduced form
NADP, nicotinamide adenine nucleotide phosphate, oxidized form 
NADPH, nicotinamide adenine nucleotide phosphate, reduced form 
NAFLD, non-alcoholic fatty disease
NASH, non-alcoholic steatohepatitis
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NFκB, nuclear factor κ B 
NO, nitric oxide 
NOS, nitric oxide synthase 
O, singlet oxygen molecules 
O2•-, superoxide anions 
OXPHOS, oxidative phosphorylation 
PC, preconditioning, 
PDK1, phosphoinositide-dependent proteinkinase-1 
phospho-ser9-GSK3β, glycogen synthase kinase 3β phosphorilated at 
ser9 residue 
PiC, phosphate carrier 
PKC, protein kinase C 
Post, postconditioning
RaM, rapide mode of calcium uptake 
RCR, respiratory control ratio;
RFUs, relative fluorescence units
ROS, reactive oxygen species
RR, ruthenium red SIRT3, sirtuin 3
SMAC, second mitochondria-derived activator of caspases
SOD, superoxide dismutase 
SR, sarcoplasmic reticulum 
stat-3, signal activator of transcription 3 
TBS, Tris-buffered saline
TIM/TOM complex, multi-subunit complexes present in both membranes 
TNF-α, tumor necrosis factor- α
TPP+,  tetraphenylphosphonium; 
UCP, uncoupling proteins 
UW, University of Wisconsin 
VDAC, voltage dependent anion channel 
VLDL’s, Very Low Density Lipoproteins 
X/XOD, xanthine/xanthine oxidase 
ΔΨ, mitochondrial membrane potential
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1.1 Liver
 Liver is a vital organ, the largest internal organ of body, 
representing 2-5% of the body weight for an adult. It is divided in 
sectors and segments; each of them has its own branch of portal 
veins, hepatic artery and bile duct. Both the left and right parts have an 
independent blood supply. This organization facilitates some hepatic 
interventions such as hepatic resections and techniques applied in liver 
transplantation.
1.1.1 Liver general structure
 Livers’ structure is adapted to meet multiple and complexes 
functions (Figure 1.1). The liver has four lobes of unequal size and 
shape, which include two major lobes (left and right) and two minor 
lobes (median and caudate). 
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Figure 1.1- Liver Anatomy: A) Anterior view; B) Portal vein, hepatic 
artery and biliary duct system (adapted from Lippincott Williams & Wilkins, 
2008).
 The hepatic lobules are the basic functional units of the liver. The 
lobules have a hexagonal shape with a portal triad (portal vein, hepatic 
artery and hepatic duct) at each corner. In the center of each lobule there 
is the central vein that coalesce in hepatic veins from where it radiates 
columns of hepatocytes distributed in the form of cords. The spaces 
between the hepatic cords are blood channels called hepatic sinusoids. 
A cleflike, the bile canaliculus, lies between the cells within each cord 
and it’s through it that the bile flows from the hepatocytes toward hepatic 
triad and exits the liver through the hepatic ducts. The sinusoids are lined 
with two cell populations: endothelial cells and Kupffer cells (KC). The 
perisinusoidal space or Space of Disse (the space between hepatic cords 
and sinusoids) is connected by lymphatic vessels that are responsible to 
remove the liquid excess.
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1.1.1.1 Hepatic cells
 Hepatocytes - The hepatocytes are the cells of the hepatic 
parenchyma and represent approximately 90% of the total cellular 
population. These cells are central to the intermediary metabolism of the 
body, so they have come to be considered the prototype cell in biochemistry. 
This high metabolic activity is related to the large amounts of mitochondria 
in these cells.
 Hepatocytes have a wide variety of functions, including bile 
production to digest and absorb fat; storage and interconversion of 
nutrients, proteins, lipids and vitamins; detoxification of endogenous and 
exogenous toxic compounds to the organism; phagocytosis and synthesis 
of blood components, such as, plasma proteins, lipoproteins, glucose, 
fatty acids, cholestherol and phospholipids. Possibly all hepatocytes are 
able to perform all functions, however, there are differences in structure 
and in enzymatic activity depending on the concentration of oxygen and 
solutes in blood. The characteristics of blood (concentration of oxygen and 
solutes) can be different depending on the distance of the hepatocyte until 
the portal vein. The proportion of hepatocytes that are in contact with the 
sinusoid is called the sinusoidal region, which is responsible for the liver’s 
exocrine function, the secretion of bile. (Cingolani et al.,2000 ; Ganong, 
2001)
 Cells of hepatic sinusoid - Endothelial cells and Kupffer cells are 
non parenchymal cells, significant in the total cellular population.
 Endothelial cells- The endothelial cells form the wall of the 
hepatic sinusoids and are separated from hepatocytes by the “Space 
of Disse”. This creates an extravascular compartment into which the 
hepatocytes project microvilosities, increasing the contact area between 
the hepatocyte and the vascular space. The presence of pores allows the 
exchange of fluids and macromolecular compounds. Vasoconstrictors and 
vasodilators derived from the sinusoidal endothelium, such as endothelin 
and nitric oxide (NO), are important to control hepatic blood flow in both 
physiological and pathological situations. Certain stimuli cause the release 
of a series of mediators by the endothelial cells that are actively involved in 
the inflammatory response. (Pocock et al.,2002; Zakim et al 2002)
 Kupffer cells - The Kupffer cells are located mainly in the wall 
of hepatic sinusoids. They act as a protective barrier because of their 
ability to eliminate by endocytosis, many potentially harmful substances 
to the body, such as microorganisms, endotoxins, immune complexes, 
tumor cells, lipids, etc. When activated, the Kupffer cells begin to generate 
22
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(ROS) and proteases. (Cingolani et al.,2000 ; Ganong, 2001; Pocock et 
al.,2002; Zakim et al 2002)
 Stellate cells - These cells are located in close contact with 
endothelial cells and are the main deposit of vitamin A to the body. They 
synthesize extracellular matrix proteins (different types of collagen), are 
important mediators of tissue repairing processes (healing) in various liver 
diseases and have the capacity to promote and amplify the inflammatory 
response. ( ; Ganong, 2001; Pocock et al.,2002; )
1.1.1.2  Hepatic vascular system 
 The liver has a dual blood supply: the portal vein carries blood 
rich in nutrients but poor in oxygen from the intestine, the spleen and the 
pancreas; the hepatic artery transports blood rich in oxygen coming from 
the heart. Blood will finally reach hepatic sinusoids, which is where takes 
place the exchange between blood and hepatocytes. The great porosity 
of sinusoidal walls facilitates this exchange of nutrients. From the blood, 
the hepatocytes can take up the oxygen and nutrients, which are stored, 
detoxified, used for energy, or used to synthesize new molecules. These 
molecules are released into the hepatic sinusoids or into bile canaliculi. 
Blood in the hepatic sinusoids flows to the central vein, where it exits the 
lobule and then exits the liver through the hepatic veins and finally into 
the inferior vena cava just below the diaphragm. So, blood flows from 
the triad toward the center of each lobule while bile flows away from the 
center of the lobule toward the triad. Bile flows across the bile canaliculi 
via the hepatic triad and exit the liver through the hepatic ducts (Cingolani 
et al.,2000 ; Ganong2001; Pocock et al.,2002; Zakim et al., 2002). (Figure 
1.2).
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Figure 1.2- The structure of the liver’s functional units, or lobules.
Blood enters the lobules through branches of the portal vein and hepatic artery, then flows 
through small channels called sinusoids that are lined with hepatocytes. The hepatocytes 
remove toxic substances, from the blood, which then exits the lobule through the central 
vein (adapted from Ross et al. ,1995).
1.1.2  Liver general function
 The liver is the organ responsible for regulating the energetic levels 
of the body. It also performs important digestive and excretory functions, 
stores and processes nutrients, synthesizes new molecules and detoxifies 
harmful chemicals. Hepatocytes serve as a glycogen store and are 
able to maintain blood glucose levels. They can also store fat, vitamins, 
copper and iron. Amino acids, carbohydrates, lipids and vitamins income 
to the liver from digestive tract via the portal vein and then are stored 
and metabolically converted, to be released into the blood and into the 
bile as required (Kodavanti and Mehendale, 1991). The bile is produced 
and secreted in liver and plays a role in digestive and excretory function. 
Liver’s core activity in metabolism makes it an easy target for various toxic 
processes and liver problems can be quickly followed by problems in other 
organs. The liver can also produce its own compounds, participating in the 
24
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 Hepatocytes also transform substances that cannot be used by 
most cells into more readily usable substances. Another very important 
function of the liver, to keep the normal body function, is the detoxification 
of harmful compounds by biotransformation. In view of this, it is a 
natural target for xenobiotic-induced injury, resulting in perturbation of 
homeostasis. The liver forms a major defense line to harmful substances, 
detoxifying many of them by altering their structure to make them less toxic 
or make their elimination easier. For example, hydrophobic substances 
are converted into water-soluble products to be excreted into the bile or 
urine. Liver also plays a role in phagocytosis: Kupffer cells remove final 
products of the endogenous metabolism and exogenous substances that 
are not desirable.
Table 1.1 Description of liver functions.
                                                        Synthesis 
Amino acids synthesis 
Protein synthesis and degradation 
 
Protein metabolism 
Albumin 
Gluconeogenesis 
Glycogenolysis 
 
Carbohydrate metabolism 
Glycogenesis 
Cholesterol synthesis 
Lipogenesis 
 
Lipid metabolism 
Lipoprotein synthesis 
Coagulation factors 
Fetal hematocyte production 
Bile 
Hormones (ex: angiotensinogen) 
Degradation 
Insulin and other hormones 
Bilirubin 
Detoxification of metabolic byproducts and xenobiotics 
Ammonia 
Storage  
(ex: glycogen, vitamins, metals, others) 
Immune activity  
 (reticuloendothelial system)  
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1.2 Mitochondria, a key organelle in cell function 
 Mitochondria are the powerhouses of the cells. Being the main 
adenosine triphosphate (ATP) source of the cell, mitochondria play 
a key role in the regulation of several aspects of cell biology such as 
molecular metabolism, redox status, calcium signaling, and programmed 
cell death (Schatz et al., 1995). As they are the descendant’s aerobic 
bacteria, it permitted the evolution of the first eukaryotic cell capable to 
aerobic respiration, which was fundamental to evolution of more complex 
multicellular organisms.
 In the past years, the view of mitochondria as a lonely participant 
in the cell working tirelessly to provide the energy required for life has 
changed, as newer approaches have allowed the examination of dynamic 
mitochondrial function and behavior in response to cellular signals within 
intact cells. 
                                     
                                                                  
1.2.1 Mitochondrial structure
 The number and morphology (size and shape) of mitochondria differ 
according to the cell type, but maintaining basic properties (Koolman and 
Röhm,1996) (Figure 1.3). Mitochondria are a double membrane-system: 
the outer membrane separates the mitochondrion from the cytosol and 
defines the outer perimeter and the inner membrane, that is invaginated, 
forms the cristae and defines the matrix of the organelle. 
                              
Figure 1.3 - Visualization of mitochondria by electron (A) and 
fluorescence microscopy (B). 
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but independent structures that are not always connected with the inner 
membrane (Manella et al., 2000; Scheffler et al., 2001; Frey et all., 2002). 
The surface area of cristae can be greater in the case of the tissues with 
the higher respiratory activity. Mitochondria are highly dynamic organelles 
that continuously change their shape through frequent fusion, fission 
and movement throughout the cell. These dynamics are crucial for the 
maintenance of cellular homeostasis, as perturbations in this balance are 
linked to apoptosis and metabolic diseases.
 The outer and inner mitochondrial membranes have different 
permeability to various metabolites and ions, so as the outer membrane 
is permeable to ions and solutes up to 10 kDa, the inner membrane is 
highly proteinaceous and serves as a permeability barrier (Stryer, 1988; 
Crompton et al., 1999). Therefore, in the inner membrane, any movement 
of solutes is tightly controlled and allowed only through membrane proteins, 
channels highly selective and regulated. Some proteins are freely attached 
to the surfaces of the membranes and others are inserted as an integral 
part of the membrane. 
 The inner membrane has diverse elements with a role in metabolic 
pathways, such as components of the electron transport chain (ETC) 
and ATPsynthase (Hatefi et al., 1985), the di- and tricarboxylate carriers, 
the phosphate carrier, the adenine nucleotide translocase (ANT) and 
uncoupling proteins (UCP) (Caldwell et al., 2004). The large content 
in cardiolipin (diphosphatidylglycerol), reduces the permeability of the 
phospholipid bilayer to protons and thus enables a proton-motive force to 
be established across the inner membrane. This lipid is also important to 
the function of several mitochondrial proteins (Hoch, 1992; Paradies et al., 
1998).
 The outer membrane is composed of about half protein and half 
lipid and is rich in cholesterol. The voltage-dependent anion channel 
(VDAC) is the most abundant protein in the outer mitochondrial membrane. 
Associated with this membrane we also find mitochondrial hexokinase 
(HK), creatine kinase (CK) and  benzodiazepines peripheral receptor 
(BPR).
 There are still multi-subunit complexes present in both membranes 
- mitochondrial inner/ outer membrane transporter (TIM/TOM), that mediate 
the translocation of peptides into mitochondria (Paschen and Neupert, 
2001).
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Figure 1.4 - Mitochondrial function in cell metabolism. The most prominent 
role of mitochondria is to produce ATP, through oxidatve fosforilation, and to regulate cellular 
metabolism. Components of the electron chain (CI, complex I; CII, complex II; CIII, complex 
III; CIV, complex IV) and ATPsynthase (CV) are present in the inner membrane. Result 
of imperfectly coupled electron transport, mitochondrion is a major intracellular source 
of reactive oxygen species (ROS). Ca2+ transport into the mitochondria occurs through 
ion channels, existing in the mitochondrial inner membrane. Present in the mitochondrial 
matrix are diverse enzymes part of the citric acid cycle or Krebs cycle (TCA cycle) and 
mitochondrial DNA (mtDNA).
 Present in the mitochondrial matrix are diverse enzymes part of the 
citric acid cycle or Krebs cycle, amino acid metabolism, the urea cycle and 
the synthesis of heme groups, among others. It is also in the matrix that 
there is mitochondrial DNA (mtDNA) as well as transcription and translation 
systems, characteristic that makes mitochondria the unique organelle 
containing their own genome (Anderson, 1981) (Figure 1.4). Mutations in 
the mtDNA disrupt mitochondrial respiration and bioenergetics, resulting in 
cell death and dysfunction as major characteristics to the pathophysiology 
of mtDNA diseases (Moraes, 1996; Smeitink et al., 2001). However, most 
of the mitochondrial proteins are nuclear-encoded (Wallace, 1994). 
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in mitochondria
 In the eukariotic cells, the mitochondria is the primary organelle 
responsible for ATP generation associated with the oxidation of 
carbohydrates, fats and amino acids (Saraste,1999) . The process of 
oxidative phosphorylation (OXPHOS) occurs in the inner mitochondrial 
membrane and the complete sequence of events was described by the 
chemiosmotic theory proposed by Mitchell in 1961. This theory describes 
the process by which creation of an electrochemical gradient of protons 
across the inner membrane, supports the synthesis of ATP through the 
mitochondrial ATPsynthase (Mitchell,1961).
 The ETC consists of five multi-subunits protein complexes located 
in the inner membrane (respiratory complexes and the F1F0-ATPsynthase) 
and two factors (cytochrome c (cyt c) and coenzyme Q10(CoQ)) (Galluzi, 
2010). The protein subunits can be grouped into four complexes: Complex 
I (NADH (nicotine adenine dinucleotide, reduced form) ubiquinone 
oxiredutase), Complex II (succinate dehydrogenase), Complex III 
(ubiquinone cytochrome c oxiredutase) and Complex IV (cytochrome c 
oxidase). ATP is then produced by the F1F0-ATP synthase, also known as 
complex V, a component of the OXPHOS system but not part of the ETC 
(Morais and De Strooper, 2010; Mattson et al., 2008). 
 The electron carriers of the respiratory chain are quinoid structures 
(flavins, quinones) and/or metal centers (centers FeS groups, heme 
centers, copper), driving electron (e- ) transfer to molecular oxygen occurs 
in the following sequence: complex I → ubiquinone → complex III → 
cytochrome c → complex IV → oxygen (O2
2). Complex I accepts e- from 
NADH and transfers them to the “pool” of ubiquinone. Complex II accepts 
e- from succinate and also transfers them to the “pool” of ubiquinone. 
This molecule is reduced to ubiquinol, a highly mobile and hydrophobic 
molecule, will then be able to transfer e- to Complex III, again passing 
through the QH and Q states. After e-  flow into Complex III, they are 
transferred to cytochrome c and then to Complex IV. Here, they are finally 
conducted to the final acceptor, O2, which together with protons originates 
H2O.
 The redox potential e- the acceptor must be more positive than the 
redox potential of the donor. This phenomenon carries some advantages 
to the cell. At first place, the energy is not totally released in a single step, 
but sequentially, which allows a better use of that energy. Second, the 
e- flux occurs without excessive loss of e- or dangerously high dissipation 
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to the cell. At last, the flux takes place without energy consumption and 
the passage of the e- through the complexes, causes a conformational 
change in their structure, allowing them to eject protons from the matrix to 
the intermembrane space, in this state of high instability. The Complex II is 
an exception to this, because due to the fact of having a “redox” potential 
similar to that of ubiquinone, it does not reach a state capable of ejecting 
protons. There are human diseases caused by an inefficient electron 
transfer through the complexes I to IV, because of two main reasons, 
which are the inability to generate ATP and the production of toxic reactive 
oxygen species due to insults to the ETC enzymes (particularly Complexes 
I, II and III).
 Thus, sequential transfer of electrons from the reducing equivalents 
to molecular oxygen and subsequent proton ejection, originates an 
electrochemical gradient (composed by a pH gradient (ΔpH) and an 
electrical gradient) between the matrix and the intermembrane space. 
Thus, there is a high concentration of protons in the intermembrane space 
that tends to be dissipated as soon as possible. As the inner membrane 
is quite impermeable to protons, this dissipation of the gradient occurs 
through ATPsynthase (Figure 1.5).
 
Figure 1.5 - Schematic representation of the mitochondrial respiratory 
chain and ATPsynthase. Represented are the four complexes of the respiratory 
chain and the F1Fo ATP-synthase. Complex I and complex II accept electrons from NADH 
and succinate, which flow to the ubiquinone pool, complex II, cytochrome c, complex 
IV to the final acceptor, molecular oxygen. Electron flow is coupled to proton ejection at 
complexes I, III and IV. Complex V harvests the resulting proton gradient to generate ATP 
(adapted from Mandavilli et al., 2002).
The ATPsynthase is a proteic complex composed by two components, the 
F0 and the F1. The F0 component is a hydrophobic segment that crosses 
the inner mitochondrial membrane, forming a proton channel. 
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is responsible for phosphorylating the ADP, being also capable, in severe 
circumstances to the mitochondrion, to hydrolyze ATP, in order to try to 
restore the proton gradient. Other subunits are also part of ATP synthase, 
including the regulatory protein of the proton flow and ATP synthesis, 
called inhibitor F1 subunit (IF1), and a protein that confers sensitivity to 
oligomycin. The ATPsynthase is specifically inhibited by oligomycin and 
DCCD (N, N’-dicyclohexylcarbodiimide) (Boyer, 1997; Boyer, 1998).
 Two models for the organization of the mitochondrial respiratory 
chain have been proposed:  the “fluid-state” model, where all OXPHOS 
complexes diffuse individually in the membrane and electron transfer 
depends on the random collision of the complexes and electron carriers; the 
“solid-state” model, which has recently received more attention, where the 
complexes together form supercomplexes or respirasomes (Dudkina et al. 
2008; Schon et al, 2009). However, is a combination of these two models 
- the “plasticity” model – that has been the model mostly accepted.  Work 
by Acin-Perz and colleagues, using mouse liver mitochondria, conclude 
that complex I is hardly found as an independent entity, being mostly 
associated with complex III in different supercomplexes (Acín-Peréz et al., 
2008). Some of these associations contain CoQ, cyt c, and complex IV, 
with or without complex II, and are able to respire. There are two abundant 
forms of I/III supercomplexes that differ in their molecular mass and do 
not associate with complex IV, but may interact with complex V. Complex 
III is also mostly associated with other complexes in liver mitochondria. 
The association with complex I was already described but it can also 
form additional associations such as II/III/IV. Despite the association of 
complexes II and IV with other complexes, there is a big part that is found 
nonassociated with any of the other respiratory complexes (Acín-Pérez et 
al., 2008 ).
1.2.3  Mitochondrial generation of reactive oxygen species
 Reactive oxygen species (ROS) is the collective term that generally 
describes a variety of molecules and free radicals derived from molecular 
oxygen: singlet oxygen molecules (O), superoxide anions (O2•-), hydrogen 
peroxide (H2O2) and hydroxyl radicals (•OH). These are products of normal 
metabolism acting as “redox messengers” in intracellular signaling and 
regulation, allowing communication between the mitochondria and the 
cytosol (D’Autréaux et al. 2007; Mittler et al., 2011). 
 The mitochondrion is a major intracellular source of ROS, as a 
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result of imperfectly coupled electron transport associated with oxidative 
phosphorylation (Boveris et al., 1976; Takeshige and Minakami, 1979; 
Turrens et al., 1985). Result of this is a particular susceptibility of 
the mitochondria to oxidative damage. Electrons released from the 
mitochondrial electron transport chain incompletely reduce O2 to form 
superoxide, which is converted into H2O2 by manganese superoxide 
dismutase (MnSOD) in the mitochondria.
 The redox state of the respiratory chain is the primary factor for 
mitochondrial ROS generation (Skulachev, 1996; Lambert and Brand, 
2004) (Figure1.6). The amplitude of the electrochemical proton gradient, 
which is known as respiratory control, regulates the overall rate of electron 
transport in the respiratory chain. When the electrochemical potential 
difference generated by the proton gradient is high (such as in high-fat or 
high-glucose states), or in conditions of inhibition of the ETC complexes, 
the life of superoxide generating electron transport intermediates, such as 
ubisemiquinone, is prolonged (Skulachev, 1998). This occurs because the 
transmembrane proton gradient and the membrane potential inherently 
govern the activity of the respiratory chain complexes as proton pumps. 
When sufficiently high, pH and potential inhibit the proton pumps.
 
Figure 1.6-  Schematic representation of the mitochondrial generation 
of reactive oxygen species in the mitochondria. The mitochondrial 
respiratory chain generates ROS mainly at the complexes I and III. Specifically, the e- 
flow from the Q pool to Complex III is the step where the major part of superoxide anion 
production occurs.The enzymatic dismutation catalyzed by the manganese superoxide 
dismutase (MnSOD) produces H2O2 and regulates the superoxide anion levels (adapted 
from Mandavilli et al.,2002).
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1.2.4 Mitochondrial role in calcium homeostasis
 Intracellular calcium (Ca2+) is vital for cell physiology and the 
disruption of its homeostasis leads to various diseases. There are 
several proteins localized in different regions of the cell, which, working 
in coordination, guarantee an effective intracellular Ca2+ dynamics (Figure 
1.6). 
 At  local micro-domains such as plasma  membrane and 
endoplasmic/sarcoplasmic reticulum (ER/SR), Ca2+ concentrations 
extremely differ between the entrance of the open Ca2+ channel, where it 
is higher, and places very close to the channel, where it reaches very low 
concentrations (Parekh, 2003). Extra mitochondrial Ca2+ concentrations, 
mitochondrial inner membrane potential and Ca2+ concentrations in the 
mitochondrial matrix, determine the dynamics of mitochondrial Ca2+ uptake. 
When the extra mitochondrial Ca2+ concentrations are high (intracellular 
calcium stores and plasma membrane calcium channels), mitochondria 
sense and respond to the Ca2+ transients by taking up Ca2+.
 This physiological increase in mitochondrial Ca2+ serves as a key 
signal to regulate mitochondrial activities. Intramitochondrial enzymes 
involved in energy metabolism are activated after a calcium signal, so 
one of the main functions of mitochondrial calcium transport is to increase 
NADH production. Mitochondrial calcium uptake stimulates the activity 
of Krebs cycle and oxidative phosphorylation, and thus ATP synthesis 
(Denton, 2009; Balaban, 2009).
 Ca2+ transport into the mitochondria occurs through ion channels 
(Bernardi 1999; Ryu et al., 2010), existing in the mitochondrial inner 
membrane. Each of calcium influx plays a role via their unique characteristics 
in Ca2+ affinity, kinetics and pharmacological properties.
 The mitochondrial Ca2+ uniporter (MCU) is a protein complex 
formed by a channel and a regulatory subunit. The MCU allows Ca2+ 
transport down the electrochemical gradient into the mitochondrial matrix 
and without coupling to ATP hydrolysis or cotransport with other ion or 
molecule (Gunter and Pfeiffer, 1990; Gunter and Gunter, 1994). The calcium 
uniporter is regulated by a number of modulators: ruthenium red and other 
drugs (Noack and Greeff, 1971; Sastrasinh et al.,1982; Schellenberg et 
al.,1985) block mitochondrial Ca2+ uptake; inorganic phosphate (Pi) and 
spermine activate MCU and facilitate Ca2+ transport (Rossi et al., 1973). 
Cytosolic Ca2+ also regulates MCU in a calmodulin-dependent manner 
(Moreau et al., 2006; Putney and Thomas, 2006).
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 Another proposed mechanism for mitochondrial Ca2+ uptake is 
the rapid mode (RaM) uptake. It was described in liver mitochondria that 
in response to a cytosolic Ca2+ pulse, mitochondrial Ca2+ concentrations 
increase very rapidly (Rizzuto et al.,1993; Rizzuto et al.,1994). Calcium 
conductivity through the RaM is many times higher than that through the 
uniporter. At higher extra mitochondrial Ca2+ concentrations, Ca2+ uptake 
is mediated by both MCU and RaM. However, MCU does not transport 
Ca2+ when the calcium concentration is below its threshold (Sparagna et 
al.,1995). Like the calcium uniporter, the RaM is inhibited by RR (but is less 
sensitive) and stimulated by spermine. ATP and guanosine triphosphate 
(GTP) can activate RaM in liver but not in heart. 
                       
Figure 1.7- Schematic diagram of calcium (Ca2+) transport systems 
in the mitochondrial.Calcium influx to the mitochondrial matrix is mediated by a 
uniporter transporter, powered by the electrochemical gradient (MCU). Ca2+ can also 
enter mitochondria by the rapid calcium uptake mode (RaM). Mitochondrial Ca2+  efflux 
is mediated by antiporter transporters: a Na+- independent mechanism (NICE) and a Na+-
dependent mechanism (NCE). MPT represents another important mechanism for Ca2+ 
release from mitochondria in physiological conditions.
 Recently, other proteins have been reported as Ca2+ transporters, 
for example, the ryanodine receptor (mRyR) (Beutner et al., 2001), 
uncoupling proteins UCP2 and UCP3 (Trenker et al.,2007) and new 
mitochondrial calcium channels voltage-dependent highly selective for 
Ca2+ (mCa1,mCa2) (Michels et al., 2009). 
 The mitochondrial calcium efflux occurs via two different routes: 
dependent (Pfeifer and Gunter, 1990) and independent of sodium (Puskin 
et al., 1976). Both systems have different kinetic, but both require energy, 
since the calcium efflux occurs against the electrochemical gradient. 
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is abundant in tissues such as heart with a stoichiometry of 3Na+:1Ca2+ 
(Gunter et al., 1994). The sodium-independent mechanism is present in 
the liver and allows efflux of one calcium in exchange of two protons. This 
pathway saturates at low calcium loads and is extremely slow (Gunter et 
al., 1994).
 The balance between Ca2+ influx and efflux across mitochondrial 
inner membrane establishes mitochondrial Ca2+ homeostasis. The 
mitochondrial Na+/Ca2+ exchanger normally serves as a major Ca2+ efflux 
mechanism, but the transient opening of MPT represents another important 
mechanism for Ca2+ release from mitochondria in physiological conditions. 
1.2.5 The mitochondrial permeability transition
 Under conditions of mitochondrial calcium overload, especially 
when accompanied by oxidative stress, elevated phosphate concentrations 
and adenine nucleotide depletion, a non-specific pore, the mitochondrial 
permeability transition (MPT), opens in the inner mitochondrial membrane. 
The MPT is a large conductance channel in the mitochondrial inner 
membrane abruptly increasing its permeability to all solutes of molecular 
weight up to about 1500 Da. This leads to an increase in mitochondrial 
matrix volume, due to water entry inside mitochondria, resulting in 
mitochondrial swelling associated with membrane depolarization and 
uncoupling of the mitochondria, calcium release and unfolding of the inner 
membrane cristae (Zoratti and Szabò, 1995; Bernardi, 1999; Crompton, 
1999).
1.2.5.1  Regulation of the mitochondrial permeability transition
 Matrix Ca2+ is an essential permissive factor for mitochondrial 
permeability transition induction. The matrix free Ca2+ that favors MPT is 
difficult to define, since the concentration required is highly variable for 
different tissues and is influenced by various factors that change together 
with the Ca2+ load (such as matrix Pi and pH). 
 Increasing Pi concentrations decrease matrix Ca
2+, which should 
in turn decrease the probability of MPT induction; on the other hand, the 
mitochondrial accumulation of Pi potentiates Ca
2+ uptake by counteracting 
matrix alkalinization established by H+ extrusion in response to Ca2+ entry 
into the matrix. Therefore, the large electrochemical gradient for Ca2+ 
existing at the level of the inner membrane of respiring mitochondria favors 
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the matrix accumulation of both Ca2+ and Pi. Therefore, Pi is normally 
referred to as a MPT inducer, whose effect is explained as the result of 
buffering matrix pH, since the transition is potently inhibited at matrix pH 
below 7.0. The open probability decreases sharply below this pH value 
through reversible protonation of critical histidyl residues that can be 
blocked by diethylpyrocarbonate ( Bernardi , 1992). The MPT-regulatory 
histidyl residues are not located on cyclophilin D (CypD) , a proposed MPT 
component, because MPT modulation by matrix pH is not affected by 
CypD deletion (Basso et al., 2005). A recent study reports mitochondrial 
phosphate carrier (PiC) (Leunget al., 2008) and CypD (Basso et al., 2008) 
as mediators of the effects of Pi on the MTP. These results have modified 
the understanding of the role of Pi in MPT regulation.
 MPT opening is favored by mitochondrial depolarization. By 
modifying the threshold potential, MPT inducers can increase the opening 
probability at physiological mitochondrial membrane potential (ΔΨ) values 
(Bernardi,1992). The dependence on ΔΨm is likely to be also related to 
redox processes, and especially to oxidative stress. Agents that promote an 
oxidized state of pyridine nucleotides and thiol cross-linkers are inducers of 
the MPT (Kowaltowski et al., 1996). On the other hand, antioxidants have a 
preventive role (Petronilli et al., 1994). The susceptibility to MPT induction 
might be increased by cellular responses triggered by intracellular Ca2+ 
elevation such as generation of arachidonic acid by phospholipase A2 and 
calpain activation (Penzo et al., 2004; Polster et al., 205; Di Lisa et al., 
2007). So, conditions and xenobiotics that cause oxidative stress, adenine 
nucleotide depletion, increased Pi concentrations and mitochondrial 
depolarization, will promote the onset of the MPT.
 A major consequence of MPT induction is inhibition of oxidative 
phosphorylation, which unrestrained will lead to necrotic cell death. The 
permeability transition has also been pointed to be involved in apoptosis, 
through the release of pro-apoptotic factors.
1.2.5.2 Molecular composition of the MPT pore
 Although the molecular identity of the MPT remains uncertain, 
several proteins have been implicated in either its structure or regulation. The 
original model for the MPT based upon biochemical and pharmacological 
studies had three components: the voltage-dependent anion channel 
in the outer membrane, the adenine nucleotide translocase in the inner 
membrane, plus cyclophilin D in the matrix (Figure 1.8) . VDAC, ANT, and 
CypD interact at membrane contact sites and reconstitution of this complex 
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in vesicles yields a Ca2+-sensitive channel reminiscent of the MPT pore 
(Cromptom et al., 1998). This working model was consistent with inhibition 
and activation of the MPT by bongkrekic acid and atractyloside, ligands of 
ANT, and blockade by CsA, which binds to CypD (Cromptom et al., 1992). 
Actually, this model is discussed since recent genetic studies have 
questioned the validity of this paradigm.
Figure 1.8- Molecular models for the mitochondrial permeability 
transition (MPT) pore. A) The original model for the MPT pore, consisting of the 
voltage-dependent anion channel (VDAC) in the outer mitochondrial membrane (OMM), 
the adenine nucleotide translocase (ANT) in the inner mitochondrial membrane (IMM), and 
cyclophilin-D (CypD) in the matrix. B) Revised models in light of recent findings in gene 
targeted mice. VDAC is no longer part of the model and it appears that an outer membrane 
component may not even be necessary for this process. ANT now appears to be more of a 
regulatory protein, and only CypD remains as an established component. In contrast, the 
mitochondrial phosphate carrier (PiC) has been added to model as a potential candidate 
for the pore-unit of the MPT pore.
1.2.5.2.1 Voltage-dependent anion channel (VDAC)
 Although VDAC has long been considered a key component of the 
MPT, the evidence supporting for its involvement is largely circumstantial. 
VDAC is the most abundant protein in outer mitochondria membrane 
and facilitates the efficient transport of ATP/ADP across the outer leaflet 
37
(Blachly-Dyson et al.,2001; Rostovtseva et al., 2005).
 Some works report that VDAC inhibitors and VDAC “blocking” 
antibodies can prevent MPT, but the specificity of these agents is uncertain 
(Cesura et al., 2003; Toth et al., 2006). On the other hand, Halestrap group 
showed that mitochondria and cell lacking all three VDAC isoforms showed 
normal MPT opening, further demonstrating that VDAC is not an essential 
component of the MPT (Halestrap et al.,2005).
1.2.5.2.2 Adenine nucleotide translocase (ANT)
 
 The ANT is the most abundant protein in mitochondria. The 
ANT family mediates the exchange of ATP and ADP across the inner 
mitochondrial membrane (ATP from the matrix to the cytosol, by exchange 
with an ADP molecule). There are three isoforms of ANT: ANT-1, ANT-2 and 
ANT-3 (Fiore et al., 1998). ANT-1 is the most abundant inner mitochondrial 
membrane protein. Some evidences suggest that ANT-1 or ANT-3 is a 
component of the MTP (Bauer et al., 1999; Pereira et al., 2007; Yang, Z. et 
al., 2007). ANT functions as a pore between two extreme conformations, 
in which the binding sites of the substrate are on cytosolic side of the inner 
membrane - c conformation - or on the side of the matrix - m conformation. 
C conformation is likely to change with the binding of Ca2+ inducing MPT. 
This does not apply in the conformation m (Crompton et al. 1999).
 Pharmacological manipulation of the ANT with atractyloside 
or bongkrekic acid influences MPT (Haworth et al.; 2000; Akao et al., 
2003). In an earlier model, the ANT was suggested to be the membrane 
component of the MPT. This model was disputed by results of gene 
targeting experiments demonstrating that the ANT is not essential for MPT 
formation. Studies by Kokoszka and colleagues, who have used mice in 
which ANT is not expressed, showed that it does not significantly alter MPT 
thus raising doubts about ANT’s identity and if it is a necessary component 
of the MPT pore (Kokoszka et al., 2004). However, the same group has 
demonstrated that even though ANT might not be a component of the PTP 
per se, it can control susceptibility to MPT induction (Lee et al., 2009).
1.2.5.2.3 Cyclophilyn D (CypD) 
 
 Cyclophilins are a family of proteins that catalyze the cis-
trans isomerization of peptidic bonds. CypD is a water-soluble protein 
(18kDa) that is located predominantly in the mitochondrial matrix. CypD, 
facilitates a conformational change in the ANT, promoting MPT. Therefore, 
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the threshold for MPT induction  CypD deficient mitochondria and cells are 
resistant to Ca2+ and oxidative stress-induced MPT and cell death. In CypD 
knockout mice, MPT induction requires greater Ca2+ and is not blocked by 
cyclosporine A (CyA), a classical pharmacological MPT inhibitor (Basso et 
al., 2005; Baines et al., 2005; Nakagawa et al., 2005). Studies have shown 
that the potency of different CyA analogues to inhibit the MPT correlates 
with their ability to inhibit the peptidyl-prolyl cis-trans isomerase activity 
within the matrix that was subsequently identified as CypD (Halestrap and 
Davidson,1990; Griffiths and Halestrap, 1991). 
 The therapeutic value of maintaining the MPT in a closed state 
is highlighted by the resistance of CypD knockout mice (Ppif-/-) to a 
variety of diseases, and made CypD a drug target of high interest. 
However, pharmacological inhibitors of CypD, such as CyA, also inhibit 
the structurally-related cyclophilins CypA and CypB, which are critical for 
immune function.
1.2.5.2.3.1 Regulation of CypD interaction with the ANT  
 
 CypD binding to the ANT increases sensitivity to Ca2+, which 
decreases the threshold for MPT induction. This binding is dependent 
on CypD activity. Recently, a relationship between sirtuin-3 (SIRT3) and 
CypD has been established (Shulga et al., 2010). Sirtuins are NAD+-
dependent protein deacetylases that mediate adaptive responses to a 
variety of stresses, including calorie restriction and metabolic stress. 
Sirtuin 3 (SIRT3) is localized in the mitochondrial matrix, where it regulates 
the acetylation levels of metabolic enzymes. Shulga showed that Sirt3 
deacetylates and inactivates CypD causing its dissociation from the ANT 
(Shulga et al., 2010). Another published study performed on heart, showed 
that the decrease in Sirt3 activity leads to increased activation of the MPT 
in response to Ca2+increases, cardiac stress and aging, resulting in a 
decline in cardiac function (Hafner et al., 2010).
 Besides acetylation, also phosphorylation of CypD favors pore 
opening. Rassola and colleagues proposed a model in which inhibition of 
glycogen synthase kinase-3β (GSK-3β) activity, prevents its association 
to CypD and CypD phosphorylation, leading to MPT desensitization, 
whereas the Ser/Thr phosphorylation of CypD favors pore opening 
(Rassola et al., 2010). GSK-3β was first identified as a regulator of 
glycogen metabolism, but is also an important regulator of cell function, 
including gene expression, cell cycle, survival and apoptosis. GSK-3β is 
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active under normal resting conditions when it is not phosphorylated, and 
its activity is regulated by several signaling pathways. GSK-3β activity is 
regulated by phosphorylation, has a high basal activity that is increased 
by phosphorylation of its Tyr216 residue, whereas phosphorylation at Ser9 
decreases GSK-3β activity (Kockeritz et al., 2006). Under physiological 
conditions, total GSK-3β is nearly undetectable in mitochondria
1.2.5.2.4- Mitochondrial phosphate carrier (PiC)
 Functional support was provided to the role of PiC as a MTP 
component by demonstrating that agents able to inhibit mitochondrial Pi 
transport activity also blocked MPT in isolated mitochondria (Petronilli 
et al., 1994; Fontaine et al.,1998; Cesura et al., 2003). It has also been 
shown that the mitochondrial phosphate transporter forms a complex with 
CypD. MPT-inducing agents enhance PiC–CypD interaction, whereas 
MPT-blocking compounds reduce it. 
 Recently, Halestrap proposed a new MPT model consisting of PiC 
and ANT, of which Ca2+ sensitivity is regulated by CypD binding to PiC and 
by oxidant stress- induced dithiol cross-links within PiC and ANT molecules 
(Halestrap et al., 2009).
 It has been suggested that several other proteins such as 
hexokinase, creatine kinase and the pro-apoptotic proteins such B cell 
lymphoma-2 (Bcl-2) may also associate with the MPT.
 The BPR is an outer mitochondrial membrane protein which 
works as pharmacological target, as well as the target of some citotoxic 
compounds. 
 Creatine kinase is a protein from the intermembrane space, which 
binds to the VDAC–ANT complex, inhibiting the MPT. This enzyme allows 
the cell to use creatine-creatine phosphate as a form of energy available 
(Vieira et al., 2000). 
 The hexokinase is an outer membrane protein that can interact 
with the complex ANT-VDAC. Binding of HK to VDAC is promoted when 
the ANT is in the cytosolic conformation. The interaction between HKII 
and VDAC might cause a conformational change that favors closure or 
prevents the interaction between pro-apoptotic Bcl-2 family members and 
MPT pore components or other regulators.
 Pro-apoptotic proteins such as Bcl-2–associated X protein (Bax) 
or Bak (Bcl-2 homologous antagonist /killer) do not appear to constitute 
the MPT pore per se, but have been suggested as proteins that can bind 
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ON to and regulate it. Recently, there are three main models relatively to 
involvement of this proteins: (1) pro-death Bcl-2 proteins form their own 
protein-permeant pore; (2) pro-death Bcl-2 proteins interact with VDAC 
to form a protein- permeant channel that specifically permeabilizes the 
outer membrane; and (3) pro-death Bcl-2 proteins bind to and induce MPT 
opening.
1.2.6 Cell death: necrosis versus apoptosis
 Death of hepatocytes and other hepatic cells is a characteristic 
feature of diverse liver diseases. Cell death can occur as a consequence 
of massive damage (necrosis) or in a controlled form, through programed 
cell death (apoptosis).
1.2.6.1 Necrotic cell death
 Necrosis is most often the consequence of acute metabolic 
perturbation with ATP depletion. ATP depletion-dependent cytoskeletal 
alterations can lead to a moderate cellular swelling. The early phase of 
necrotic cell death is characterized by loss of plasma membrane integrity, 
which is usually anticipated by mitochondrial depolarization, lysosomal 
breakdown, ion deregulation and mitochondrial and cellular swelling 
(Herman et al., 1988; Niemaen et al., 1988,Gores et al.,1989; Zahrebelski 
et al., 1995) . As a consequence of plasma membrane permeabilization 
and cell lysis, the intracellular components are released and the damage-
associated molecular patterns may modulate inflammation, which results 
in damage to the adjacent cellular population. The swelling is a prominent 
feature of necrosis. 
 The proton electrochemical gradient is maintained by reversal of 
the mitochondrial proton-translocating ATPase. This actively stimulates 
the hydrolysis of ATP produced by glycolysis, leading to general metabolic 
failure. Induction of the MPT as an irreversible process of mitochondrial 
damage is associated with a necrotic-like terminal degradation of the cell.
1.2.6.2  Apoptotic cell death
 Apoptosis represents the execution of a death program often 
initiated by quite specific stimuli. In apoptosis, individual cells dye 
separately and shrink rather than swell. There are several morphological 
and biochemical changes that can define apoptosis, such as plasma and 
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nuclear membrane blebbing, shrinkage of the cell, chromatin condensation 
and nuclear fragmentation (Wyllie et al., 1980). Fragmentation of the cell 
into membrane-defined bodies, termed apoptotic bodies, is a hallmark of 
apoptosis. The machinery of apoptosis is well conserved and it is composed 
of caspases (the proteases which execute cell death), adapter proteins 
(caspase activators), Bcl-2 family proteins and Inhibitor of Apoptosis 
Proteins (IAPs) (Muñoz-Pinedo, 2012). 
 Apoptosis can be triggered by a variety of intra- and extra-cellular 
stimuli. The intracellular stimuli (such as DNA damage, high levels of 
calcium, intracellular proteins, reactive oxygen intermediates) normally 
result in mitochondrial outer membrane permeabilization and release 
of pro-apoptotic factors (cytochrome c, second mitochondria-derived 
activator of caspases (SMAC)/ direct IAP-binding protein with low PI 
(DIABLO), apoptosis-inducing factor (AIF)) from the intermembrane space 
into the cytosol. This intrinsic pathway (or mitochondrial) of apoptosis, is 
initiated by the activation of pro-apoptotic BH3-only (Bid, Bim, Bad, PUMA, 
Noxa) and multi-domain (Bax and Bak) members of the Bcl-2 family, and 
antagonized by the anti-apoptotic members of the same family (Bcl-2, Bcl-
xL, Mcl-1) (Nieminen et al., 1988). Bcl-2 is the founding member of a family 
of proteins that regulate apoptosis. Bcl-2 localizes to the mitochondria, 
where it reduces both apoptotic and necrotic cell death caused by 
several stressors. In addition to reducing cytochrome c release, Bcl-2 
overexpression reduces acidification, as well as the rate of mitochondrial 
ATP consumption when ATP hydrolysis is stimulated. This is accomplished 
by limiting ATP entry into the mitochondria through VDAC or ANT or by 
direct inhibition of the F1F0-ATPase.
 The balance between pro-/anti-apoptotic Bcl-2 proteins, is 
determinant in the response to apoptotic stimuli (Adams and Cory, 1998). 
Released cytochrome c associates with apoptotic protease activating 
factor 1 (Apaf-1) to form the apoptosome, which recruits procaspase 9 
and facilitates its autoactivation (Trump et al., 1965). Caspases (such 
as caspase-3, -8, -9, -12) are a family of cysteine proteases, known as 
the effector molecules of apoptosis, because most of the morphological 
hallmarks of this type of cell death result from their activity (Chang and 
Yang, 2000). Caspases are constitutively expressed as inactive pro-
caspases and are activated by a regulated proteolytic cleavage of inhibitory 
sequences. Caspase-9 triggers the activation of caspase-3 and leads to 
the execution and degradation phases, resulting in the morphological 
changes associated to apoptosis (such as cellular and nuclear collapse). 
Mitochondria play a key role in the apoptotic process, functioning as a link 
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ON between apoptotic mediators and effector molecule (Gross et al., 1999).
 The extracellular stimuli through the binding of death receptors, 
such as tumor necrosis factor-α (TNFα) or Fas  their receptors in the 
plasma membrane, can induce apoptosis (Kerr et al., 1979). This 
leads to the activation of procaspase-8, which cleaves and activates 
procaspase-3 and initiates the caspase cascade (Ashkenazi and Dixit, 
1998). Additionally, caspase 8 can involve the mitochondrial pathway by 
cleaving the BH3-only protein Bid, whose mutilated fragment translocates 
to the mitochondrial outer membrane causing its permeability (Dickson 
et al.1992); Marsh, 1993).  Kupffer cells activation and TNF-α production 
increase the sensitivity of hepatocytes to TNF-α-mediated apoptosis 
(Shimizi et al., 2000). ER stress could also partly contribute to apoptosis 
by releasing calcium into the cytosol and so activating procaspase-12. 
1.2.6.3  Necrapoptosis
 A necroapoptosis theory proposed by Lemasters refers to a 
process that begins with the same death signal and ends in either necrosis 
or apoptosis depending on conditions (decline of cellular ATP levels or 
fat content) (Lemasters et al., 1999). It is proposed that an abrupt MPT 
onset causes ATP depletion, blockage of caspase activation and plasma 
membrane rupture, deviating cell death from apoptosis to necrosis.
1.3  Non-Alcoholic Fatty Liver Diseases (NAFLD) 
 
 Fatty liver or steatosis, is characterized by the accumulation of 
fat in the cytoplasm of hepatocytes derived from adipocytes, intestinal 
absorption or hepatic lipogenesis (Haque and Sanyal, 2002); Browning 
and Horton, 2004). Alcoholic steatosis is caused by alcohol consumption. 
Non-alcoholic fatty liver diseases (NAFLD) are associated with obesity 
and type II diabetes and is increasing rapidly in Western countries due to 
a fat rich diet and lack of exercise, reaching epidemic proportions with an 
incidence of 20% to 30% of individuals. 
 The mechanisms involved in the development of NAFLD are under 
intensive research. Deletion or over-expression of genes involved in
lipid metabolism and modulation of appetite, or administration of modified 
diets, leads to the development of a steatotic phenotype. 
 Zucker  fatty rats are a well-characterized model of obesity 
associated with over nutrition, which simulates very closely the most 
common cause of steatosis in the western countries (Figure 1.9). These 
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animals have a missense point mutation (fa/fa) of the leptin receptor, 
which impairs the ability of leptin to bind to the receptor in order to induce 
satiety. Different metabolic dysfunctions, such as insulin resistance, 
hyperglycemia or raised lipid levels have been described in these rats. 
Moreover, an important fact is that steatosis in Zucker rats is not associated 
with inflammation, in opposite to other models of steatosis using ethanol 
ingestion or a choline-deficient diet (CDD). 
 Data gathered from both humans and experimental animals 
suggest that fatty livers are more prone to a variety of insults such as 
ischemia/reperfusion (I/R) being hepatic steatosis a major risk factor for 
liver surgery and success in the transplant of fatty donor organs. 
                               
Figure 1.9 -  Hepatic histology of normal (A) and fatty livers (B) 
showing fat acumulation (Teodoro et al., 2006).
 
1.3.1 The biochemistry of pathology 
 A deregulation in fatty acid’s metabolism leads to an overproduction 
of triglycerides with subsequent fat accumulation inside the liver cells. Very 
Low Density Lipoproteins (VLDL’s) are the main vehicle of triglyceride 
exportation from the liver to the peripheral adipose tissue. These lipoproteins 
are formed by triglycerides and cholesteryl esters and phospholipids 
surrounded by a protein called Apolipoprotein B (ApoB), and its synthesis 
is dependent upon the availability of triglycerides. So, alterations in one of 
these pathways may result in liver lipid metabolism perturbations (Haque 
& Sanyal, 2002).
 The excessive abundance of free fatty acids causes a shift in 
metabolism, turning these molecules into the main energy source of the 
cell (Haque and Sanyal, 2002; McClain et al., 2004). So, degradation of 
glucose as main energy source is substituted by β-oxidation of fatty acids 
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ON (FFAs). Although FFA are used as a source of energy, continues to exist 
an overload in the cell, because the “pool” of FFAs in hepatocytes is in 
equilibrium with the level of FFAs in circulation, the synthesis of FFA’s, 
the β-oxidation and the “pool” of cellular triglycerides. Such alteration 
increases lipid peroxidation, destabilizing the inner cell redox environment.
1.3.2 Mitochondrial dysfunction in NAFLD
 Mitochondria is the dominant oxidative pathway for the disposition 
of fatty acids under normal physiologic conditions. In order to counteract 
excessive fat storage, there is a compensatory stimulation of mitochondrial 
β-oxidation of fatty acids. As the oxidative capacity of the mitochondria 
becomes impaired or is exceeded, cytosolic fatty acids accumulate 
activating alternative pathways in the peroxisomes and in microsomes 
(Johnson et al.,1996; Reddy and Mannaerts,1994). This increases ROS 
generation, destabilizes the redox environment of the cell causing cellular 
damage. As major ROS generators, mitochondria are often targets of 
high ROS exposure with deleterious consequences, such as oxidative 
damage to the ETC complexes and mtDNA (Ricci et al., 2008; Racheket 
al., 2009). All these effects may further block the flow of electrons in the 
ETC, leading to a vicious cycle in which accumulating oxidative damage 
affects the efficiency of mitochondria and further increases the rate of ROS 
production (Petrosillo et al., 2007).
 There are consistent evidences for a central role of mitochondrial 
dysfunction in the pathophysiology of NAFLD, whatever its origin, such 
as drug-induced or associated with insulin-resistance. Impairment of 
hepatic ATP synthesis, reductions in the activities of complexes of 
the ETC and increased ROS production have been reported (Cortez-
Pinto et al.,1999; Hensley et al., 2000). These biochemical changes 
are associated with ultrastructural abnormalities indicative of impaired 
oxidative phosphorylation. Liver mitochondria appear scarce in number, 
swollen and rounded with loss of cristae and presence of paracristalline 
inclusions (Chavinet al., 1999; Pérez-Carreras et al., 2003; Teodoro et al., 
2006; Teodoro et al., 2008) .
1.3.3  Diagnosis 
 Most individuals with NAFLD have no symptoms and the diagnosis 
can be made with routine examination, such as biochemistry (Preiss and 
Sattar, 2008) .The patient with abnormal liver function tests, with raised 
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or high–normal fasting blood glucose, low HDL (high-density lipoprotein), 
high cholesterol and elevated fasting triacylglycerols is likely to have 
NAFLD. 
 The only proven techniques to confirm diagnosis and different 
stages of NAFLD are invasive, including a liver tissue biopsy. The 
percentage of fat present on livers defines the level of hepatic steatosis, 
which is graded as mild, moderate or severe (Kleiner et al., 2005). Steatosis 
is usually macrovesicular and the hepatocytes have a single large intra 
cytoplasmic fat droplet or smaller well-defined droplets moving the nucleus 
to the cell periphery. When there are groups of hepatocytes with centrally 
placed nuclei and numerous lipid droplets in the cytoplasm, in addition 
to macrovesicular steatosis, it is defined as mixed steatosis (Brunt and 
Tiniakos, 2010).
 Although NAFLD is considered a relatively benign condition, this 
pathology can progress to more severe stages of liver disease including 
NASH (non-alcoholic steatohepatitis), with or without fibrosis, cirrhosis 
and occasionally hepatocellular carcinoma (Preiss et al., 2008). These 
stages can be reached due to additional cellular events that promote 
oxidative stress and production of inflammatory cytokines causing cell 
death, inflammation and fibrogenic response. 
1.3.4  Liver Transplantation
 Over the past decade, the gap between the number of patients 
awaiting an organ and the number of available organs has dramatically 
increased. 
Actually, the main restriction of hepatic transplantation is the shortage of 
donors. To minimize the lack of organs available to transplant, several 
strategies have been developed to optimize the use of liver donors. These 
strategies have been designed to increase the number of organs that are 
transplanted by reevaluation and increase of the variables of acceptance 
of an organ for transplantation and the development of various alternative 
and conventional transplant techniques. 
 In 2008, Portugal was the country that did more liver transplants 
in the world performing 25.8 per million of habitants, in other words, 274 
transplants were done (Figure 1.10). This was only possible due to an 
increase of collection centers resulting in a higher number of donors by 
more than 50% compared to previous years. This has led to a high incentive 
to use extended criteria donor organs, which include organs distinguished 
by hepatic steatosis, old donor age, prolonged cold ischemia, or donation 
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after cardiac death. Many of the current research in liver transplantation 
are directed to the possible use of suboptimal or marginal organs as a 
strategy to increase the number of organs available for transplant. There is 
the special interest for steatotic organs, due to its high prevalence among 
the potential liver donors. 
        Figure 1.10-  Hepatic transplantations in Portugal 2007-2010 (data 
of the Sociedade Portuguesa de Tansplantação).
 
Hepatic steatosis is a major risk factor for liver surgery and success in the 
transplant of fatty donor organs, since it is associated with a significantly 
increased risk of primary graft nonfunction.  
 Operative mortality rate associated with steatosis after major liver 
resection has been reported as high as 14% compared with 2% for healthy 
livers (Behrns et al.,1998). Fatty liver grafts are more frequently used in 
the context of transplantation and they are associated with a primary non-
function rate of 60% compared with 5% for non-steatotic grafts (Canelo 
et al.1999; D’Alexandro et al., 1999). Livers with 30% or more fat content 
have a high prohibitive rate of primary nonfunction, being 25% of liver 
donors rejected due to steatosis (He et al., 2009). Therefore, developing 
protective strategies to minimize the adverse effects of I/R injury in steatotic 
livers is of paramount importance (Degle Esposti et al., 2011).
1.4  Ischemia/reperfusion
 Ischemia/reperfusion injury is a phenomenon whereby damage to 
a hypoxic organ is accentuated following the return of oxygen delivery. 
Toledo-Pereyra and collaborators, in 1975, recognized this form of injury 
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as a clinically important pathological disorder. Only in the mid-1980s the 
term “reperfusion injury” began to be used when an association was 
made between congestion, progressive thrombosis and/or graft necrosis, 
resulting in organ failure in transplanted liver. I/R may occur in many clinical 
situations such as transplantation, resection, trauma, shock, hemorrhage, 
and thermal injury. 
 The mechanism of organ damage after I/R has been extensively 
studied and consists of complex interactions of multiple pathways. The 
major contributors to I/R injury include production of ROS, release of 
proinflammatory cytokines and chemokines, and activation of immune 
cells to promote inflammation and tissue damage.
 Warm I/R injury occurs in settings of transplantation, trauma, shock, 
and selective liver surgery in which hepatic blood supply is temporarily 
interrupted. There are two distinct phases that occur in warm I/R injury. The 
early phase occurs in the period less than 2 hours after reperfusion and is 
characterized by activation of immune cells and oxidative stress. Kupffer 
cells are a key cell type involved in the initial stages of I/R injury (Teoh et al., 
2003; Jaeschke et al., 1990). The activation of KC leads to ROS generation 
that provokes moderate hepatocellular injury characterized by a mediate 
increase in serum transaminase levels, and a partial preservation of the 
hepatic structure. In addition to oxidative-mediated damage, oxidative 
stress leads to the production of several proinflammatory cytokines and 
chemokines, such as TNF-α, interleukin (IL)-12 and IL-1b Jaeschke et 
al.,1988; Wanner et al.,1996; Lentsch et al.,1999). These molecules have 
the role to start and perpetuate a later secondary inflammatory phase, 
which causes more damages to the liver. The expression of the cytokines 
is mediated by transcription factors, nuclear factor κ B (NF-κB) and hypoxia 
inducible factor-1α (HIF-1α).
 The late phase, involved in warm I/R damage, occurs from 6 to 48h 
after reperfusion, and it is an inflammatory disorder mediated by neutrophils, 
attracted by chemokines released in the early stage and attached to the liver 
by adhesion molecules (Lentsch et al.,1998). TNF-α also has an essential 
role in the induction and release of neutrophil chemoattractants, especially 
CXC chemokines from KCs and hepatocytes. Neutrophils also cause some 
of the damage to hepatocytes by releasing ROS via nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (Jaeschke et al.,1990; Jaeschke 
et al.,1991). Because of that, knockout mice deficient in the gp91-phox 
component of NADPH are protected against I/R injury. Another neutrophil-
mediated injury occurs through enzyme-mediated degradation of cellular 
membranes and matrix components. Neutrophils release proteases and 
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ON other cytotoxic enzymes through granule exocytosis, such as elastase, 
cathepsin G, heparanase, collagenase and other hydrolytic enzymes.
 Damage associated with cold ischemia occurs exclusively in the 
transplant setting, when a donor graft is harvested. Cold storage aims to 
reduce metabolic activities of the graft while the organ awaits implantation. 
This requires the use of preservation solutions at low temperatures (2-
4ºC), being the most used University of Wisconsin (UW). Some strategies 
have been developed to improve preservation solutions, to expand the 
preservation periods and to reduce the negative effects of preservation. 
Studies with animals are normally focused on storage times up to 18h, 
although some increase cold storage to 24h or more. In clinical situation, 
using human livers, these can be successfully stored at 4°C for up to 12 h in 
UW solution, but if storage periods are extended the graft failure is greatly 
increased (Furukawa et al.,1991; Ploeg et al.,1993; Porte et al.,1998).
 While there are many common pathogenic mechanisms between 
warm and cold IR injury, there are also several important differences. 
Cold storage has specific effects on the various cellular subsets within 
the liver graft, such as endothelial cells, which are more susceptible to 
cold storage. Several studies showed that endothelial cells have higher 
mortality than hepatic parenchymal cells at the same time point, which 
means that it occurs independently of apoptosis and coagulative necrosis 
(Caldwell-Kenkel et al.,1991; Gao et al.,1998). The cause of this higher 
damage of endothelial cells is the functional impairment of the liver after 
reperfusion. The endothelial cells that remain viable accentuate I/R injury 
by expression of adhesion molecules. Increasing cold storage times is 
closely related to increasing KC activation on reperfusion, which result in 
increased ROS and cytokine production (Caldwell-Kenkel et al.,1991).
 For the study of hepatic IR injury three models can be used: in 
vivo models, in vitro cell culture systems and ex vivo intact organ models. 
There are two main in vivo models of hepatic IR injury: total hepatic 
ischemia and partial hepatic ischemia. When livers are subjected to total 
hepatic ischemia there is an occlusion of the hepatic artery, portal vein 
and common bile duct. In this case, the period of ischemia using this 
model is limited (20 min), as longer occlusion times result in high mortality. 
Kawamoto has demonstrated that global ischemic periods of more than 
30 min cause irreversible hemodynamic instability and severe splanchnic 
congestion. In 1982, Yamauchi and colleagues described a model of partial 
hepatic ischemic (70%) where the hepatic artery and portal vein to the left 
and median liver lobes were occluded. This model was used in order to 
prevent mesenteric venous congestion by permitting portal decompression 
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through the right and caudate lobes. There are models that use the isolated 
perfused liver, in which the excised organ is perfused via the portal vein 
using a system with buffer as perfusate, where buffer flow rates can be 
adjusted. In vivo models are faithful to the clinical reality of IR injury, while 
cell culture systems fail to reproduce the dynamic conditions that liver cell 
types are exposed to in vivo during ischemia and I/R. 
1.4.1  Mitochondrial alterations associated with I/R
 One of the most important features of I/R injury is the alteration 
of energy metabolism due to impairment of mitochondrial function. 
Removal of oxygen during ischemia leads to the cessation of oxidative 
phosphorylation. This causes tissue ATP and creatine phosphate 
concentrations to decrease with a concomitant rise in ADP, AMP and Pi 
concentrations. Although glycolysis is activated, it is unable to meet the 
demand for ATP. Mitochondrial ATPase consumes ATP during ischemia to 
temporarily maintain mitochondrial membrane potential. Since maintenance 
of ion gradients across the plasma membrane and between cellular 
compartments depends on ATP-driven reactions, metabolic disruption by 
injurious stresses may quickly perturb cellular ion homeostasis.
 Ischemia elevates intracellular H+, Na+, and Ca2+ levels, induces 
osmotic stress and causes mitochondrial damage. Intracellular Na+ 
concentrations rise during ischemia due to stimulated Na+ influx via the 
Na+–H+ exchanger, caused by intracellular H+ accumulation, and reduced 
Na+ efflux via the Na+–K+ pump (Inserte et al., 2006; Inserte et al., 2002; 
Murphy et al., 2006). Although Na+ overload stimulates Ca2+ influx by the 
Na+–Ca2+ exchanger and depletion of ATP reduces Ca2+ uptake by the 
endoplasmic reticulum, Ca2+ level is kept modest during ischemia since 
acidosis inhibits the Na+–Ca2+ exchanger, and cytosolic Ca2+ is taken up 
by the mitochondria as long as its membrane potential is maintained. Influx 
of extracellular Ca2+ is responsible for irreversible cell injury as shown by 
studies in which removal of extracellular Ca2+ protects against various 
hepatotoxicants (Farber et al.,1982; Schanne et al.,1979).
 Immediately after an organ becomes ischemic there is an increase 
in ROS generation that is thought to play a major role in damaging the 
organ during ischemia and sensitizing it to reperfusion. The source of 
the ROS is unclear, as further discussed, and might involve Complexes I 
and III of the ETC or perhaps xanthine/xanthine oxidase (X/XOD), acting 
on xanthine formed from the degradation of adenosine. AMP is slowly 
converted into adenosine and then inosine and xanthine through a purine 
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 The depletion of ATP combined with elevated intracellular Ca2+ 
and ROS leads to a gradual decline in cellular integrity as degradative 
enzymes are activated and ATP-dependent repair processes are unable 
to operate. If the tissue remains ischemic for only short periods and the 
mitochondria remain sufficiently intact to generate ATP, tissue damage is 
slight and can be repaired upon reperfusion. However, a critical point is 
reached when recovery is not possible. In this case, although reperfusion 
restores ATP production, it will actually cause further damage to the organ 
due to the metabolic derangements accumulated during ischemia, causing 
cell death.
 Reperfusion is associated with increased Ca2+ but is also associated 
with a burst in ROS generation. Although ROS may be produced by 
xanthine oxidase and NADPH oxidase, probably the majority is formed 
by uncoupled mitochondria, mainly from mitochondrial complexes I and 
III of the ETC (Jaeschke et al.,1989; Turrens et al., 2003). When the 
respiratory chain is inhibited by lack of oxygen and then re-exposed to 
oxygen, ubiquinone can become partially reduced to ubisemiquinone. 
This can then react with the oxygen to produce superoxide that is reduced 
to hydrogen peroxide by superoxide dismutase. Hydrogen peroxide is 
removed by glutathione peroxidase or catalase, but if ferrous ions (or 
other transition metals such as copper) are present it will form the highly 
reactive hydroxyl radical through the Fenton reaction (Becker et al., 2004). 
Damage to mitochondrial lipids and proteins caused by ischemia favors 
ROS generation during reperfusion (Insert et al., 2008). ROS cause 
peroxidation of the unsaturated fatty acid components of the phospholipids, 
and especially cardiolipin of the inner mitochondrial membrane, impairing 
electron flow through the ETC (Petrosillo et al., 2003; Paradies et 
al.,2004). Furthermore, lipid peroxidation causes the release of reactive 
aldehydes such as 4-hydroxynonenal that modifies membrane proteins 
(Echtay et al., 2003). ROS also have direct effects on several respiratory 
chain components and other iron sulphur proteins such as aconitase. ROS 
can also cause thiol oxidation and inhibition of the ATPase and ANT. In 
addition, glutathione oxidation and protein modification is thought to have 
inhibitory effects on ion pumps and therefore exacerbate the effects of 
ATP deprivation on ionic homeostasis (Hool et al., 2006). Oxidative stress 
is enhanced by the depletion in superoxidase dismutase, glutathione 
peroxidase and reduced glutathione that occurs during reperfusion (Dhalla 
et al., 2000).
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Figure 1.11- The combined action of ROS and elevated [Ca2+] cause 
cell death. Rapid ATP depletion inhibits the Na+/K+ ATPase, which leads to a rise in 
intracellular [Na+] and impairs the ability to restore the pHi. This increases intracellular 
[Ca2+] since the Na+/Ca2+ antiporter is inhibited or reversed. The conversion of ATP to ADP 
and AMP is rapid and reversible. AMP is slowly converted into adenosine and then inosine 
and xanthine , that might be involved in ROS generation through the action of xanthine 
oxidase. The elevated [Ca2+] leads to a gradual decline in cellular integrity, activating 
phospholipases, proteases and endonucleases that contribute to membrane, cytoskeletal 
and cromatine damage, respectively. 
 
 The combined effects of ROS and mitochondrial Ca2+ overload play 
a critical role in the transition from reversible to irreversible reperfusion 
injury (Figure1.11). Mitochondria are the major target of these agents since 
they are potent inducers of the MPT, resulting in mitochondrial-initiated 
cell death. As a consequence of the MPT, mitochondrial depolarization, 
uncoupling of oxidative phosphorylation and large-amplitude mitochondrial 
swelling driven by colloid osmotic forces occur.
 MPT induction causes the release of apoptotic factors, such as 
cytochrome c and the apoptosis-inducing factor, into the cytosol (Forbes 
et al., 2001; Murata et al., 2001). Additionally, the release of cytochrome 
c from the mitochondrial intermembrane space may also occur through 
channels formed by Bax, a proapoptotic Bcl-2 family (Borutaite et al., 2003). 
This may occur due to increased translocation of Bax to the mitochondria 
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ON in response to pro-apoptotic signals (Figure 1.12).
  Figure 1.12- Elevated ROS and calcium induce the MPT. MPT induction 
causes the release of apoptotic factors, such as cytochrome c and the apoptosis-inducing 
factor (AIF). Cyt c release may also occur through channels formed by Bax, a proapoptotic 
Bcl-2 family protein. ATP depletion may block caspase activation, deviating cell death from 
apoptosis to necrosis.
 There is still controversy about the significance of necrotic or 
apoptotic cell in parenchymal injury observed during hepatic reperfusion. 
Some investigators reported massive necrotic alterations as responsible for 
the main part of parenchymal injury. However, other works demonstrate that 
specific inhibition of apoptosis notably prevented parenchymal injury and 
improved animal survival after prolonged periods of ischemia.  In conditions 
of ATP depletion, apoptosis can deviate to necrosis (necroapoptosis). 
It has been recently reported that autophagy, a catabolic pathway that 
crosstalk’s with apoptotic and necrotic cell death pathways is involved 
in I/R. Autophagy is a catabolic pathway triggered by several stresses 
such as starvation and hypoxia that favors cell survival by preserving 
energy levels and eliminating damaged organelles (Huang et al., 2007; 
Scherz-Shouval et al., 2007). Autophagy has been shown to retard cell 
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death by suppressing ER stress (Choi et al., 2010) that is involved in 
the pathogenesis of fatty liver (Demetris et al.,2006; Arkadopoulos et al., 
2009). ER stress inhibition has been shown to be protective under I/R 
in an experimental model of steatotic/ non-steatotic partial hepatectomy 
(Mosbah et al., 2010).
1.4.2 ROS generation associated with I/R independent on the ETC
 There is controversy regarding sources of ROS generation during 
hepatic I/R. Experiments with allopurinol, an inhibitor of X/XOD, have 
indicated this system as a major ROS generation in the setting of I/R 
(Grattagliano et al.,1999). On the other hand, results from studies with 
the isolated perfused liver showed that the main ROS generator in I/R is 
mitochondria and not the X/XOD system. Inactivation of KC as also been 
shown to attenuate the increased vascular oxidant stress after 30 and 60 
min of ischemia, while high doses of allopurinol didn´t afford protection 
(Metzger et al.,1988; Jaeschke et al.,1991). Besides KC, activation of 
neutrophils as also been implicated in reoxygenation injury.
 A possible explanation for these conflicting results are the 
differences in experimental models and parameters, including the time of 
ischemia, which is particularly significant when assessing the relevance 
of mitochondria or X/XOD for ROS generation. Prolonged cold ischemia 
leads to a significant conversion of XDH to XOD. Therefore, in this case, 
X/XOD has a crucial role in hepatic I/R injury. But in shorter ischemic 
periods, such as 6h of cold ischemia, the major ROS generation occurs 
in the mitochondria (Fernandez et al., 2002). The pleiotropic range of 
effects of compounds tested, as protective against in I/R, also has to be 
taken into account. Allopurinol, besides inhibiting XOD, may also improve 
ischemia-induced mitochondrial dysfunction. In a warm hepatic I/R model, 
high doses of allopurinol preserved mitochondrial function. Besides time, 
the temperature of ischemia (4°C or 37°C) also influences oxidative stress 
in hepatocytes and the stimulatory state of KC after I/R, determining the 
relevant of intracellular vs vascular oxidative stress to hepatic I/R injury 
(Mochida et al.,1994).
1.4.3 The role of nitric oxide
 The role of nitric oxide (NO) in I/R is complex, and it is difficult to 
distinguish between beneficial and harmful mediators in I/R injury. 
NO is an important signaling molecule in the liver produced by nitric oxide 
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ON synthase (NOS) through the conversion of arginine. The inducible (iNOS) 
and the endothelial form (eNOS) are two isoforms of nitric oxide synthase 
(NOS) that are involved in NO production during I/R injury. The eNOS 
form is expressed in endothelial cells and eNOS-derived NO has been 
reported as protective. On the other hand, the iNOS form is regulated by 
many of the same cytokines, such as TNF-α and IL-1, contributing for 
I/R injury. Although the source of NO may determine whether NO plays 
a protective or damaging role, there are other factors, such as, timing, 
release or downstream activation of NO-responsive elements that may be 
decisive in NO effects.
1.4.4 The role of TNF-α and Nuclear factor κ B (NFkB)
 The role of TNF-α in I/R injury is also complex and controversial and 
depends on the cell type and/or experimental or pathologic circumstances. 
Accordingly, TNF-α can be either protective or damaging during episodes 
of hepatic I/R: TNF-α may promote cell death or it may produce effects 
mediated by antioxidant, anti-apoptotic or anti-stress mediators, therefore 
promoting hepatoprotection and a proliferative biologic response (Bradham 
et al., 1998; Aggarwal et al., 2000; Dieh et al., 2000). For example, 
although the deleterious effect of TNF-α in local and systemic damage 
associated with hepatic I/R is well established, this mediator is also a 
key factor in hepatic regeneration which is very important in children liver 
transplantation, and pre-treatment with a low dose of TNF-α was highly 
protective against hepatic I/R injury (Peralta et al., 1999; Teoh et al., 2006). 
TNF-α contributes significantly to mitochondrial dysfunction by promoting 
ROS (possibly through direct effect on the ETC) and ROS production by 
iNOS. TNF-α also has the ability to induce cell death through caspase 8 
activation (Wang et al., 2008; Hatano et al., 2007; Badiola et al., 2009). This 
leads to a partial block in the flow of electrons in the ETC and increases 
mitochondrial ROS formation that induces MPT.
 The differential effects observed for TNF-α can be extrapolated 
from transcription factors, such as NFkB. Being able to modulate several 
pathways it is known that NFkB can induce both pro- or anti-apoptotic 
effects. Currently it is not very clearly whether the beneficial effects of 
NFκB activation against I/R result from reducing apoptotic cell death or 
if it is pro-inflammatory role that prevails in hepatic I/R. Suppression of 
NFkB activation in mice, following partial hepatic I/R, leads to a significant 
reduction in neutrophil recruitment and hepatocellular damage (Yoshidome 
et al., 2006). It has also reported that NFκB activation is crucial for hepatic 
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regeneration after rat liver transplantation (Bradham et al., 1999). Thus, one 
has to consider several aspects in order to better understand and clarify 
the dual role of NFkB in hepatic I/R situations. In first place, differences can 
be detected between the species used in different studies; for instance, 
some mechanisms that give protection against apoptosis may be different 
in rats and mice. Additionally, the experimental design used to evaluate the 
role of this transcription factor may also be important. As an evidence for 
this, it is reported that the use of adenoviral vectors containing a repressor 
to prevent NFκB activation may not accurately modulate the role of NFκB 
signaling in regenerating liver, since adenoviral vectors themselves cause 
increased TNF-α levels, DNA synthesis, and apoptosis in the liver before 
partial hepatectomy (Lieber et al.,1997; Limuro et al., 1998).
1.5 Causes for increased susceptibility of fatty livers to I/R
 Different hypothesis have been proposed for the increased 
susceptibility of fatty organs to ischemic injury. These include impaired 
microcirculation, ATP depletion, Kupffer cell dysfunction, impaired 
mitochondrial function and increased adhesion of leukocytes, but the role 
that each of these mechanisms play in injury is not yet elucidated (Figure 
1.13).
1.5.1 Impaired microcirculation
 Diverse authors consider that the alterations in hepatic sinusoidal 
microcirculation present in fatty livers as one of the principal factors for the 
higher susceptibility to I/R (Behrns et al., 1998; Caraceni et al., 1999). 
 The result of the accumulation of fat in the cytoplasm of hepatocytes 
is an enlargement of these cells. This can cause compression and 
distortion of sinusoidal vascular channels, conducting to an increase of 
hepatic intraportal resistance and a decrease of blood flow. Fatty livers 
present a decrease in blood flow at approximately 50% compared with 
livers without fat, which can induce chronic hypoxia (Bradham et al.,1998; 
Peralta et al., 
1999).
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       Figure 1.13- Susceptibility of fatty livers to I/R injury. Different 
hypothesis have been proposed for the increased susceptibility of fatty organs to ischemic 
injury: ATP depletion, Kupffer cell dysfunction, impaired mitochondrial function, impaired 
microcirculation and increased leukocyte adhesion. 
Narrowing of sinusoidal lumen leads to activation and accumulation of neutrophils. The 
accumulated CD4+ T-lymphocytes in the liver produce factors that amplify Kupffer cells 
activation and promote neutrophil recruitment into the liver. Kupffer cells are an important 
source of ROS and cytokines, such as TNF-alpha. Release of cytokines up-regulate the 
production of adhesion molecules (ICAM and vascular cell adhesion molecule [VCAM]) 
and chemokines, which promote neutrophil activation and accumulation. These neutrophils 
then extravasate, causing cellular injury by ROS and protease generation. ROS may derive 
from xanthine/xanthine oxidase (X/XOD) and mitochondria. ROS and ATP depletion lead 
the cellular injury.
  Diverse authors propose that these alterations in hepatic sinusoidal 
microcirculation in fatty livers can amplify the negative effects produced 
by I/R and worsen the hepatic damage (Sun et al., 2001; Clemens et al., 
1999). 
 So, in fatty livers, the damaged sinusoidal endothelium, the 
liberation of fat droplets during organ preservation, even as formation of 
little fibrin thrombi and cellular elements in blood, adhesion of neutrophils 
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and platelets to sinusoidal endothelium during reperfusion, the reduction 
of sinusoidal space can all contribute for major susceptibility to I/R injury 
(Fukumori et al., 1997; Selzner et al., 2000; Teramoto et al., 1993).
1.5.2 Kupffer cell dysfunction
 Kupffer cells are the resident macrophages of the liver and are 
involved in the pathogenesis of liver parenchymal cell damage as seen 
during I/R injury. Diverse studies show that after I/R there are more KC 
and higher phagocytic activity of these cells in fatty livers than in normal 
livers (Wanner et al., 1996). KC produce substances that can modulate 
sinusoidal blood flow and are an important source of ROS and cytokines, 
such as TNF-α and IL-1, which increases during reperfusion. Inhibition of 
KC activity in models of fatty livers reduces hepatic IR injury and increases 
the survival after transplantation (Mosher et al., 2001).
1.1.5.3 Increased adhesion of leukocytes
 The excess of fat in steatotic livers produces an alteration in 
membrane fluidity due to the reduced presence of cholesterol and 
polyunsaturated fatty acids (Fukumori et al., 1999). After cold preservation, 
there are alterations in sinusoidal endothelium of fatty livers that can induce 
an increase of infiltration an adhesion of neutrophils during reperfusion 
(Fukumori et al., 1999). However, it is not yet elucidated how neutrophils 
actually accumulate in the liver. It may involve adhesion molecules, such 
as intercellular adhesion molecule-1 (ICAM-1) and P-selectin (Banga et 
al., 2005; Cutrin et al., 2002). However, several authors reported that the 
increased expression of ICAM-1 and P-selectin is not the main cause for 
neutrophil accumulation, but an extensive vascular injury during reperfusion 
disrupt the sinusoidal endothelial cell barrier allowing neutrophils to access 
hepatocytes (Jaeschke et al., 2003; Caldwell-Kenkel et al., 1991; Peralta 
et al., 2001).
1.5.4  Impaired mitochondrial function and ATP depletion
 Steatosis is associated with a decreased ability of the liver to 
generate ATP. Ischemic injury causes low intracellular ATP levels, which 
are rapidly restored to normal levels in lean hepatocytes, but steatotic 
livers are unable to restore ATP contents after reperfusion (Teodoro et 
al., 2008; Teodoro et al., 2006). These low intracellular ATP levels might 
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ischemia. The difference in the ability to generate ATP and the mechanism 
of cell death between lean and fatty livers might be important because 
different strategies might be necessary to protect the fatty and lean livers 
(Vendemiale et al., 2001; Caraceni et al., 2004). The lower ATP content in 
fatty livers, associated with higher levels of oxidized lipids and proteins, 
is the probable cause for higher necrotic cell death following I/R injury, 
comparatively to lean livers. It is noteworthy that high ATP levels have 
been correlated with better post-transplantation outcomes (Lanir et al., 
1988; Marni et al., 1988).
 Various models of NAFLD show altered mitochondrial morphology, 
impaired mitochondrial bioenergetics, increased mitochondrial peroxides 
and decreased ATP content. Although the increased expression of UCP-2 
in the livers of patients with fatty liver disease decreases ROS generation, it 
still compromises the capacity to address energy demands, which reflects 
impairment oxidative phosphorylation (Chavin et al., 1999). A possible 
cause for the loss of oxidative phosphorylation efficiency observed in fatty 
liver is the decreased ANT content. During I/R, oxidative phosphorylation 
activity is greatly exacerbated by fatty infiltration likely resulting from 
oxidative damage to lipid and proteins.
1.6 Protective strategies
 In the past few years, data from several experimental investigations 
suggested that different drugs could be useful to prevent and/or reduce 
damage associated with I/R. Given that fatty livers are considerably more 
susceptible to acute stressors, such as I/R, and knowing that the incidence 
of this pathology is deeply increasing, there is an urgent need to find 
strategies against I/R injury in fatty livers (Figure 1.14).
 Identification of the molecular mechanisms responsible for I/R 
injury allows focusing research on the genetic modulation of the involved 
pathways. This approach aims not only for a better knowledge of the 
mechanisms involved in IR injury, but also and especially for potential 
therapeutic applications (Ke et al., 2006). In order to suppress the ROS 
burst in IR injury, adenovirus, liposomes or polyethyleneglycol were used 
to transfect superoxide dismutase and catalase enzymes (Banga et al., 
2005; Mari et al., 2002). Also the overexpression of Bcl-2 associated 
athanogene (BAG-1) and Bcl-2 using adenovirus has been tested to 
inhibit apoptosis (Selzner et al., 2003). These genetic tools have also been 
used to express some genes that provide cytoprotection, such as Heme 
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oxygenase-1 (HO-1), anti-inflammatory cytokine interleukin-13 (IL-13) and 
interleukin-1 receptor antagonist (IL-1Ra) (Coito et al., 2002; Harada et al., 
2002; Pachori et al., 2004). In addition, some authors have tried strategies 
which purpose is the amelioration of the hepatic inflammatory response 
to I/R, namely by inhibiting NFκB pathway through adenoviral transfection 
of a mutant inhibitor of kB-α (IκB-α) (Banga et al., 2005; Lentsch et 
al., 2000).    Supression of Fas by siRNA was shown 
to inhibit cellular apoptosis in vivo and may consequently mitigate I/R 
injury in rat liver transplantation (Li,X et al., 2007). Nevertheless, a gene 
therapy approach brings also some difficulties; for example, vector toxicity, 
problems regarding transfection efficiencies and protein expression at the 
appropriate time and site.
 
Figure 1.14- Therapeutic strategies against Ischemia / Reperfusion 
injury. Preconditioning and Postconditioning are endogenous adaptive mechanism of 
protection that can be actived surgical or pharmacologically. Indirubin-3’oxime, Diazoxide, 
CGS 21680, Trimetazidine (TMZ), 5-amino-4-imidazole carboxamideriboside (AICAR), 
Losartan, S-nitroso-N-acetylcysteine (SNAC) are some examples of compounds which 
may be used as pharmacological therapeutic.
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injury. Although the perfect drug does not exist at the moment, there 
are some synthetic and natural derivatives presenting metabolic and/or 
antioxidative effects that can directly or indirectly improve hepatic function 
after I/R (Varela et al., 2010). A drug that reduces I/R injury associated 
with hepatic surgery and transplantation would constitute a major medical 
breakthrough. Natural products are important therapeutic tools in several 
clinical areas since they are viable sources and resources for drug 
discovery and development. It is possible to relate the chemical structures 
of the pharmacological drugs and natural derivatives to their correspondent 
protective action against I/R injury. This can be of interest in order to 
create new natural remedies in I/R therapy. Also, brief intermittent periods 
of ischemia and reperfusion, before I/R, termed ischemic preconditioning 
(IPC), are also protective. One exciting new development with important 
clinical implications is the observation that protection can be initiated by 
the activation of signaling pathways after reperfusion. 
 It is a procedure based on the induction of intracellular protective 
reactions by the application of brief periods of ischemia and reperfusion, 
at the immediate onset of reperfusion. From the first report of Zhao et al., 
several studies have demonstrated that in other organs, such as heart, 
brain, kidney and liver, the method of postconditioning seems to be simple 
to apply and potentially effective in reducing reperfusion injury. 
 Zeng et al. shows that in the liver transplantation model, 
postconditioning (treatment immediately with six cycles of 60s of 
reperfusion and 60s of ischemia at the onset of reperfusion) can improve 
the liver function, reduce oxygen-free radicals production and cytokines 
expression, and leads to increased expression of HO-1 in liver.
1.6.1 – Preconditioning (PC)
 Ischemic preconditioning refers to an endogenous adaptive 
mechanism of protection against a sustained ischemic insult by exposure 
to an initial, brief ischemic stimulus followed by a period of reperfusion. 
This phenomenon was first described in heart and brain and only later was 
evidenced in other organs including the liver. 
 Administration of chemical agents is another way to achieve PC, 
which is known as pharmacological PC. The pathways by which PC and 
compounds afford protection, usually converges on the activation of 
signaling cascades that involves phosphoinositide 3-kinase (PI3K), protein 
kinase C (PKC), nitric oxide synthase (NOS), glycogen synthase kinase-
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3β (GSK-3β) and protein kinase B (Akt). Although the precise targets and 
mechanisms are still unclear, mitochondria are a major target of these 
protective events.
 PC strategy may find new surgical and/or pharmacologic therapeutic 
applications in complex hepatic resections in livers with underlying disease 
or steatosis, as well as in liver transplantation. PC may be beneficial for 
both patients receiving either steatotic or non-steatotic grafts, although 
biological mechanisms mediating PC effects can be different, as well as 
pharmacologic treatments (Peralta et al., 1999).
1.6.1.1  Molecular basis and cellular mechanisms 
 The precise mechanism of PC-induced hepatoprotection is 
unknown but it is likely to be a receptor-mediated process, related with 
preservation of energy metabolism. IPC occurs in a biphasic pattern: an 
early phase, which wanes for several hours (early IPC), and involves direct 
modulation of cell function as a result of accumulation of adenosine and/
or nitric oxide and activation of PKC, and a late phase (late IPC), which 
requires synthesis of multiple stress-response proteins, including heat 
shock proteins (HSP), NOS and HO-1 (Schulz et al., 2001; Takano et al., 
1998; Massip-Salcedo et al., 2006).
 There is an indication that PC prevents I/R-induced mitochondrial 
dysfunction by preserving the integrity of mitochondrial oxidative 
phosphorylation and increasing the resistance to MPT induction. 
Preservation of mitochondrial function by IPC favors the restoration of 
sufficient energetic levels in injured hepatocytes may thus be correlated 
with better post-transplantation outcomes (Lanir et al., 1988; Marni et al., 
1988). A recent study has shown that induction of autophagy by PC limits 
necrosis in human recipients of fatty liver grafts, resulting in a decreased 
incidence of rejection episodes (Degle Esposti et al., 2011). It is suggested 
that the trigger of autophagy switches off necrosis in fatty livers subjected 
to I/R, by preserving ATP content and decreasing ROS generation.
 Several mediators have been proposed to play a critical role in 
the protective pathways activated by PC, including adenosine, nitric oxide, 
oxidative stress, some HSP and TNF–α (Peralta et al., 1999; Carini et al., 
2003; Morihira et al., 2006; Bolli et al., 2000; Teoh et al., 2003) (Figure 
1.15).
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 Adenosine is a major homeostatic modulator in eukaryotic tissues 
since it is produced according to tissue stress or workload and protects from 
subsequent injury by decreasing metabolic rate. In particular, adenosine 
receptors have been shown to be responsible for the phenomena of PC in 
tissues such as the brain, heart or liver. 
 Adenosine receptors are G-protein-coupled receptors and there 
are 4 subtypes: A1, A2A, A2B and A3. The A1 and A3 receptors are coupled to 
Gi/Go proteins and A2A and A2B are linked to Gs proteins. 
 All these receptors have been proved to be cardioprotective against 
ischemia/reperfusion-induced injury, even though different receptor 
subtypes may be related to distinct signaling pathways. A1 adenosine 
receptors were also shown to protect lung and brain from this injury.
 In the liver, Peralta et al. identified a protective pathway in which 
adenosine-induced protection involves the induction of the enzyme nitric 
oxide synthase. The protective effect of adenosine receptors has been 
demonstrated by the administtration of agonists and antagonists. The 
agonists reproduced the beneficial effects of PC and the antagonists 
suppress them. Several studies show the intervention of intracellular 
messengers on the protective effect of PC. PKC, AMP-dependent protein 
kinase (AMPK), p38, and some translator’s signs and transcription factors 
activated by the release of adenosine are involved. The release of adenosine 
into the extracellular space causes the activation of A2 receptors coupled 
to G protein. These activate a membrane phospholipase (phospholipase 
CorD) that generates inositol triphosphate (inducing the release of Ca2+ 
from the intracellular mitochondrial reserves) and diacylglycerol (DAG), 
activates PKC.
 PKC has an important role in cellular protection and regulates 
some biological processes such as metabolism, ions transport and 
gene expression. Several studies refer to this kinase as the head of the 
protective effects of PC in the liver (Inagaki et al., 2006). The activation of 
PKC promotes the phosphorylation of various molecules such as tyrosine 
kinase and mitogen-actived protein kinase (MAPK), including MAPK p38. 
The associated increase in the tolerance of hepatocytes and endothelial 
cells to I/R injury may thus imply the entry of these cells into cell cycle, 
promoting hepatic regeneration. The PKC activation can induce the 
activation of many transcription factors, such as NFκB, probably the main 
responsible for the protective effects during the late phase.  
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Increased synthesis of proteins such as HSP have been proposed as 
effectors of the protective effect of PC. 
Figure 1.15-  Preconditioning pathway. The release of adenosine causes the 
activation of G protein-coupled receptors and stimulation of phospholipase C, producing 
diacylglycerol that activates Protein kinase C (PKC). PKC actives the MAP p38 that 
promotes hepatic regeneration.PKC activation can also induce the activation of NFκB that 
is responsible for the protective effects during the late phase of preconditioning, through 
the activation of signal activator of transcription 3 (stat-3) or through synthesis of proteins 
such as heat shock proteins (HSP). HSP reduces the nuclear union of pro-inflammatory 
transcription factors and increases the antioxidant capacity of the cell. These effects may 
contribute to the reduction of TNF-alpha and attenuation of inflammatory response.PI3K/Akt 
pathway is activated by receptor tyrosine kinases, integrins, cytokine receptors, G protein 
coupled receptors and other stimuli that induce the production of phosphatidylinositol 3,4,5 
triphosphates (PIP) by phosphoinositide 3-kinase (PI3K). Activated Akt is released from 
the plasma membrane and targets substrates in the cytosol, nucleus, and mitochondria. In 
the mitochondria, Akt is responsible for the phosphorylation of glycogen synthase kinase-
3β (GSK-3β) on serine 9 thereby inhibiting GSK-3β and MPT induction, promoting cell 
survival. AKT also leads to enhanced activity of eNOS and augments NO.
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HSP70, HSP72, HSP73 and HO-1 (Ye et al., 2011).The induction of HSP 
reduces the nuclear union of pro-inflammatory transcription factors and 
increases the antioxidant capacity of the cells. Both effects may contribute 
to the reduction of TNF-α and attenuation of inflammatory response in 
preconditioned livers. PC can decrease the transcription of genes such as 
c-fos and c-jun that are involved in the development of hepatic I/R injury 
(Saito et al., 2001). On the other hand, the activation of NFκB could induce 
the activation of signal activator of transcription 3 (stat-3) implicated in 
hepatoprotection and cell proliferation. Diverse studies have showed that 
PC protects fatty liver from IR and maintains hepatic oxygenation, tissue 
perfusion, and mitochondrial redox state (Hafez et al., 2010).
 PI3K/Akt signaling to the mitochondria also plays a crucial role in 
the protection against cell death induced by I/R. Accumulation of PIP3 
following P activation, leads to recruitment of Akt to the membrane, 
where Akt is converted to the active form by phosphoinositide-dependent 
proteinkinase-1 (PDK1)-mediated phosphorylation at Thr308. Activated 
Akt is released from the plasma membrane and targets substrates in the 
cytosol, nucleus, and mitochondria (Kockeritz et al., 2006; Matsui et al., 
2005; Bijur et al., 2003). Ischemic and pharmacological PC, as discussed 
further on, enhances Akt phosphorylation and translocation to the 
mitochondria (Bijur et al., 2003). In the mitochondria, Akt phosphorylates 
GSK-3β on serine 9 (phospho-Ser9-GSK-3β ) and inactivates it. 
1.7 Objectives of this thesis:
 The main goal of this project was to define and approach protective 
strategies against I/R injury in fatty liver by an in vivo warm I/R protocol, 
with either lean or fatty livers, an approach allowing retrieving conclusions 
relevant for the distinct clinical settings. 
 Fatty livers cause an increased susceptibility to I/R injury, thus 
bearing additional risks of primary nonfunction subsequent to liver surgery 
or transplantation. There is an urgent need for strategies against I/R injury 
in fatty livers, due to the increased incidence of this pathology. 
 Defining IPC underlying mechanisms will allow drug targeting to 
induce the preconditioning response in fatty livers as a developing strategy 
to reduce hepatic injury observed in transplantation and hepatic resections. 
Understanding key aspects of mitochondrial dysfunction, is a necessary 
step towards the elaboration of new protective strategies against I/R injury, 
since mitochondria are a major target of the protective signalling cascades 
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induced by preconditioning, this is not surprising given their important 
role in the regulation of cell energetics and death, ROS, and calcium. 
Pharmacological modulation could maybe be improved by examining the 
mechanisms responsible for mitochondrial alterations in steatotic livers. 
 The hope of finding new surgical and pharmacological therapeutic 
applications provides a strong impetus to identify the mechanisms 
responsible for the failure of fatty livers ( Figure 1.16).
Figure 1.16 - Schematic representation relating fatty liver with I/R 
injury . Possible strategies to protect fatty livers by reducing preconditioning as proposed 
work.
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2.1 Materials
 Indirubin-3’-oxime, NAD+ and 2’,7’-dichlorodihydrofluorescein 
diacetate (H2DCFDA) were purchased from Sigma Chemical Co (St. 
Louis, MO). 8-cyclopentyl-1,3-dipropulxanthine (DPCPX) and 2-chlloro-
N6-cyclopentyladenosine (CCPA) and were purchased from Tocris 
Biosciences (United Kingdom). Indirubin-3’-oxime and H2DCFDA were 
dissolved in DMSO, all others in saline solution.
 ANT crosslinked to agarose beads was obtained from MitoSciences. 
WesternDot 625 goat anti-rabbit and goat anti-mouse, Ca2+-Green, Tau 
protein and Tau [pS199] phosphoELISA kit and TNF-alpha ELISA kit 
were purchased from Invitrogen (Invitrogen,UK). SIRT3 direct fluorescent 
screening assay kit was purchased from Cayman Chemical Company.  
 The ALT, AST and LDH kits obtained from Hospitex Diagnostics.
All other reagents and chemicals used were the highest grade of purity 
commercially available.
2.2 Animals
 Seven-weeks-old male Wistar and Zucker fatty rats were obtained 
from Charles River (France). Upon arrival, animals were allowed 7 days to 
acclimatize (room temperature was 22-24º C) and housed under controlled 
light (12h-light cycle) and humidity (moisture 50-60%) conditions with 
free access to food and water. All animals received care according to 
institutional guidelines.
2.3 Hepatic ischemia/ reperfusion
 Animals were weighed and anaesthetized with ketamine (50 mg/
kg) and chlorpromazine (50 mg/kg) by intramuscular injection. A model of 
partial ischemia (70%) was used in order to prevent mesenteric venous 
congestion by permitting portal decompression through the right and 
caudate lobes. After a midline laparotomy, the hepatic artery and portal 
vein to the left and median liver lobes were occluded. Reperfusion was 
initiated by removal of the clamp. 
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Figure 2.1- Hepatic ischemia. Model of partial ischemia (70%): the hepatic artery 
and portal vein to the left and median liver lobes were occluded.
2.4 Experimental Groups:
 • Ischemic preconditioning and DPCPX and CCPA 
administration
 In preconditioning group (IPC), before I/R, brief (5 minutes) ischemic 
episodes were applied, and followed by a 10 min period of reperfusion. 
In the treated groups, DPCPX and CCPA, 0,5mg/Kg compound was 
administered intraperitonially 2 hours before IPC or IR, respectively. 
Both control (sham-operated) and I/R (subjected to ischemia/reperfusion 
without treatment) animals were injected with an equal volume of saline 
buffer also for 2 hours. 
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Figure 2.2 - Schematic representation of the experimental protocols 
of I/R and DPCPX and CCPA treatment. In the treated group, antagonist 
(DPCPX) and agonist (CCPA) were administered intraperitonially 2 hours before ischemic 
preconditioning (IPC) or ischemia/reperfusion (I/R), respectively. Ctl (sham-operated), I/R 
and IPC animals were injected with an equal volume of vehicle (saline solution) also for 
2h. In preconditioning group (IPC), before I/R, brief (5 minutes) ischemic episodes were 
applied, and followed by a 10 min period of reperfusion. A model of partial ischemia (70%) 
was used during 2h. Reperfusion was initiated by removal of the clamp (16h).
 • Indirubin-3’-oxime administration
 In the treated group, 1 µM indirubin-3’-oxime (Ind) was administered 
in the hepatic artery 30 min before ischemia. Both control (sham-operated) 
and I/R (subjected to ischemia/reperfusion without Ind treatment) animals 
were injected with an equal volume of vehicle (DMSO) also for 30 min. 
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of I/R and indirubin-3’-oxime treatment in lean and fatty livers. In the 
treated group, 1 µM indirubin-3’-oxime (Ind) was administered in the hepatic artery 30 min 
before ischemia. Both Ctl (sham-operated) and I/R  animals were injected with an equal 
volume of vehicle (DMSO) also for 30 min. A model of partial ischemia (70%) was used 
during 2h30 in lean livers and 2h in fatty livers. Reperfusion was initiated by removal of the 
clamp (12h or 16h).
 • NAD+ administration 
 In the treated group, 50mg/Kg NAD+ was administered in the 
hepatic artery 30 min before ischemia. Both control (sham-operated) and 
I/R (subjected to ischemia/reperfusion without NAD+ treatment) animals 
were injected with an equal volume of saline solution also for 30 min 
before. 
 
Figure 2.4- Schematic representation of the experimental protocols 
of I/R and NAD+ treatment. In the treated group, NAD+ was administered in the 
hepatic artery 30 min before ischemia. Both Ctl (sham-operated) and I/R animals were 
injected with an equal volume of vehicle (saline solution) also for 30 min. A model of partial 
ischemia (70%) was used during 2h. Reperfusion was initiated by removal of the clamp 
(12h).
 All procedures were conducted according to the guidelines for the 
care and use of laboratory animals approved by our Institution.
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2.5 Plasma biochemical determination 
 Following reperfusion, animals were killed by decapitation. Blood 
were collected and centrifuged at 5000 rpm for 5 min. Plasma samples 
were collected and enzymatic determinations of ALT, AST and LDH 
performed using commercial kits. 
2.6 TNF-α
 Plasma samples were diluted in Incubation Buffer and Tumor 
Necrosis Factor- α (TNF-α) was determined using commercial kit (Rt 
TNF-α ELISA, Invitrogen) according to the manufacturer’s recommended 
protocol.
2.7 Preparation of liver mitochondria
 Mitochondria were isolated from liver rats by conventional methods 
(Gazzoti et al.,1979), with slight modifications (Palmeira et al., 1994). All 
isolation material was kept on ice during the isolation procedure. Briefly, 
animals were and the liver was immediately excised and finely minced in 
an ice-cold homogenization medium. Homogenization medium contained 
250mM sucrose, 10mM HEPES (pH 7.4), 0.5mM EGTA, and 0.1% fat-
free bovine serum albumin (BSA). The minced blood-free tissue was 
then homogenized with a tightly fitted homogenizer (Teflon: glass pestle). 
The homogenate was then centrifuged at 3000 rpm for 10 min at 4°C. 
The resulting supernatant was spun at 10 000 rpm for 10 min (4°C), to 
pellet mitochondria which were resuspended with a paintbrush in a final 
washing medium (250mM sucrose, 10mM HEPES (pH 7.4)). The resulting 
supernatant of first centrifuge at 10 000 rpm was used as the cytosolic 
fraction. The mitochondrial pellet was then washed twice, suspended in the 
washing medium, and immediately used. Protein content was determined 
by the biuret method (Gornall et al., 1949), calibrated with BSA. 
2.8 Measurement of mitochondrial oxygen consumption
 Oxygen consumption of isolated mitochondria was polarographically 
determinated with a Clark oxygen electrode (Estabrook, 1967) connect to a 
suitable recorder, through an oxygen electrode control system (YSI model 
5300). The electrode was calibrated as previously described (Rickwood et 
al., 1987). Mitochondria (1 mg) were suspended under constant stirring, 
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rotenone. The succinate, as respiratory substrate (5 mM), was added. 
 State 3 respiration was induced by adding 200 nmol adenosine 
diphosphate (ADP). The oxygen consumption was also measured in the 
presence of 1 μM carbonylcyanide-p-trifluoromethoxyphenylhydrazon 
(FCCP). 
 The respiratory control ratio (RCR) was calculated taking into 
account oxygen consumption rates during state 3 (following ADP 
phosphorylation) and subsequent state 4 respiration. State 3 and state 4 
respiration rates are expressed as nmol oxygen per minute per mg protein. 
The ADP/O ratio was calculated as the nmol of ADP phosphorylated by 
natom oxygen consumed (Chance and Williams, 1956).
 The specific experimental procedures in each section are described 
in the legends to the figures.
2.9 Mitochondrial membrane potential (ΔΨ) measurements
 The mitochondrial transmembrane potential, was estimated 
using an ion- selective electrode to measure the distribution of 
tetraphenylphosphonium (TPP+), according to previously established 
methods (Kamo et al., 1979; Palmeira et al., 1994). 
TPP+ is a membrane-permeable cation that accumulates electrophoretically 
in mitochondria upon energization. The reference electrode was Ag/ AgCl2 
(model MI 402, Microelectrodes Inc, Bedford, NH). Both electrodes were 
connected to an adequate potentiometer (Jenway pH meter 3305). The 
signal was delivered to a Kipp and Zonen recorder via a manufactured 
potential compensatory box (Madeira, 1975). Reactions were carried 
out at 25 ºC, in a temperature-controlled water-jacketed chamber with 
magnetic stirring. Mitochondria (1 mg) were suspended in 1 ml of standard 
respiratory medium (130 mM sucrose, 50 mM KCl, 5 mM MgCl2, 5 mM 
KH2PO4, 50 μM EDTA, 5 mM HEPES (pH 7.4), and 3 μM rotenone) 
supplemented with 3 µl TPP+ and were energized by adding succinate to 
a final concentration of 5 mM. 
 The electrode was calibrated with TPP+, assuming Nerstian 
distribution of the ion across the synthetic membrane. ΔΨ, which is 
expressed in millivolts (mV), was calculated using the equation ΔΨ = 59 
log (v/V) –59 log 10ΔE/59 – 1) (Muratsugu et al., 1977; Kamo et al., 1979). 
v, V, and ΔE represent the mitochondrial matrix volume, the volume of 
the incubation medium and the potential deflection, respectively. A matrix 
volume of 1.1 μl/mg protein was assumed (Masini et al., 1984). 
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 In our experiments, we didn’t take into account the “passive” binding 
of TPP+ to the mitochondrial membrane, since we were interested in relative 
alterations in the potential rather than absolute values. Consequently, we 
predict that the obtained ΔΨ values were overestimated. 
 The specific experimental procedures in each section are described 
in the legends to the figures.
2.10 Titration with carboxyatractyloside (CAT)
 Carboxyatractyloside (CAT) is a highly selective inhibitor of cytosolic 
side-specific ANT that causes stabilization of the c conformation of ANT 
leading to MPT induction and loss of mitochondrial membrane potential.
 The mitochondrial transmembrane potential, was estimated as 
described in 2.9. Energized mitochondria were titrated with 0,02 nmol 
carboxyatractyloside (CAT). Successive additions of CAT aliquots before 
ADP addition, progressively block a higher number of ANT units contributing 
to the observed decreased number of phosphorylation cycles induced by 
successive ADP additions.
2.11 Determination of ATP content 
 Adenosine nucleotide extraction was performed as follows. Tissue 
samples (20 mg) were pulverized with a mortar and pestle in liquid N2 
and homogenized in ice-cold 25 μl of KOH buffer (KOH 2.5M, K2HPO4 1.5 
M), on ice. For mitochondria were added 10ul KO buffer. Samples were 
vortexed and centrifuged at 14 000 g for 2 min., at 4 ºC. The supernatants 
were collected and dissolved in 100 μl of K2HPO4 1 M. pH was adjusted to 
7 and samples were frozen at -80 ºC for posterior use. 
 Adenosine nucleotides were separated by reverse-phase high 
performance liquid chromatography as previously described (Stocchi et 
al., 1985) or were quantified with an ATP bioluminescent assay kit (Sigma-
Aldrich) on a Victor 3 plate reader.
2.12 Evaluation of reactive oxygen species (ROS) generation
 ROS were determined fluorometrically using a Perkin-Elmer 
VICTOR 3 plate-reader fluorometer, with an excitation wavelength 485 
nm and an emission wavelength 538 nm, corresponding to the excitation 
and emission wavelengths of H2DCFDA (Zhou et al.,2001). Isolated 
mitochondria (1 mg/ml) were suspended in standard respiratory medium 
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DS (130 mM sucrose, 50 mM KCl, 5 mM MgCl2, 5 mM KH2PO4, 50 μM EDTA, 
5 mM HEPES (pH 7.4), and 3 μM rotenone) loaded with 50 µM H2DCFDA 
(in DMSO) for 15 min at 25ºC. After incubation, the samples were spun 
at 3000 rpm for 3 min and the resultant pellet was suspended in medium. 
200 µl of the mitochondrial suspension were loaded into a 96-well plate 
and the fluorescence monitored. After basal fluorescence measurement, 
antimycin A was added to all preparation to block complex III of the 
mitochondrial chain, to induce maximal ROS generation.The results were 
expressed are expressed as relative fluorescence units (RFUs).
2.13 Measurement of the mitochondrial permeability transition (MPT)
 Mitochondrial swelling was estimated by changes in light scattering, 
as monitored spectrophotometrically (Heλiosy spectrophotometer, Thermo 
ElectronCorporation) at 540 nm (Palmeira and Wallace, 1997). The 
experiments were started by the addition of mitochondria (1 mg) to reaction 
medium (200 mM sucrose, 10 mM Tris-MOPS (pH 7.4), 1mM KH2PO4, 5 
mM succinate and 10 uM EGTA supplemented with 3 µM rotenone and 
5 mM succinate) (final volume 2ml). Reactions were carried out at 25ºC 
and MPT induced with Ca2+. The specific experimental procedures in each 
section are described in the legends to the figures.
2.14 Measurement of mitochondrial calcium fluxes 
 The accumulation and release of calcium by isolated rat liver 
mitochondria were determined using a calcium-sensitive fluorescent dye, 
Calcium Green-5 N (Rajdev and Reynolds, 1993). The reactions were 
carried out at 25ºC, in 2 ml of MPT medium (200 mM sucrose, 10 mM Tris-
MOPS (pH 7.4), 1mM KH2PO4, and 10  EGTA) supplemented with 3 µM 
rotenone. Free calcium was monitored with 100 nM Calcium Green 5-N.
Mitochondria (1 mg) were energized with succinate (5 mM) after the 
addition of 15 nmol Ca2+. Fluorescence was recorded continuously using 
a Perkin-Elmer VICTOR 3, with excitation and emission wavelengths 
of 485 and 535, respectively. Calcium fluxes are expressed as relative 
fluorescence units (RFUs). 
2.15 ATPase activity
 ATPase activity of the mitochondrial ATP shynthase complex 
(or complex V) was determined spectrophotometrically at 660 nm, in 
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association with ATP hydrolysis (Varela et al., 2008). The reaction was 
carried out at 37 °C, in 2 ml reaction medium (100 mM NaCl, 25 mM KCl, 
5 mM MgCl2, and 50 mM HEPES, pH 7.4). After the addition of freeze-
thawed mitochondria (0.25 mg), the reaction was initiated by adding 2 mM 
Mg2+ -ATP, in the presence or absence of oligomycin (1 ug /mg protein) 
protein). After 10 min, adding 1 ml of 40% trichloroacetic acid stopped the 
reaction. 2 ml of ammonium molybdate plus 2 ml dH2O were then added 
to 1 ml of supernatant. ATPase activity was calculated as the difference in 
total activity and activity in the presence of oligomycin.
2.16 Western blotting analysis
 Tissue homogenates (10 μg), mitochondrial pellets (25 μg) or cy-
tosolic fractions (25 μg) were lysed in ice-cold lysis buffer supplemented 
with a cocktail of protease, phosphatise and acetilase inhibitors. 
Table 2.1 List of utilized antibodies for Western blot, source and utilized 
dilution. 
´
Antibody Specie Dilution Supplier Reference 
Acetilated lysine rabbit 1:100 Cell Signalling 9441 
Actin mouse 1:5000 Sigma A 5441 
Akt rabbit 1.500 Cell Signaling 9272 
ANT mouse 1:500 MitoSciences MSA02 
Bax rabbit 1:1000 Cell Signaling 2772 
Bcl-2 rabbit 1:1000 Cell Signaling 2870 
Cleaved caspase-3 rabbit 1:500 Cell Signaling 9664 
Cyp D mouse 1.1000 MitoSciences MSA04 
Cytochrome-c mouse  1:5000 BD Biosciences 556433 
COX IV mouse 1:5000 MitoScience MS407 
LC3 rabbit 1:1000 Sigma L7 543 
phospho-Ser9-GSK-3β rabbit 1:100 Cell Signalling 9272 
phospho-Thr308-Akt rabbit 1:100 Santa Cruz SC 16646 
phospho-threonine mouse 1:100 Qiagen 37420 
GSK-3β rabbit 1:500 Cell Signalling 9315 
HIF-1 α rabbit 1.1000 Santa Cruz SC 10790 
HSP70 mouse  1:1000 Santa Cruz SC 137210 
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SDS-polyacrylamide 15% gel and transferred to a PVDF membrane. 
Membranes were blocked with 5% nonfat milk and incubated with anti-
body overnight at 4ºC. Immunodetection was performed with Western-
Dot 625 goat anti-rabbit or goat anti-mouse western blot kits. Membranes 
were imaged using a Gel Doc instrument and the densiometric analysis 
was performed with the ImageJ software. (Bio-Rad Laboratories, Hercu-
les, CA).
2.17 Evaluation of GSK-3β activity
 GSK-3β activity was evaluated by promoting the in vitro reaction of 
phosphorylation of exogenous Tau by GSK-3β present in liver homogenates. 
To promote the reaction (100 µl), 250 ug of liver homogenates were 
incubated with 10 ng/ml exogenous Tau and 200 µM ATP for 1 hr at 30ºC. 
Phosphorylated Tau was detected using a Tau[pS199] phosphoELISA kit. 
Lithium chloride (10 mM) was used as an inhibitor of GSK-3β. Samples 
and standard dilutions were read in a Perkin-Elmer VICTOR 3 plate-reader 
at 450 nm. 
2.18 Measurement of sirtuin-3 activity 
 Sirtuin-3 activity was measured in mitochondrial extracts using 
the SIRT3 direct fluorescent screening assay kit (Cayman Chemical 
Company). A sirtuin-3 peptide substrate that is acetylated and fluorescently 
labeled is mixed with the mitochondrial extract (25 μg) at 37º C for 45 min, 
25 μl of developer was added and following 30 minutes of incubation. 
Fluorescence intensity was measured on a Perkin-Elmer VICTOR 3, with 
excitation and emission wavelengths of 340 and 440, respectively. 
2.19 Myeloperoxidase (MPO) activity
 MPO activity was determined by spectrophotometrically using 
tetramethylbenzidine (TMB) as substrate. The reaction mixture consisted 
of 40% phosphate-buffered saline (PBS), 8% DMFA, 0.3 mM H2O2, 80 
mM phosphate buffer (pH 5.4), and 1.6 mM TMB in a total volume of 1 ml. 
The mixture is incubated at 37 °C for 3 min and the reaction is initiated 
by the addition of 20 μl of homogenate tissue containing 40 μg protein. 
The reaction was terminated after 3 min by addition of sodium acetate 
buffer (200 mM, pH 3.0). The rate of MPO-catalyzed oxidation of TMB was 
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followed by recording the increase of absorbance at 655 nm at 37 °C. We 
measured the absorbance change per minute, and one enzyme unit was 
defined as the amount of enzyme producing one absorbance change per 
minute under assay conditions. Enzyme activity was calculated as units 
per milligram of protein. 
2.20 Immunoprecipitation of ANT and detection of cyclophilin D
 ANT was immunocaptured from mitochondrial extracts using 
monoclonal antibodies to ANT crosslinked to agarose beads . Mitochondria 
(1mg) collected after Ca2+ -induced MPT were resuspended in 300 μl of IP 
buffer (250 mM sucrose, 20 mM MOPS, 10 mM Tris, 0.5% Triton, protease 
Inhibitor cocktail, pH 7.2) and freeze in liquid N2. Samples (250 μl) were 
incubated overnight at 4ºC with 8 μl of agarose beads. Beads were washed 
four times with ice-cold buffer. Elution of immunocomplexes with Laemmli 
sample buffer and heat-denaturation were performed immediately prior 
to separation on 15% SDS-polyacrylamide gels and electroblotted onto 
PVDF membranes. The western blots were then probed with antibody 
against CypD.
2.21 Immunoprecipitation of ac-Lys and detection of cyclophilin D 
 Mitochondria (2mg) were resuspended in a 500 μl IP buffer (250 
mM sucrose, 20 mM MOPS, 10 mM Tris, 0.5% Triton, protease Inhibitor 
cocktail, pH 7.2) and lysed by sonication. CypD antibody was used for 
immunoprecipitation of endogenous CypD. Immunoprecipitated material 
was washed four times for 15 min each in low stringency lysis buffer, and 
immune complexes were resuspended in SDS-PAGE buffer. The western 
blots were developed using antibody against acetylated lysine, then 
stripped and reprobed with antibody against anti-CypD. 
2.22 Immunoprecipitation of phospho-Thr and detection of cy-
clophilin D 
 
Mitochondria (2mg) were resuspended in a 500 ul IP buffer (250 mM 
sucrose, 20 mM MOPS, 10 mM Tris, 0.5% Triton, protease Inhibitor 
cocktail, pH 7.2) and lysed by sonication. CypD antibody was used for 
immunoprecipitation of endogenous CypD. Immunoprecipitated material 
was washed four times for 15 min each in low stringency lysis buffer, and 
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The western blots were developed using antibody against phosphorylated 
threonine, then stripped and reprobed with antibody against anti-CypD .
2.23 Statistic analyses 
 Data are presented as mean ± S.E.M and were obtained from five 
different experiments. Statistical significance was determined using one-
way ANOVA followed by Bonferroni post hoc test. A value of P<0.05 was 
considered as statistically significant. 
81
82
83
84
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
RE
SU
LT
S:
 A
DE
NO
SI
NE
 A
1 R
EC
EP
TO
RS
 IN
 P
RE
CO
ND
ITI
ON
IN
G
3.1
85
ADENOSINE A1 RECEPTORS AS REGULATORY ELEMENTS IN THE 
RECOVERY OF MITOCHONDRIAL FUNCTION INDUCED BY HEPATIC 
PRECONDITIONING
Abstract
 Preservation of energy production in mitochondria is a key 
determinant for recovery following ischemia/reperfusion.
Activation of adenosine receptors has been shown to be involved in the 
protective effect of ischemic preconditioning against I/R-induced injury in 
tissues such as the brain or heart. However, direct evidence that adenosine 
receptors preserve the efficiency of oxidative phosphorylation in conditions 
of hepatic I/R is still missing.
 In this study, we evaluated the role of adenosine receptors 
in preconditioning in the liver by comparing the extent of injury upon 
preconditioning in the absence and in the presence of selective A1 
receptor antagonists (DPCPX). We also explored the potential of perfusion 
with selective A1 receptor agonists (CCPA) to attempt a pharmacological 
preconditioning in vivo. Wistar rats were subjected to 120 min of 70% 
warm ischemia and 16 hrs of reperfusion (I/R). In preconditioning group 
(IPC), before I/R, brief (5 minutes) ischemic episodes were applied, and 
followed by a 10 min period of reperfusion. In the treated groups, DPCPX 
and CCPA, 0,5mg/Kg compound was administered intraperitonially 2 
hours before IPC or IR, respectively.  
 PC (ischemic and pharmacological) decreased blood serum alanine 
aminotransferase , aspartate aminotransferase, lactate dehydrogenase 
and tumor necrosis factor- α plasma levels, comparatively to I/R livers. 
Administration of DPCPX abolished IPC effects while activation of A1 
receptors by CCPA mimicked the beneficial action of IPC. Furthermore, IPC 
and CCPA livers displayed improved OXPHOS with higher state 3 rates 
and RCR, as well as increased ATP content and decreased lag phase. 
The susceptibility to mitochondrial permeability transition (MPT) and the 
rate of ROS generation was higher in I/R livers, but prevented by both IPC 
and CCPA. Titration with carboxyatractyloside (CAT), a selective inhibitor 
of cytosolic side-specific adenine nucleotide translocase, showed that less 
CAT was needed to completely abolish repolarization after phosphorylation 
in I/R livers, but not in IPC or CCPA. DPCPX administration abrogated IPC 
effects .This impairment in the phosphorylative system was associated 
with a decrease in the mitochondrial content of GSK-3β phosphorylation 
at Ser9, the inactive form of GSK-3β. Both IPC and CCPA increased 
mitochondrial phospho-Ser9-GSK-3β, possibly due to a reduction in 
the affinity of ANT to CypD , thus suppressing the MPT and decreasing 
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 These results show that suppression of GSK-3β activity by Akt-
mediated Ser9-GSK-3β phosphorylation in the mitochondria is involved in 
the cytoprotective signaling mediated by receptors activation, preserving 
OXPHOS efficiency and preventing cell death.
3.1.1 Introduction
 I/R injury is a common clinical problem responsible, at least in 
part, for the morbidity associated with liver surgery under total vascular 
exclusion or after liver transplantation (Tsung et al., 2005). This has 
motivated a search for new approaches to reduce ischemic injury, 
propelled by the discovery of ischemic preconditioning. This endogenous 
adaptive mechanism of protection against a sustained ischemic insult is 
afforded by exposure to an initial, brief ischemic stimulus followed by a 
period of reperfusion (Yoshizumi et al., 1998, Koti et al., 2003) or by the 
administration of chemical agents, which is known as pharmacological 
preconditioning (Nakayama et al., 1999; Andraus et al., 2010).
 PC reduces the release of transaminases (Yoshizumi et al., 1998) , 
increases rat survival after liver transplantation (Yin et al., 1998), and even 
improves human hepatic functions after major liver surgery in patients 
subjected to 30 min of ischemia (Clavien et al., 2000). In livers, IP decreases 
liver injury after both warm and cold I/R (Arai et al., 1999; Centurion et 
al., 2007). Several mechanisms have been proposed for protection by 
IP, including activation of adenosine receptors (Peralta et al., 1999), 
increased nitric oxide production (Carini et al., 2003), activation of protein 
kinase C (Downey et al., 2004),HSP up-regulation of heat shock proteins 
(Ye et al.,2011) and increases of antioxidant capacity. Decrease tolerance 
to I/R injury is also related with the inability to restore energetic balance 
following I/R. IPC also prevents I/R-induced mitochondrial dysfunction 
suggesting that PC protects the integrity of mitochondrial OXPHOS and 
increases the resistance to mitochondrial permeability transition induction 
[5]. The precise mechanism of PC-induced hepatoprotection is unknown 
but it is likely to be a receptor-mediated process, related with preservation 
of energy metabolism (Lanir  et al.,1988; Marni et al., 1988).
 Adenosine is a major homeostatic modulator in eukaryotic tissues 
since it is produced according to tissue stress or workload and protects from 
subsequent injury by decreasing metabolic rate. In particular, adenosine 
receptors have been shown to be responsible for the phenomena of PC 
in tissues such as the brain, heart and liver (Liu et al., 1991,Peralta et 
87
al.,1999; Hu et al., 2012).
 Ischemic and pharmacological PC enhances Akt phosphorylation 
and translocation to the mitochondria (Bijur and Jope, 2003). In the 
mitochondria, Akt phosphorylates GSK-3β on serine 9 and inactivates it 
(Jope and Johnson, 2004). The mitochondrion is a platform of cell signaling 
and decision-maker of cell death, with multiple roles in the development 
of I/R injury (Di Lisa et al., 2003). Cell viability is compromised by energy 
deficiency due to impaired OXPHOS, increased generation of ROS, 
mitochondrial calcium overload and induction of the MPT. In response 
to cellular stresses, MPT induction abolishes mitochondrial membrane 
potential and compromises ATP generation. MPT induction can be 
suppressed by IPC and other interventions that increase phospho-Ser9-
GSK-3β (Juhaszova et al., 2004; Miura et al., 2009; Nishihara et al., 2007; 
Park et al., 2006; Xi et al., 2009). GSK-3β is an important regulator of 
cell function, including gene expression, cell cycle, survival and apoptosis 
(Kockeritz et al., 2006). Phospho-Ser9-GSK-3β in mitochondria physically 
interacts with the ANT upon reperfusion, which inhibits interaction of the 
ANT with CypD, elevating the threshold for MPT induction.
 Mitochondrial function has an essential key role in adenosine 
receptors-mediated effects, but the link between both is still to be discovered. 
A1 receptors may also be involved in the maintenance of mitochondrial 
membrane potential and sensitivity to pro-oxidant stressors, acting as 
determining mitochondrial vulnerability factors (Alba et al., 2010). The 
present study was designed to identify mitochondrial downstream targets 
involved in hepatic PC protection activated by A1 receptors. Analysis of 
mitochondrial OXPHOS and MPT susceptibility shows that activation of 
A1 receptors protects the liver by targeting the MPT through inhibition of 
GSK-3β and modulating mitochondrial bioenergetics.
3.1.2  Results
3.1.2.1 Plasma markers of liver injury:
 
 Analysis of serum levels of AST, ALT and LDH showed that warm 
I/R induced liver injury. IPC and CCPA administration before ischemia 
were effectives in reducing plasma levels of markers of liver injury. Such 
as in the I/R group, AST, ALT and LDH levels were increased in DPCPX 
group (Figure 3.1.1). 
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Figure 3.1.1 The effects of PC on plasma levels of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and 
lactate dehydrogenase (LDH). Plasma samples were collected and enzimatic 
determinations of alanine aminotransferase (ALT) (A), aspartate aminotransferase (AST) 
(B) and lactate dehydrogenase (LDH) (C) performed using commercial kits. Data are 
means ± S.E.M of experiments performed with six animals/group. * Indicates statistically 
significant difference (P<0.05) versus Ctl, # indicates statistically significant difference 
versus I/R, & indicates statistically significant difference versus IPC, $ indicates statistically 
significant difference versus DPCPX.
 Since TNF-α, a proinflammatory cytokine, has the role to start 
and perpetuate a later secondary inflammatory phase, causing further 
hepatic damage, TNF-α concentration in plasma was determined. Figure 
3.1.2 shows that it was significantly higher in the I/R group than the other 
conditions.
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Figure 3.1.2  The esffects of PC on TNF- α levels. Plasma samples were 
collected and TNF- α was measure using commercial kits. Data are means ± S.E.M of 
experiments performed with six animals/group. * Indicates statistically significant difference 
(P<0.05) versus Ctl, # indicates statistically significant difference versus I/R, & indicates 
statistically significant difference versus IPC, $ indicates statistically significant difference 
versus DPCPX.
             
3.1.2.2 HSP70, Bcl-2 and Cleaved caspase-3 content:
 In I/R animals, there was a higher content in cleaved caspase-3, 
as evaluated by western blotting in hepatic tissue homogenates, as well 
as a decrease in the content of the anti-apoptotic Bcl-2. IPC and CCPA 
livers showed a higher content in Bcl-2 and decreased cleaved caspase-3 
in contrast to I/R animals.
 Up-regulation of HSPs has been proposed as a mechanism for 
PC protection (Ye et al., 2011). Specifically, HSP70 as an anti-apoptotic 
function associated with mitochondrial stabilization and decreased 
caspase-3 activity. HSP70 content was increased by IPC, while decreased 
by I/R. PC by CCPA administration did not alter HSP70 content (Figure 
3.1.3).
   
                     
   
Figure 3.1.3 HSP70 , Bcl-2 and cleaved caspase-3 content were 
evaluated  by western blotting. A representative blot from six independent 
experiments is shown.
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G 3.1.2.3 Mitochondrial membrane potential (ΨΔ) and oxygen 
consumption:
 
 Comparatively to mitochondria isolated from I/R animals, ΔΨ 
was significantly increased in preconditioned livers (IPC and CCPA). ΔΨ 
developed by mitochondria isolated from DPCPX livers was similar to that 
from I/R liver (Figure 3.1.4 A). 
                                  
 
Figure 3.1.4  The effects of PC on mitochondrial transmembrane 
potential (ΔΨ) in succinate-energized isolated liver mitochondria. 
ΔΨ was measured with a TPP+-selective electrode. Reactions were carried out in 1 
ml of reaction medium, supplemented with 3 μM rotenone and 1 mg of freshly isolated 
mitochondria, as described in materials and methods. Energization was achieved with 5 
mM succinate and phosphorylation induced by 200 nmol ADP. Data are means ± S.E.M of 
experiments performed with six animals/group. * Indicates statistically significant difference 
(P<0.05) versus Ctl, # indicates statistically significant difference versus I/R, & indicates 
statistically significant difference versus IPC, $ indicates statistically significant difference 
versus DPCPX.
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 DPCPX also decreased the capacity to establish ΔΨ after 
repolarization, conversely, CCPA increased mitochondrial ΔΨ after 
repolarization.
 The lag phase (time necessary for ADP phosphorylation) that 
precedes repolarization, was significantly increased by I/R comparatively 
to control, and preconditioning (IPC and CCPA) (Figure 3.1.4 B). This 
suggested that preconditioning was able to preserve the efficiency of 
mitochondrial phosphorylation. In the presence of DPCPX the effect of 
preconditioning was blocked, with the lag phase increased relatively to 
PC. 
 State 3 respiration (Figure 3.1.5 A) and the respiratory control 
ratio (RCR)  (Figure 3.1.5 B) were significantly decreased in mitochondria 
isolated from livers subjected to I/R, when compared to the control. 
Preconditioning (IPC and CCPA) prevented I/R deleterious action on 
mitochondrial respiration, increasing respiratory state 3 to a value similar 
to the Ctl group. 
 
Fig. 3.1.5 The effects of PC on state 3 (A) respiration and respiratory 
control ratio (RCR) (B).  Oxygen consumption of isolated mitochondria was 
polarographically determined with a Clark oxygen electrode. Mitochondria (1mg) were 
suspended under constant stirring, at 25ºC, in 1.4 ml of standard respiratory medium 
and energized by adding succinate to a final concentration of 5mM, 2 µM rotenone were 
previously added. State 3 respiration was induced by adding 200 nmol ADP. The oxygen 
consumption was also measured in the presence of oligomycin (0.5 µg/mg protein) and 
1 µM FCCP. Data are means ± S.E.M of experiments performed with six animals/group. 
* Indicates statistically significant difference (P<0.05) versus Ctl, # indicates statistically 
significant difference versus I/R, & indicates statistically significant difference versus IPC, 
$ indicates statistically significant difference versus DPCPX.
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 To further determine whether preconditioning is able to preserve 
mitochondrial ATP production upon I/R, endogenous ATP content was 
evaluated in isolated mitochondria (Figure 3.1.6 A) , energized mitochondria 
(Figure 3.1.6 B) and tissue (Figure 3.1.6 C). As shown in figure, ATP content 
was decreased in I/R and DPCPX animals associated with the observed 
decreased phosphorylation efficiency. PC and CCPA administration before 
ischemia were able to significantly preserve mitochondrial energy level.
 
Figure 3.1.6 The effects of PC on ATP content in isolated mitochondria 
(A), energized mitochondria (B) and tissue (C).  ATP content was evaluated 
by bioluminescent assay kit. Data are means ± S.E.M of experiments performed with six 
animals/group. * Indicates statistically significant difference (P<0.05) versus Ctl, # indicates 
statistically significant difference versus I/R, & indicates statistically significant difference 
versus IPC, $ indicates statistically significant difference versus DPCPX.
3.1.2.5 Generation of reactive oxygen species (ROS):
 
 A pathological increase on the endogenous production of ROS 
after I/R has been associated with decreased capacity for cell survival. In 
the presence of antimycin A, an inhibitor of the electron transport chain, 
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mitochondria isolated from I/R livers exhibited increased ROS generation, 
when compared to the control group. The generation of reactive oxygen 
species (ROS) was decreased in mitochondria isolated from PC and CCPA 
livers, demonstrating that preconditioning is able to control mitochondrial 
ROS generation induced by I/R and thus prevent the deleterious cycle of 
ROS-induced ROS generation (Figure 3.1.7).
        
                                   
Figure 3.1.7 The effects of PC on reactive oxygen species (ROS) 
generation. ROS were estimated fluorometrically using the probe H2DFDA (485 nm, 
538 nm). After basal fluorescence (white) measurement, antimycin A was added to all 
preparation (black) to block complex III of the mitochondrial chain, to induce maximal ROS 
generation.  Data are means ± S.E.M of experiments performed with six animals/group. 
* Indicates statistically significant difference (P<0.05) versus Ctl, # indicates statistically 
significant difference versus I/R, & indicates statistically significant difference versus IPC, 
$ indicates statistically significant difference versus DPCPX.
3.1.2.6 Interference with ADP-induced depolarization:
 The adenine nucleotide translocase (ANT) facilitates the one-
for-one exchange of extramitochondrial ADP for intramitochondrial ATP 
during oxidative phosphorylation. Assuming that ADP/ATP transport is 
the rate-limiting step in OXPHOS, depression of the ANT activity would 
impair the energy-producing capacity of the mitochondria. The observed 
increase in the lag phase induced by I/R could thus be related with an 
impaired activity of the ANT. In view of this, energized mitochondria 
were titrated with carboxyatractyloside (CAT).  CAT is a highly selective 
inhibitor of cytosolic side-specific ANT that causes stabilization of the 
c conformation of ANT and blocks the exchange of matrix ATP and 
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G cytoplasmic ADP. Matrix ADP is an important modulator of pore opening 
and acts by decreasing the sensitivity of the calcium trigger site to [Ca2+]; 
therefore CAT is also a mitochondrial permeability transition (MPT) inducer. 
Measuring mitochondrial membrane potential after ADP addition showed 
that, in mitochondria subjected to I/R, less CAT was needed to completely 
abolish repolarization after phosphorylation (Figure 3.1.8), indicating 
that I/R mitochondria already had ANT inhibition and thus an impaired 
phosphorylative system. PC (IPC and CCPA) prevented this effect of I/R.
                     
     A
                      
    B            
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Figure 3.1.8 Interference with ADP-induced depolarization. ΔΨ was 
measured with a TPP+-selective electrode. Energization was achieved with 5 mM succinate 
and phosphorylation induced by 200 nmol ADP. Energized mitochondria were titrated with 
carboxyatractyloside (CAT). Successive additions of CAT aliquots before ADP addition, 
progressively block a higher number of ANT units contributing to the observed decreased 
number of phosphorylation cycles induced by successive ADP additions, as well as to the 
observed increasing in lag phase corresponding to successive phosphorylation cycles. A) 
Ctl,violet; IR,blue; IPC green; B) IPC green, DPCPX,red; C) IR,blue CCPA, orange. The 
traces are representative of experiments performed with six independent mitochondrial 
preparations.
3.1.2.7 Mitochondrial permeability transition (MPT):
 In isolated mitochondria, the ability to tolerate a calcium challenge 
is an indicator of the susceptibility to the MPT. Thus, as mitochondria 
possess a finite capacity for accumulating calcium before undergoing the 
MPT, calcium-induced mitochondrial swelling was evaluated.
 Mitochondria isolated from I/R animals were more susceptible 
to undergo mitochondrial swelling induced by calcium, comparatively to 
control (Figure 3.1.9). In vitro pre-treatment of mitochondria isolated from I/R 
livers with the MPT inhibitor cyclosporine A (CyA), prevented mitochondrial 
swelling induced by calcium, demonstrating that the swelling was caused 
by MPT induction. IPC and CCPA increase the threshold to MPT induction. 
Acute treatment of livers, before preconditioning, with DPCPX increases 
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blocking IPC protective action. 
                              
Figure 3.1.9  The effects of PC on the susceptibility to the induction 
of mitochondrial permeability transition (MPT). Mitochondrial swelling was 
spectrophotometrically monitored at 540 nm. Experiments were started by the addition of 
mitochondria (1 mg) to 2 ml of reaction medium supplemented with 3 μM rotenone and 5 
mM succinate. MPT was induced with 20 nmol CaCl2. Cyclosporin A (CyA )(1 μM) , was 
added to the reaction medium prior to calcium addition. The traces are representative of 
experiments performed with six independent mitochondrial preparations
3.1.2.8 Mitochondrial calcium flux
 Since mitochondria isolated from PC livers decreased the 
susceptibility to calcium –induced swelling, mitochondrial calcium fluxes 
were evaluated. 
 Mitochondria isolated from control animals were able to accumulate 
the added calcium after energization with succinate and retained it during 
the entire time of the assay (Figure 3.1.10). Conversely, mitochondria 
isolated from animals subjected to I/R, displayed an immediate release of 
calcium into the media assay. Pre-treatment with CyA prevented calcium 
release, implying that increased calcium efflux from mitochondrial isolated 
from I/R animals was the result of MPT induction. PC and treatment with 
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CCPA before ischemia prevented mitochondrial calcium efflux after calcium 
challenge. On the other hand, in DPCPX mitochondria the accumulated 
calcium was early released, demonstrating the increased susceptibility to 
a calcium challenge.
                                    
Figure 3.1.10 The effects of PC on mitochondrial calcium fluxes. 
Calcium fluxes were fluorometrically monitored using the probe Calcium Green (485 
nm, 535 nm). Mitochondria (1mg) were incubated in 2 ml of standard incubation 
medium prior to calcium addition (20 nmol). Energization was achieved with 
succinate 5 mM. Calcium fluxes, expressed as relative fluorescence units (RFU). 
Cyclosporin A (CyA) 1µM was added to the reaction prior to calcium addition. 
The traces are representative of experiments performed with six independent 
mitochondrial preparations.
3.1.2.9 Phosphorylation of Akt and GSK-3β status
 Activation of A1 receptors has been shown to protect liver from I/R 
injury via pathways involving Akt activation (Park et al., 2010). Taking into 
account that activated Akt decreases GSK-3β activity, which is related 
with modulation of the MPT ,we determined if PC protective effect against 
hepatic I/R injury involves the activation of the Akt / GSK-3β signaling 
pathway to inhibit mitochondria-mediated I/R injury. 
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Figure 3.1.11  Phospho-Thr308-Akt and Akt content were evaluated by 
western blotting. A representative blot from six independent experiments is shown.
 On western blot analysis, compared with control, I/R decreased 
the ratios of phospho-Thr308-Akt/Akt (Figure 3.1.11) and mitochondrial 
phospho-Ser9-GSK-3β /GSK-3β (Figure 3.1.12), indicating decreased 
Akt and increased GSK-3β activities. IPC and CCPA blocked this effect 
of I/R, suggesting the involvement of the Akt/ GSK-3β pathway on the 
improvement of mitochondrial function by IPC. Thus, PC maintains the 
phosphorylated inactive GSK-3β that regulates the threshold for MPT 
induction.
                     
Figure 3.1.12  Phospho-Ser9-GSK-3β and GSK-3β content in isolated 
mitochondria were evaluated by western blotting. A representative blot 
from six independent experiments is shown.
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3.1.3 Discussion
 Accumulated evidence suggest that A1 adenosine receptors (A1R) 
play a role in the protection from I/R injury in several organs such as, 
heart (Koeppen et al., 2009; Yang et al., 2009 a,b), lung (Wilson et al., 
2009; Schepp and Reutershan, 2008), and brain (Ilie et al., 2009; Stone 
et al., 2009). Since IPC has been demonstrated to preserve mitochondrial 
efficiency following I/R, this study examined if A1R modulation during 
PC induces mitochondrial adaptation and could protect the liver from I/R 
injury. This study demonstrated that A1R agonist (CCPA) reproduced the 
beneficial effects of PC, an effect abolished by the antagonist (DPCPX), 
indicating the importance of this receptors subtype in preconditioning. 
Moreover, A1R protective effects involved preservation of mitochondrial 
OXPHOS efficiency. 
 Since ATP content declines substantially during I/R, which is 
associated with hepatocellular injury and higher mortality, prevention of 
defective energy production plays an important role in the resistance to I/R 
injury. Associated with alterations in pH, Na+, and oxidative phosphorylation, 
I/R triggers a cascade of events that involve increased ROS generation 
and loss of Ca2+ homeostasis. This culminates in MPT induction and cell 
death. Therefore, modulation of mitochondria has emerged as a critical 
survival strategy in the prevention against I/R injury. IPC-triggered signal 
transduction appears to directly preserve several cell functions including 
intracellular energy state, pH, and redox system (Rehman et al., 2008). 
Our data show that preconditioning (ischemic and pharmacological) was 
capable to decrease plasmatic ALT, AST and LDH activities, indicating 
a clear hepatoprotective effect against warm I/R injury. Preconditioning 
(ischemic- PC and pharmacological - CCPA) reduced TNF-α concentration, 
while blocking A1R aggravated the release of this cytokine. The decrease 
in TNF-α by both types of could be associated with decreased ROS 
generation in IPC and CCPA conditions .
 PC action was associated with increased performance of 
mitochondrial function, as shown by the preservation of ATP content. 
Oxidative phosphorylation efficiency was impaired in mitochondria 
isolated from I/R and DPCPX livers, but PC and administration of CCPA 
was able to maintain ΔΨ, state 3 respiration, RCR and the lag phase to a 
level compared to the control. CCPA reproduced the beneficial effects of 
PC and DPCPX suppress them. The increased lag phase may be caused 
by disruption of mitochondrial ATP/ADP exchange mediated by the ANT. 
The drop in cytosolic ATP levels caused by impaired mitochondrial ATP/
100
3Regulation of 
m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
RE
SU
LT
S:
 A
DE
NO
SI
NE
 A
1 R
EC
EP
TO
RS
 IN
 P
RE
CO
ND
ITI
ON
IN
G ADP exchange could stimulate metabolic pathways related to cytosolic 
acidification in the aerobic cell and initiate apoptosis in these cells (Vander 
Heiden et al., 1999). The involvement of the ANT in the inhibition of 
mitochondrial phosphorylation was supported by the fact that less CAT 
was needed to abolish ADP-induced depolarization, indicating that the ANT 
was rate-limiting phosphorylation in I/R conditions and implying that I/R 
was enhancing the “c” conformation of the ANT. In energized mitochondria, 
stabilization of the “c” conformation of the ANT (as it is by CAT) sensitizes 
the MPT to calcium. Also, oxidative stress activates the MPT by inhibiting 
ADP binding to the ANT and enhancing CypD-ANT interaction, decreasing 
the sensitivity of the calcium trigger site to [Ca2+]. Thus, inhibition of 
ATP/ADP translocation sensitizes mitochondria to MPT.
 Mitochondria isolated from I/R animals were highly susceptible 
to undergo mitochondrial swelling induced by calcium, but PC (ischemic 
and pharmacological) was able to restore the capacity of mitochondria to 
accumulate calcium, without inducing the MPT. The population undergoing 
the MPT was increased in mitochondria from I/R livers, as demonstrated by 
the inhibition of mitochondrial swelling and calcium efflux in the presence 
of CyA. The MPT leads to decreased mitochondrial membrane potential, 
causing failure of oxidative phosphorylation and necrotic cell death. The 
MPT also causes release of cytochrome c from mitochondria, triggering 
apoptosis. By preventing MPT induction, PC prevented caspase-3 activation 
after warm hepatic I/R. This was also associated with increased Bcl-2 
content, which was not abolished by A1R antagonist, although induced by 
A1R agonist. This may be caused by increased HSP70 levels induced by 
IPC (not prevented by DPCPX) but not by pharmacological preconditioning. 
HSP70 has multiple anti-apoptotic mechanisms that involve mitochondrial 
protection; it functions both upstream and downstream from the caspase 
cascades and in a caspase-independent manner via direct association 
with apoptosis-inducing factor (AIF) (Nylandsted et al., 2000; Garrido et 
al., 2003; Lee et al., 2005). 
 HSP70 upregulates Bcl-2 and interferes with apaf-1 function, 
thereby preventing the formation of the apoptosome, and also block Bax 
translocation to the mitochondria (Stankiewicz et al., 2005). In fact, up-
regulation of HSP’s has been associated with maintenance of mitochondrial 
integrity and function during I/R. Early on, hypothermic adaptation in a 
perfused rabbit heart model has been shown to involve preservation of 
HSP response and signaling for mitochondrial biogenesis (Ning et al., 
1998). Deletion of HSP70 exacerbates I/R-induced cardiac apoptosis, 
mediated by AIF activation (Choudhury et al., 2011). In rat neonatal 
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myocytes, overexpression of HSP60 and HSP10 protect cells against 
apoptosis induced by I/R (Lin et al., 2011). Overexpression of HSP70 is also 
associated with a reduction of cytochrome c release from the mitochondria 
in focal ischemia (Tsuchiya et al., 2003), and postconditioning increases the 
level of HSP70 in the cortex during cerebral I/R (Stroke et al., 2008). Also 
up-regulation of HSP’s facilitates protein import into mitochondria, such 
as mitochondrial Mn-SOD, decreasing ROS production and preventing 
mitochondrial dysfunction (Rehman et al., 2008). Recently, Yang and 
colleagues showed that activation of adenosine receptors induces 
translocation of PKCε to the mitochondria, and this process is regulated by 
HSP90-dependent mitochondrial import mechanism (Yang et al., 2012).
Although HSP´s overexpression block MP pore conductance due to 
HSP binding to protein aggregates, formed by aggregation of damaged, 
misfolded integral membrane proteins in association with CypD under 
MPT-inducing conditions (He et al., 2002; He et al., 2003). Modulation of 
MPT sensitivity by IPC may also be explained by modulation of CypD-ANT 
binding via Akt/GSK-3β pathway. It has been proposed that IPC increases 
the levels of mitochondrial phospho-Ser9-GSK-3β and that phospho-Ser9-
GSK-3β physically interacts with the ANT, which inhibits interaction of the 
ANT with CypD (Nishiara et al., 2007) .This may alter mitochondrial function 
in a way that makes the MPT less likely to form, under oxidant stress and 
high calcium concentrations, conditions that are associated with I/R. Both 
IPC and CCPA increase the levels of active Akt and phospho-Ser9-GSK-
3β, which may modulate MPT induction.
 In conclusion, this study demonstrates that A1R agonist CCPA 
reproduced the beneficial effects of PC, an effect abolished by the 
antagonist DPCPX. This involves preservation of OXPHOs efficiency 
and increase resistance to MPT onset. Both IPC and pharmacological 
preconditioning may modulate the MPT in a GSK-3β-dependent manner. 
The increase in HSP70 induced by IPC may further protect mitochondria 
and prevent the MPT, thus maintaining restoring the ability to generate 
ATP and recover from I/R insult.
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Figure 3.1.13 – Mytochondrial dysfunction increases the susceptibility 
of fatty livers to I/R injury. Preconditioning via modulation of adenosine receptores 
prevents MPT induction.
103
104
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
3.2
R
ES
U
LT
S:
  I
N
D
IR
U
B
IN
-3
’-O
XI
M
E 
PR
EV
EN
TS
 I/
R
 D
A
M
A
G
E
105
INDIRUBIN-3’-OXIME PREVENTS I/R DAMAGE BY INHIBITING GSK-
3β AND MITOCHONDRIAL PERMEABILITY TRANSITION
Abstract
 Higher susceptibility to the mitochondrial permeability transition 
and decreased phosphorylative capacity are causes for impaired hepatic 
function in fatty livers exposed to ischemia/reperfusion I/R. Thus, 
preserving mitochondrial function increases the success rate following 
surgery of fatty livers. In view of this, we tested if an acute treatment with 
indirubin-3’-oxime, an inhibitor of glycogen synthase kinase 3β, prevents 
mitochondrial dysfunction caused by I/R in lean and fatty livers. For that 
we investigated the regulation of MPT by GSK-3β and its relation to 
mitochondrial damage. 
 Wistar rats were subjected to 150 min and Zucker fatty rats 
were subjected to 120 min of 70% warm ischemia and 16 and 12 hrs of 
reperfusion (I/R) respectively. In the treated group (Ind) 1 µM indirubin-3’-
oxime was administered in the hepatic artery 30 min before ischemia. Acute 
treatment of livers before ischemia, with indirubin-3’-oxime, decreased 
serum markers of injury and also preserved mitochondrial cytochrome 
c content, comparatively to I/R livers. Indirubin-3’-oxime also protected 
mitochondria from calcium-induced MPT, prevented the impairment in 
oxidative phosphorylation as well as decreased the formation of ROS.
 Evaluation of GSK-3β status in both liver homogenates and 
isolated mitochondria, showed that treatment with indirubin-3′-oxime 
preserves the phosphorylation of GSK-3β at Ser9 which prevents the 
increase in phosphorylated and active CypD, induced by I/R. This in turn, 
was associated with suppression of the ANT-CypD interaction, therefore 
increasing the threshold for MPT induction and preserving cytochrome c 
content, preserving fatty liver from I/R damage. These findings indicate 
that, although fatty livers exhibit increased susceptibility to mitochondrial 
damage, indirubin-3′-oxime could protect fatty livers against injury after 
I/R.
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 Accumulation of fat in the liver increases the risk of damage following 
I/R, thus bearing additional risks of primary nonfunction subsequent to liver 
surgery or transplantation (Fukumori et al., 1997; Selzner et al., 2001). 
The increased incidence of this pathology demands new and effective 
strategies that preserve fatty liver function when subjected to I/R. 
 Different hypothesis, have been proposed for the increased 
susceptibility of fatty organs to ischemic injury (Selzner et al., 2000; 
Teramoto et al., 1993; Selzner et al., 2006). Under I/R conditions fatty 
livers are ATP-depleted, and the predominant hepatocellular fate is shifted 
from apoptosis to necrosis, strongly implicating inappropriate energy 
homeostasis as the primary cause of liver sensitivity (Caraceni et al., 2005; 
Vendemiale et al., 2001). Fatty degeneration, which induces a series of 
alterations in mitochondria, renders these organelles intrinsically more 
susceptible to I/R injury (Caraceni et al., 2005; Vendemiale et al., 2001; 
Honda et al., 2005; Rolo et al., 2009).
 Impairment of oxidative phosphorylation and induction of the 
mitochondrial permeability transition (MPT) are critical determinants for 
mitochondrial dysfunction induced by prolonged periods of ischemia 
followed by reperfusion (Halestrap et al., 2004; Juhaszova et al., 2008). 
Inhibition of the MPT by preconditioning and postconditioning has been 
proposed to mediate the protective effect of these interventions against 
I/R injury, highlighting the significance of this mitochondrial event as a 
therapeutic target (Rolo et al., 2009; Varela et al., 2010; Park et al., 2006; 
Hausenloy et al., 2004; Murphy et al., 2007).
 Cyclophilin D (CypD) plays a critical role in MPT opening and 
consequent cell death. It is predominantly localized in the mitochondrial 
matrix and when it binds to the adenine nucleotide translocator (ANT) 
increases calcium sensitivity, promoting mitochondrial dysfunction (Zorov 
et al., 2009). Xi et al suggested that reperfusion injury may be prevented by 
targeting the MPT through translocation of glycogen synthase kinase 3β 
(GSK-3β) from cytosol to mitochondria, which may ultimately interact with 
CypD thus modulating the MPT (Xi et al., 2009). Studies have shown that 
GSK-3β inhibition by phosphorylation plays a central role in the beneficial 
action of ischemic and pharmacological preconditioning, involving 
modulation of the MPT (Varela et al., 2010; Juhaszova et al 2004; Nishihara 
et al., 2007; Miura et al., 2009). With GSK-3β inhibited, the GSK3β-
mediated phosphorylation of CypD is prevented and the consequent MPT, 
assuring normalization of intracellular ATP content (Zorov et al., 2009). In 
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situations of I/R, GSK3β promotes the systemic inflammatory response, 
increases the proinflammatory release of cytokines and induces apoptosis 
(Ren et al., 2011).  
 Indirubin 3’-oxime (Ind), a chemical agent of the indirubin family, 
inhibits GSK-3β by competing with ATP for binding to the catalytic site 
(Zorov et al., 2009). A previous work by Barillas and co-workers has 
shown that reperfusion of isolated hypertrophied hearts with lithium or 
indirubin-3’-monoxime-5’ iodo prevents the decrease in contractile function 
induced by I/R (Xi et al., 2009). While inhibition of GSK-3β by indirubin-
3’-monoxime,5-iodo has been shown to protect the heart from I/R injury, 
it has not been examined if this cardioprotection involves increased 
tolerance to MPT induction. In addition, it has not been yet evaluated if 
GSK-3β inhibition by phosphorylation-independent mechanisms results 
in adaptation of the liver to withstand I/R injury. It should be taken into 
consideration that incubation of isolated rat liver with indirubin 3’-oxime 
prevents MPT induction but impairs oxidative phosphorylation, therefore 
decreasing the ability to generate ATP (Jope et al., 2004).
 In this study, we propose to evaluate the effects of indirubin-3’-
oxime given before ischemia on the mitochondrial function of livers 
subjected to warm ischemia/reperfusion. We plan to address if indirubin-
3’-oxime protects the liver by increasing the threshold for MPT induction 
through inhibition of GSK-3β. 
3.2.2 Results
3.2.2.1 Indirubin-3’-oxime prevents hepatic I/R damage in lean livers
3.2.2.1.1 Plasma markers of liver injury:
 To determine if indirubin-3’-oxime given before ischemia protects 
liver from I/R injury, serum levels of AST and ALT were evaluated. As 
shown in Figure 3.2.1, warm I/R significantly increased plasma AST and 
ALT levels relative to the control group. Administration of indirubin-3 -oxime 
(Ind before ischemia (30 min), was effective in reducing the increase in 
plasma levels of AST and ALT caused by I/R.
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Figure 3.2.1 The effects of indirubin-3’-oxime (Ind) administered 
before ischemia on plasma levels of alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST). Plasma samples were collected and 
enzimatic determinations of ALT (A) and AST (B) performed using commercial kits. Data 
are means ± SEM of experiments performed with six animals/group. * Indicates statistically 
significant difference versus Ctl and Ind groups (P < 0.05).
3.2.2.1.2 Mitochondrial membrane potential (ΔΨ) and oxygen 
consumption:
 Taking into account the fundamental role of mitochondrial 
membrane potential for the phenomenon of oxidative phosphorylation, 
ΔΨ was evaluated in succinate-energized mitochondria. Although not 
statistically significant, mitochondria isolated from livers subjected to I/R 
exhibited decreased mitochondrial membrane potential, when compared 
to mitochondria from both control and Ind animals (Figure 3.2.2 A). The 
lag phase (time necessary for ADP phosphorylation) was significantly 
increased in animals subjected to I/R, comparatively to control (Figure 3.2.2 
B). Treatment with Ind before ischemia markedly reduced the lag phase to 
a level compared with control animals suggesting that Ind administration 
is able to preserve the efficiency of mitochondrial phosphorylation.
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Figure 3.2.2 The effects of indirubin-3’-oxime (Ind) administered 
before ischemia on mitochondrial membrane potential (A,B) and lag 
phase (A,C). ΔΨ was measured with a TPP+-selective electrode. Reactions 
were carried out in 1 ml of reaction medium, supplemented with 3 μM rotenone 
and 1 mg of freshly isolated mitochondria, as described in materials and methods. 
Energization was achieved with 5 mM succinate and phosphorylation induced by 
200 nmol ADP. Data are means ± SEM of experiments performed with six animals/
group. * Indicates statistically significant difference versus Ctl and Ind groups (P 
< 0.05).
 Mitochondrial  state 3 respiration (ADP-induced oxygen 
consumption) and the respiratory control ratio (RCR, ratio between 
mitochondrial state 3 and rate of oxygen consumption after ADP 
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E phosphorylation) were significantly decreased in mitochondria isolated 
from livers subjected to I/R, when compared to mitochondria from both 
control and Ind-treated mitochondria (Figure 3.2.3 A and B). Uncoupled 
respiration (maximal rate of oxygen consumption induced by FCCP) was 
identical between the three experimental groups.
  
Figure 3.2.3 The effects of indirubin-3’-oxime (Ind) administered 
before ischemia on state 3 (A) respiration and respiratory control ratio 
(RCR) (B). Oxygen consumption of isolated mitochondria was polarographically 
determined with a Clark oxygen electrode. Mitochondria (1mg) were suspended 
under constant stirring, at 25ºC, in 1.4 mlof standard respiratory medium and 
energized by adding succinate to a final concentration of 5mM, 2 µM rotenone 
were previously added. State 3 respiration was induced by adding 200 nmol ADP. 
The oxygen consumption was also measured in the presence of oligomycin (0.5 
µg/mg protein) and 1 µM FCCP. Data are means ± SEM of experiments performed 
with six animals/group. * Indicates statistically significant difference versus Ctl 
and Ind groups (P < 0.05).
3.2.2.1.3 Adenine nucleotides content:
 To further determine whether indirubin-3-oxime treatment is able 
to preserve mitochondrial ATP production upon I/R, endogenous ATP 
content was evaluated in isolated mitochondria. As shown in Figure 3.2.4, 
ATP content was decreased in I/R animals associated with the observed 
decreased phosphorylation efficiency. Ind administration before ischemia 
was able to significantly preserve mitochondrial energy level.
     
111
Figure 3.2.4- The effects of indirubin-3’-oxime (Ind) administered 
before ischemia on mitochondrial endogenous ATP content. ATP 
content was determined by HPLC. Data are means ± SEM of experiments 
performed with six animals/group. * Indicates statistically significant difference 
versus Ctl and Ind groups (P < 0.05).
3.2.2.1.4  Generation of reactive oxygen species (ROS):
 A pathological increase on the endogenous production of ROS 
after I/R has been associated with decreased capacity for cell survival. 
In the presence of antimycin A, an inhibitor of the electron transport 
chain, succinate-energized mitochondria isolated from I/R livers exhibited 
increased ROS generation, when compared to the control group (Figure 
3.2.5). 
 As shown in the figure, mitochondria isolated from the livers treated 
with Ind revealed decreased ROS generation, indicating that Ind is able to 
control mitochondrial ROS generation induced by I/R and thus prevent the 
deleterious cycle of ROS-induced ROS generation.
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Figure 3.2.5 The effects of indirubin-3’-oxime (Ind) administered 
before ischemia on reactive oxygen species (ROS) generation. ROS 
were estimated fluorometrically using the probe H2DFDA (485 nm, 538 nm). After basal 
fluorescence (white) measurement, antimycin A was added to all preparation (black) to 
block complex III of the mitochondrial chain, to induce maximal ROS generation.  Data are 
means ± S.E.M of experiments performed with six animals/group. * Indicates statistically 
significant difference versus Ctl and Ind groups (P < 0.05).
3.2.2.1.5  Mitochondrial permeability transition:
 Since induction of the mitochondrial permeability transition is a 
critical determinant of I/R injury, we evaluated whether treatment of livers 
submitted to I/R with indirubin-3-oxime protects from MPT induction. In 
isolated mitochondria, the ability to tolerate a calcium challenge is an 
indicator of the susceptibility to the MPT since mitochondria possess a 
finite capacity for accumulating calcium before undergoing the MPT. 
Calcium-induced mitochondrial swelling was measured as a decrease in 
absorbance at 540 nm. Prior to calcium addition, mitochondria isolated 
from I/R animals exhibited decreased absorbance at 540 nm compared 
with control and Ind, indicating swelling of the mitochondrial population 
(Figure 3.2.6). Additionally, mitochondria isolated from I/R animals were 
more susceptible to undergo mitochondrial swelling induced by calcium, 
comparatively to both control and Ind treatment. In fact, Ind restored the 
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capacity of mitochondria isolated from livers subjected to I/R to accumulate 
calcium, without inducing the MPT. In vitro pre-treatment of mitochondria 
isolated from I/R livers with the MPT inhibitor cyclosporine A (CyA), 
prevented mitochondrial swelling induced by calcium, demonstrating that 
the swelling was caused by MPT induction.
 
Figure 3.2.6  - The effects of indirubin-3’-oxime (Ind) administered 
before ischemia on the susceptibility to the induction of 
mitochondrial permeability transition (MPT). Mitochondrial swelling was 
spectrophotometrically monitored at 540 nm. Experiments were started by the 
addition of mitochondria (1 mg) to 2 ml of reaction medium supplemented with 
3 μM rotenone and 5 mM succinate. MPT was induced with 20 nmol CaCl2. 
Cyclosporin A CyA (1 μM) was added to the reaction medium prior to calcium 
addition. The traces are representative of experiments performed with six 
independent mitochondrial preparations.
3.2.2.1.6 Mitochondrial calcium fluxes:
 Since mitochondria isolated from I/R livers pre-treated with 
indirubin-3-oxime decreased the susceptibility to calcium-induced 
swelling, mitochondrial calcium fluxes were evaluated. Mitochondria 
isolated from control animals were able to accumulate the added calcium 
after energization with succinate and retained it during the entire time 
114
3
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
RE
SU
LT
S:
 IN
D
IR
U
B
IN
-3
’-O
XI
M
E 
PR
EV
EN
TS
 I/
R
 D
A
M
A
G
E of the assay (Figure 3.2.7). Conversely, mitochondria isolated from 
animals subjected to I/R, displayed an immediate release of calcium into 
the media assay before the calcium challenge. This indicated that I/R 
caused a disturbance on mitochondrial calcium homeostasis leading to 
increased calcium efflux. Since succinate addition lead to a decrease in 
fluorescence, mitochondria isolated from I/R livers showed no alterations 
in the ability for calcium uptake from the media. However, the accumulated 
calcium was early released, demonstrating the increased susceptibility to 
a calcium challenge. Pre-treatment with CyA prevented calcium release, 
implying that increased calcium efflux from mitochondrial isolated from I/R 
animals was the result of MPT induction. Treatment with indirubin-3-oxime 
before ischemia prevented mitochondrial calcium efflux before and after a 
calcium challenge.
 
Figure 3.2.7 The effects of indirubin-3’-oxime (Ind) administered 
before ischemia on mitochondrial calcium fluxes.  Calcium fluxes were 
fluorometrically monitored using the probe Calcium Green (485 nm, 535 nm). Mitochondria 
(1mg) were incubated in 2 ml of standard incubation medium prior to calcium addition (20 
nmol). Energization was achieved with succinate 5 mM. Calcium fluxes, expressed as 
relative fluorescence units (RFU). Cyclosporin A (CyA) 1µM was added to the reaction 
prior to calcium addition. The traces are representative of experiments performed with six 
independent mitochondrial preparations.
3.2.2.1.7 Cytochrome c and Bcl-2 content and Bax translocation:
 Because treatment with indirubin-3’-oxime prevented the increased 
calcium efflux observed in mitochondria isolated from animals subjected to 
hepatic I/R, endogenous cytochrome c content was evaluated. As shown in 
Figure 3.2.8, mitochondria from livers treated with Ind exhibited preserved 
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cytochrome c content to a level compared to the control. However, in the 
I/R group there was a significant decrease in mitochondrial cytochrome 
c. Since cytochrome c release from the mitochondria is an important 
downstream occurrence following Bax translocation to the mitochondria, 
mitochondrial Bax content was evaluated. In this model, Bax translocation 
to the mitochondria occurs during I/R and is prevented by Ind treatment. 
Additionally, due to the survival function of Bcl-2, by preventing apoptosis 
induction, we also evaluated Bcl-2 content. Mitochondria from livers 
treated with Ind before I/R showed a higher content in Bcl-2 in contrast to 
mitochondria from I/R animals.
     Figure 3.2.8  Bcl-2, Bax and Cyt c content were evaluated by 
western blotting. A representative blot from six independent experiments is 
shown.
3.2.2.1.8 GSK-3β content and activity:
 Since indirubin-3-oxime is an inhibitor of GSK-3β, we evaluated 
if administration of Ind before ischemia was associated with decreased 
hepatic activity of GSK-3β after an episode of warm I/ R.  As shown in 
Figure 3.2.9, GSK-3β activity was increased in livers from animals 
subjected to I/R but treatment with Ind inhibited the activity of this kinase.
 Accordingly, in I/R animals, there was a decrease in the content 
of GSK-3β phosphorylation at Ser9, as evaluated by western blotting in 
hepatic tissue homogenates (Figure 3.2.10 A). 
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Figure 3.2.9 The effects of indirubin-30-oxime (Ind) administered 
before ischemia on GSK-3β activity on liver homogenates. Tau 
phosphorylation by GSK-3β was detected using a Tau(pS199) phosphoELISA kit. Data are 
means ± SEM of experiments performed with six animals/group. * Indicates statistically 
significant difference versus Ctl and Ind groups (P < 0.05).
 Treatment with Ind before ischemia, maintained the content of 
phosphor-Ser9-GSK-3β to a level compared to the control. Because Ind 
was able to prevent increased mitochondrial calcium efflux and decreased 
cytochrome c content induced by I/R, and the threshold for MPT induction 
in myocardial I/R injury has been shown to be elevated by increased 
phosphorylation of GSK-3β at Ser9, we evaluated mitochondrial GSK-3β 
content.
 
Figure 3.2.10 Phospho-Ser9-GSK-3β and GSK-3β content in liver 
homogenates (A)  and isolated mitochondria (B) were evaluated by 
western blotting. A representative blot from six independent experiments is shown.
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 I/R induced the translocation of GSK-3β to the mitochondria and a 
reduction in the content of phospho-Ser9-GSK-3β (Figure 3.2.10 B). GSK-
3β inhibition by Ind was able to maintain the mitochondrial con- tent of total 
GSK-3β and phospho-Ser9- GSK-3β at to a level compared to the control, 
indicating that Ind treatment maintains the phosphorylated GSK-3β that 
regulates the threshold for MPT induction.
                   
 This work shown that indirubin 3’-oxime prevents mitochondrial 
dysfunction in lean livers subjected to warm I/R. Since fatty livers exhibit 
mitochondrial dysfunction before I/R, with this study we propose to 
evaluate if pre-treatment with indirubin 3’-oxime in conditions of hepatic 
I/R in fatty livers, protects the liver by maintaining mitochondrial calcium 
homeostasis, thus preserving mitochondrial function and hepatic energetic 
balance.
3.2.2.2 Indirubin-3’-oxime prevents hepatic I/R damage in fatty livers
3.2.2.2.1 Plasma markers of liver injury:
 To determine if indirubin-3’-oxime given before ischemia protects 
liver from I/R injury, serum levels of AST and ALT were evaluated. As 
shown in Figure 3.2.11, warm I/R significantly increased plasma AST and 
ALT levels relative to the control group. Ind administration before ischemia 
was effective in reducing plasma levels of AST and ALT. 
 Figure 3.2.11 Fatty livers and effects of indirubin-3’-oxime 
(Ind) administered before ischemia on plasma levels of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST). Plasma 
samples were collected and enzimatic determinations performed using commercial kits. 
Data are means ± S.E.M of experiments performed with four animals/group. *Ctl versus 
I/R; # I/R versus Ind; & Ctl versus Ind.
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consumption:
 Mitochondria isolated from livers subjected to I/R exhibited 
decreased mitochondrial membrane potential, when compared to 
mitochondria from both control and Ind animals (Figure 3.2.12 A).
  
Figure 3.2.12 Fatty livers and the effects of indirubin-3’-oxime (Ind) 
administered before ischemia on mitochondrial membrane potential 
(A,B) and lag phase (A,C). ΔΨ was measured with a TPP+-selective electrode. 
Reactions were carried out in 1 ml of reaction medium, supplemented with 3 μM rotenone 
and 1 mg of freshly isolated mitochondria, as described in materials and methods. 
Energization was achieved with 5 mM succinate and phosphorylation induced by 200 nmol 
ADP. Data are means ± S.E.M of experiments performed with four animals/group. *Ctl 
versus I/R; # I/R versus Ind; & Ctl versus Ind.
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 The lag phase  (time necessary for ADP phosphorylation) was 
significantly increased in animals subjected to I/R, comparatively to 
control (Figure 3.2.12 B). Treatment with Ind before ischemia markedly 
reduced the lag phase to a level similar to control animals, suggesting 
that Ind administration is able to preserve the efficiency of mitochondrial 
phosphorylation.   
 Mitochondrial state 3 respiration and the respiratory control ratio 
(RCR) were decreased in mitochondria isolated from livers subjected to 
I/R, when compared to mitochondria from both control and Ind-treated 
mitochondria (Figures 3.2.13 A and B). Uncoupled respiration was identical 
between the three experimental groups. This suggests that Ind treatment 
preserves the electrochemical gradient necessary for ATP synthesis but 
has no effect on the rate of electron flux through the electron transport 
chain.
 
Figure 3.2.13 Fatty livers and effects of indirubin-3’-oxime (Ind) 
administered before ischemia on state 3 (A) respiration and 
respiratory control ratio (RCR) (B). Oxygen consumption of isolated mitochondria 
was polarographically determined with a Clark oxygen electrode. Mitochondria (1mg) were 
suspended under constant stirring, at 25ºC, in 1.4 ml of standard respiratory medium 
and energized by adding succinate to a final concentration of 5mM, 2 µM rotenone were 
previously added. State 3 respiration was induced by adding 200 nmol ADP. The oxygen 
consumption was also measured in the presence of oligomycin (0.5 µg/mg protein) and 1 
µM FCCP. Data are means ± S.E.M of experiments performed with four animals/group. *Ctl 
versus I/R; # I/R versus Ind; & Ctl versus Ind.
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3.2.2.2.3 ATPase activity
 The decreased performance of phosphorylation in I/R fatty livers, 
as reflected by an increased lag phase, suggested alterations in the F1F0-
ATPsynthase, a key component of the phosphorylative system. 
ATPase activity was decreased in mitochondria from I/R animals, 
comparatively to control. Ind preserved ATPase activity similarly to the 
observed in control group (Figure 3.2.14).
Figure 3.2.14 Fatty livers an the effects of indirubin-3’-oxime (Ind) 
administered before ischemia on ATPase activity. ATPase activity was 
determined spectrophotometrically at 660 nm and was calculated as the difference 
in total activity and activity in the presence of oligomycin. Data are means ± S.E.M 
of experiments performed with four animals/group. *Ctl versus I/R; # I/R versus 
Ind; & Ctl versus Ind.
3.2.2.2.4 Adenine nucleotides content:
 To further determine whether Ind treatment is able to preserve 
mitochondrial ATP production upon I/R, endogenous ATP content was 
evaluated in isolated mitochondria. 
 As shown in Figure 3.2.15 , ATP content was decreased in I/R 
animals associated with the observed decreased phosphorylation 
efficiency. Ind administration before ischemia was able to significantly 
preserve mitochondrial energy level.
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Figure 3.2.15 The fatty livers and the effects of indirubin-3’-oxime 
(Ind) administered before ischemia on mitochondrial endogenous 
ATP content. ATP content was evaluated by a bioluminescent assay kit. Data are 
means ± S.E.M of experiments performed with four animals/group. *Ctl versus I/R; # I/R 
versus Ind; & Ctl versus Ind .
3.2.2.2.5  Generation of reactive oxygen species (ROS)
 In the presence of antimycin A, mitochondria isolated from I/R 
livers exhibited increased ROS generation, when compared to the control 
group (Figure 3.2.16).   Mitochondria isolated from the livers treated with 
Ind revealed decreased ROS generation, indicating that Ind is able to 
control mitochondrial ROS generation induced by I/R and thus prevent the 
deleterious cycle of ROS-induced ROS generation. 
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Figure 3.2.16 The effects of indirubin-3’-oxime (Ind) administered 
before ischemia in fatty livers on reactive oxygen species (ROS) 
generation. ROS were estimated fluorometrically using the probe CM-H2DFDA (485 
nm, 538 nm). After basal fluorescence (white) measurement, antimycin A was added to all 
preparation (black) to block complex III of the mitochondrial chain, to induce maximal ROS 
generation. Data are means ± S.E.M of experiments performed with four animals/group. 
*Ctl versus I/R; # I/R versus Ind; & Ctl versus Ind.
3.2.2.2.6 Mitochondrial permeability transition
 In isolated mitochondria, the ability to tolerate a calcium challenge 
is an indicator of the susceptibility to the MPT, since mitochondria possess 
a finite capacity for accumulating calcium before undergoing the MPT. 
             
Figure 3.2.17 Fatty livers and the effects of indirubin-3’-oxime (Ind) 
administered before ischemia in fatty livers on the susceptibility to the 
induction of mitochondrial permeability transition (MPT). Mitochondrial 
swelling was spectrophotometrically monitored at 540 nm. Experiments were started 
by the addition of mitochondria (1 mg) to 2 ml of reaction medium supplemented with 3 
μM rotenone and 5 mM succinate. MPT was induced with 15 nmol CaCl2. Cyclosporin A 
(CyA) (1 μM), was added to the reaction medium prior to calcium addition. The traces are 
representative of experiments performed with four independent mitochondrial preparations. 
 Prior to calcium addition, mitochondria isolated from I/R animals 
exhibited decreased absorbance at 540 nm compared with control and 
Ind, indicating swelling of the mitochondrial population. Additionally, 
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mitochondria isolated from I/R animals were more susceptible to undergo 
mitochondrial swelling induced by calcium, comparatively to both control 
and Ind treatment (Figure 3.2.17). Ind restored the capacity of mitochondria 
to accumulate calcium, without inducing the MPT. In vitro pre-treatment of 
mitochondria isolated from I/R livers with the MPT inhibitor cyclosporine A 
(CyA), prevented mitochondrial swelling induced by calcium, demonstrating 
that the swelling was caused by MPT induction.
3.2.2.2.7 Mitochondrial calcium fluxes:
 Mitochondria isolated from control animals were able to accumulate 
the added calcium after energization with succinate and retained it during 
the entire time of the assay (Figure 3.2.18). 
Figure 3.2.18 Fatty livers and the effects of indirubin-3’-oxime (Ind) 
administered before ischemia on mitochondrial calcium fluxes. 
Calcium fluxes were fluorometrically monitored using the probe Calcium Green (485 nm, 
535 nm). Mitochondria (1mg) were incubated in 2 ml of standard incubation medium prior 
to calcium addition (15 nmol). Energization was achieved with succinate 5 mM. Calcium 
fluxes, expressed as relative fluorescence units (RFU) ,were recorded for an additional 
25min. Cyclosporin A (CyA) 1µM was added to the reaction prior to calcium addition. The 
traces are representative of experiments performed with four independent mitochondrial 
preparations.
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displayed an immediate release of calcium into the media assay before 
the calcium challenge. Since succinate addition lead to a decrease in 
fluorescence, mitochondria isolated from I/R livers showed no alterations in 
the ability for calcium uptake from the medium. However, the accumulated 
calcium was early released, demonstrating the increased susceptibility to 
a calcium challenge. Pre-treatment with CyA prevented calcium release, 
implying that increased calcium efflux from mitochondrial isolated from 
I/R animals was the result of MPT induction. Treatment with indirubin-3’-
oxime before ischemia prevented mitochondrial calcium efflux before and 
after a calcium challenge.
3.2.2.2.8 Cytochrome c , cleaved caspase-3 and Bcl-2 content :
 Because treatment with indirubin-3’-oxime prevented the increased 
calcium efflux observed in mitochondria isolated from animals subjected 
to hepatic I/R, endogenous cytochrome c content was evaluated. As 
shown in Figure 3.2.19, mitochondria from livers treated with Ind exhibited 
preserved cytochrome c content to a level compared to the control. 
However, in the I/R group there was a significant decrease in mitochondrial 
cytochrome c. In I/R animals, there was a higher content in cleaved 
caspase-3 comparatively to control and Ind treatment, as evaluated by 
western blotting in hepatic tissue homogenates.
Figure 3.2.19  Bcl-2 , cleaved caspase-3 and cytochrome c content 
was evaluated by western blotting. A representative blot from four independent 
experiments is shown.
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 Additionally, due to the survival function of Bcl-2, by preventing 
apoptosis induction, we also evaluated Bcl-2 content. Livers treated with 
Ind before I/R showed a higher content in Bcl-2 in contrast to mitochondria 
from I/R animals.
3.2.2.2.9 GSK-3β content and its relationship with acetylation and 
binding of cyclophilin-D to ANT:
 Since indirubin-3’-oxime is an inhibitor of GSK-3β, we evaluated if 
administration of Ind before ischemia was associated with decreased hepatic 
activity of GSK-3β after an episode of warm I/R. In I/R liver homogenates, 
there was a decrease in the content of GSK-3β phosphorylation at Ser9, 
the inactive form of GSK-3β (Figure 3.2.20 A ). 
 Treatment with Ind before ischemia, maintained the content of 
phospho- Ser9-GSK-3β to a level compared to the control. Because 
Ind was able to maintain the threshold for MPT induction and prevented 
cytochrome c release by I/R, we evaluated if alterations on mitochondrial 
GSK-3β content were involved in the effects of In on mitochondria. I/R 
induced the translocation of GSK-3β to the mitochondria and a reduction 
in the content of phospho-Ser9- GSK-3β (Figure 3.2.20 B). 
Figure 3.2.20 Phospho-Ser9-GSK-3β and GSK-3β content in liver 
homogenates and isolated mitochondria were evaluated by western 
blotting. A representative blot from four independent experiments is shown. 
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of total GSK-3β and phosphorylated GSK-3β at Ser9 to a level compared 
to the control.
 Since treatment with indirubin decreases the susceptibility to the 
MPT, phosphorylation and the binding of CypD to ANT modulates MPT 
induction, we evaluated the association between these mitochondrial 
proteins. As shown in Figure 3.2.21, mitochondria isolated from liver 
subjected to I/R displayed increased levels of phosphorylated CypD.
Figure 3.2.21 Phosphorylated CypD in mitochondria isolated 
from livers pre treated with Ind. CypD was immunoprecipitated from isolated 
mitochondria. The immunoprecipitates were separated by SDS-PAGE and electroblotted 
onto PVDF membranes. Western blots were then probed with antibodies against CypD. 
To access CypD phosphorylation, the CypD blots were stripped and then re-probed with 
antibody against phosphorylated threonine (phospho-Thr).
 
 When phosphorylated in Thr residue, CypD is active, causing its 
association to the ANT, which was evaluated by immunoprecipitation. As 
shown in Figure 3.2.22, I/R promoted an increase in the level of CypD that 
was co-immunoprecipitated with ANT. In contrast, treatment with Ind before 
ischemia prevented phosphorylation of CypD causing its dissociation from 
the ANT. 
 These data show that I/R promotes an enhancement of CypD 
phosphorylation, resulting in an increase in CypD associated with the 
ANT and consequently MPT induction. This phenomenon was reversed in 
mitochondria isolated from I/R livers pre-treated with indirubin. 
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Figure 3.2.22 CypD-ANT interaction in mitochondria isolated from 
livers pre treated with indirubin-3’-oxime (Ind). ANT was immunoprecipitated 
from isolated mitochondria. The immunoprecipitates were separated by SDS-PAGE and 
electroblotted onto PVDF membranes. Western blots were then probed with antibodies 
against CypD or ANT.
 
3.2.2.2.10 HIF-1α content and TNF-α levels:
 The hypoxia inducible factor-1α (HIF-1α) mediates the expression 
of cytokines, for example tumor necrosis factor-α (TNF-α). As shown in 
Figure 3.2.23, the content of HIF-1α is increased in I/R comparatively to 
Ctrl and Ind livers.  
Figure 3.2.23  HIF-1α  content in liver homogenates was evaluated by 
western blotting. A representative blot from four independent experiments is shown.
 Kupffer cell activation results in production of several 
proinflammatory cytokines, such as TNF-α. This molecule has the role 
to start and perpetuate a later secondary inflammatory phase, which 
causes more damages to the liver. The TNF-α concentration in tissue 
was significantly higher in the I/R group than both control and Ind (Figure 
3.2.24). 
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Figure 3.2.24 Fatty livers and effects of indirubin-3’-oxime (Ind) 
administered before ischemia on TNF-α levels.  TNF-α levels in tissue was 
measure using commercial kits. Data are means ± S.E.M of experiments performed with 
four animals/group. *Ctl versus I/R; # I/R versus Ind; & Ctl versus Ind .
3.2.2.2.11 MPO activity
 Neutrophil recruitment in liver was assessed by biochemical 
analysis (MPO activity). MPO activity was low and similar between control 
and In-treated groups. In animals that just underwent hepatic I/R, MPO 
activity was significantly increased, indicating relevant neutrophil migration 
into liver tissue (Figure 3.2.25). 
Figure 3.2.25 Fatty livers and the effects of indirubin-3’-oxime (Ind) 
administered before ischemia on MPO activity. MPO activity was evaluated 
in tissue homogenates by spectrophotometrically at 655 nm. Data are means ± S.E.M of 
experiments performed with four animals/group. *Ctl versus I/R; # I/R versus Ind; & Ctl 
versus Ind .
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3.2.3 Discussion
 Clinical data has shown that fatty livers are more susceptible to 
I/R injury, leading to diminish liver function (Selzner et al., 2000; Teramoto 
et al., 1993; Selzner et al., 2006; Caraceni et al., 2005; Vendemiale et 
al., 2001; Honda et al., 2005; Rolo et al., 2009). Regarding this, we have 
aimed to improve fatty condition to produce better outcomes following I/R.
 Fatty livers intracellular accumulation of nonesterified fatty acids 
that increases mitochondrial uncoupling and inhibit gluconeogenesis, 
which leads to impaired ATP synthesis. Previous works has demonstrated 
that in fatty livers, IPC preserves ATP content during ischemia and restores 
intrahepatic ATP after reperfusion (Rolo et al., 2009). 
 Accumulating evidence suggests that decreased activity of GSK-
3β caused by phosphorylation at Ser9 (Dajani et al., 2001), converges 
the signalling protective pathways by which ischemic and pharmacological 
preconditioning are effective in myocardial protection against ischemia/
reperfusion injury (Juhaszova et al., 2004; Miura et al., 2009; Nishihara et 
al., 2007; Park et al., 2006; Xi et al., 2009). The end effector is modulation 
of the mitochondrial permeability transition, with an increased threshold 
for MPT induction in conditions of GSK-3β inhibition (Juhaszova et al., 
2004). This study demonstrates that livers treated with indirubin-3’-oxime, 
an inhibitor of GSK-3β (Leclerc et al., 2001) are resistant to I/R injury, 
suggesting that indirubin-30-oxime has great therapeutic potential in the 
clinical setting of hepatic ischemia/reperfusion.
 Induction of the MPT is an important cause for impairment of 
mitochondrial function after ischemia/reperfusion injury. Induction of 
the MPT after reperfusion mediates cell death by uncoupling oxidative 
phosphorylation, inducing mitochondrial swelling and collapsing 
mitochondrial membrane potential, thus blocking cellular ATP formation 
(Halestrap et al., 2004; Hausenloy et al., 2004; Juhaszova et al., 2008; 
Park et al., 2006). The essential role of the MPT in mediating protection 
against myocardial I/R injury has been demonstrated in hearts deficient 
in cyclophilin D, a component of the MPT. In these animals, ischemic and 
pharmacological preconditioning and postconditioning are not able to 
protect from I/R injury (Lim et al., 2007). GSK-3β inhibition as a successful 
therapeutic strategy to prevent impairment of hepatic mitochondrial 
function and preservation of cellular ATP content after I/R damage has not 
yet been evaluated.
 We observed that indirubin-3’-oxime administered 30 min prior 
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Pretreatment with indirubin-3’-oxime also decreased plasmatic ALT and 
AST activities, indicating a relevant hepatoprotective effect against warm 
I/R injury. This hepatoprotective effect and preservation of ATP content 
were associated with increased performance of mitochondrial function. 
 Decreased ΔΨ and oxygen consumption and also decreased 
efficiency of the phosphorylation system, caused by depletion of the ANT, are 
more consequences of fat accumulation in the liver. Direct measurement of 
mitochondrial membrane potential in isolated mitochondria shows that ΔΨ 
was decreased in livers from I/R animals but indirubin-3’-oxime preserved 
mitochondrial membrane potential. In mitochondria isolated from I/R livers, 
oxidative phosphorylation efficiency was impaired, but administration of 
indirubin-3’-oxime was able to maintain state 3 respiration, RCR and the 
lag phase to a level compared to the control.
 The decrease in ATPase activity in I/R fatty livers supports the 
loss of mitochondrial phosphorylative efficiency, which was maintained 
by pre-treatment with indirubin-3’-oxime. Preservation of mitochondrial 
bioenergetics and cellular ATP by treatment with indirubin-3’-oxime is also 
due to protection against MPT induction (Varela et al., 2010).
 Mitochondria isolated from I/R animals were highly susceptible 
to undergo mitochondrial swelling induced by calcium. Treatment with 
indirubin-3’-oxime was able to restore the capacity of mitochondria to 
accumulate calcium, without inducing the MPT. The population undergoing 
the MPT was increased in mitochondria from I/R livers, as demonstrated by 
the inhibition of mitochondrial swelling and calcium efflux in the presence 
of cyclosporine A. 
 Furthermore, mitochondrial swelling caused loss of the integrity of 
the mitochondrial outer membrane that lead to cytochrome c release into 
the cytosol, which is a cause for apoptotic cell death after I/R (Juhaszova et 
al., 2008; Murphy and Steenbergen, 2007). By preventing MPT induction, 
indirubin-3’-oxime preserved cytochrome c content and prevented 
caspase-3 activation after warm hepatic I/R. This was associated with 
decreased mitochondrial ROS production. Since oxidative stress favors 
MPT induction, the decrease in ROS generation by indirubine-3’-oxime 
also decreases the probability for this event to occur.
 I/R has been shown to induce cell death by inducing Bax 
translocation to the mitochondria (Anderson et al., 2004). The Bcl-
2 proteins are a family of proteins involved in the apoptotic pathway of 
cell death. The sensitivity of cells to apoptotic stimuli can depend on the 
balance of pro- and anti-apoptotic Bcl-2 proteins. Bax translocation from 
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the cytosol to the mitochondrial membrane is a critical step in apoptosis 
induction. Through interactions with pore proteins on the mitochondrial 
membrane, Bax increases mitochondrial membrane permeability and 
leads to cytochrome c release. The preservation of cytochrome c by Ind 
was associated with decreased Bax content in isolated mitochondria, 
as well as increased content of Bcl-2. Bcl-2 has been shown to prevent 
mitochondrial dysfunction associated with apoptosis by preventing the 
decrease in mitochondrial membrane potential observed in conditions of 
hypoxia (Shimizu et al., 1998).
 Although GSK-3β mainly localizes in the cytosol its activity of GSK-
3β is higher in mitochondria (Bijur et al., 2003). According to diverse studies, 
GSK-3β inhibition (increased mitochondrial content in phospho-Ser9-
GSK-3β) converge the signalling protective pathways by which ischemic 
and pharmacological preconditioning are effective in protection against 
ischemia/reperfusion injury (Varela et al., 2010; Park et al., 2006; Xi et al., 
2009; Juhaszova et al., 2004; Nishihara et al., 2007; Miura et al., 2009). 
The study in lean livers showed that I/R induces translocation of GSK-
3β from the cytosol to the mitochondria, increasing mitochondrial GSK-3β 
activity (Varela et al., 2010). On the other hand, treatment of livers before 
ischemia with indirubin-3’-oxime preserves the level of the inactivated 
form (phospho-Ser9-GSK-3β) in the mitochondrial pool of GSK-3β. We 
conclude that the effects of indirubin-3’-oxime on mitochondrial function in 
conditions of hepatic I/R are mediated by GSK-3β inhibition. 
 Interactions between GSK-3β and components of the MPT 
have been indicated as the mechanism by which I/R increases the 
susceptibility to MPT induction (Varela et al., 2010; Xi et al., 2009; Das 
et al., 2009). Rasola and colleagues proposed a model in which inhibition 
of GSK-3β activity, decreases its association with CypD leading to MPT 
desensitization, whereas the Ser/Thr phosphorylation of CypD by GSK-3β 
favours pore opening (Rasola et al., 2010). When phosphorylated, CypD 
binds to the ANT and increases sensitivity to calcium promoting MPT 
induction and thus, cell death after I/R. I/R promotes an enhancement 
of CypD phosphorylation, resulting in increased CypD associated with 
the ANT and consequently MPT induction (Zorov et al., 2009; Bao et al., 
2012). So, as for a mechanism of phospho-GSK-3β-mediated protection 
by indirubin-3’-oxime, we demonstrated that by maintaining the levels of 
inhibited mitochondrial GSK-3β, indirubin-3’-oxime inhibits the interaction 
between CypD–ANT. In organs such as the heart, perfusion with GSK-3β 
inhibitors have been shown to reduce cell death induced by I/R, when 
added before ischemia or at the start of reperfusion (Tong et al., 2002; 
132
 This study shows that indirubin-3’-oxime acts as pharmacological 
preconditioning, modulating mitochondrial function and energy metabolism 
caused in conditions of I/R. Indirubin-3’-oxime preserves oxidative 
phosphorylation and decreases the probability for MPT induction, by 
inhibiting GSK-3β and the interaction CypD-ANT.
Figure 3.2.26 – Mitochondrial dysfunction increase the susceptibility 
of fatty livers to I/R injury. Inhibition of GSK-3β by indirubin-3’-oxime decreases 
CypD binding ANT, preventing MPT induction. 
133
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NAD+ PREVENTS I/R DAMAGE IN FATTY LIVERS: MODULATION OF 
THE MPT BY THE SIRT3 CYPD-ANT AXIS
Abstract
 In this study, we wanted to establish if an acute treatment with 
NAD+, a sirtuin cofactor, prevents mitochondrial dysfunction associated 
with warm I/R injury in fatty livers. Zucker fatty rats were subjected to 
120 min of 70% warm ischemia and 12 h of reperfusion. In the treated 
group (NAD+) NAD+ was administered in the hepatic artery 30 min before 
ischemia. Acute treatment of livers before ischemia, decreased serum 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
lactate dehydrogenase (LDH) levels and also preserved mitochondrial 
cytochrome c content, comparatively to I/R livers. NAD+ also prevented 
calcium-induced mitochondrial permeability transition (MPT), the decline 
in mitochondrial respiratory state 3 and ATP content caused by I/R. 
The generation of reactive oxygen species (ROS) was also decreased 
in mitochondria isolated from I/R livers pre-treated with NAD+. Data 
shows that deacetylation of cyclophilin D (CypD) at Lys residue causes 
dissociation from the adenine nucleotide translocator (ANT), contributing 
to an increase in MPT threshold in NAD+-treated animals. This is due 
to a stimulation of the activity of mitochondrial SIRT3 that reduces the 
content in acetylated CypD in mitochondria from control and NAD+ livers, 
compared to the I/R group. These observations point  CypD as a new 
protective target against I/R injury in fatty livers. 
 Pre-treatment with NAD+ protects the fatty liver by maintaining 
mitochondrial calcium homeostasis, thus preserving mitochondrial function 
and hepatic energetic balance
3.3.1 Introduction
         Prevention of MPT induction by preconditioning and postconditioning 
has been proposed to mediate the protective effect of these interventions 
against I/R injury (Halestrap et al., 2004; Hausenloy et al., 2004; Park et 
al., 2006; Lemasters, 2007; Murphy et al., 2007; Rolo et al., 2009; Varela 
et al., 2010). The therapeutic potential of maintaining the MPT in a closed 
state is highlighted by the resistance of Cyclophilin D (CypD) knockout 
mice (Ppif-/-) to a variety of diseases (Baines et al., 2005). Binding of 
CypD to the adenine nucleotide translocator (ANT) increases sensitivity to 
Ca2+, promoting mitochondrial dysfunction and cell death after I/R (Zorov 
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 Recently, Zheng and colleagues suggested that NAD+ prevents 
MPT induction and decreases brain ischemic damage (Zheng et al., 2012). 
NAD+ plays an important role in energy metabolism and mitochondrial 
functions, but also, gene expression, calcium homeostasis and 
immunological functions (Ying, 2008). NAD+ is required as a co-substrate 
for the activity of sirtuins, a family of protein deacetylases with beneficial 
effects on several human diseases (Ma et al., 2012). Recent reports have 
indicated that exogenous NAD+ prevents neurons from degeneration 
and I/R-induced cell death as well as cardiac hypertrophic damage, by 
activating SIRT3 (Ying et al., 2007; Pillai et al., 2010). SIRT3 activity 
correlates with the level of mitochondrial protein acetylation (Schwer et 
al., 2008). Studies have established a relationship between SIRT3 and 
CypD: SIRT3 deacetylates and inactivates CypD causing its dissociation 
from the ANT and increasing the threshold to the MPT (Shulga et al., 2010; 
Hafner et al., 2010). Fatty liver is associated with decreased NAD+ levels 
and decreased SIRT3 activity, mitochondrial protein hyperacetylation and 
reduced mitochondrial function (Hirschey et al., 2010; Kendrick et al., 2011; 
Teodoro et al., 2006). Fatty liver is also associated with down-regulation 
of nicotinamide phosphoribosyltransferase that is necessary for NAD+ 
synthesis (Dahl et al., 2010). Therefore, fatty livers exhibit a background 
that increases the susceptibility to undergo the MPT, diminishing the 
possibilities of organ recovery after I/R injury. There is an urgent need for 
strategies against I/R injury in fatty livers, due to the increased prevalence 
of this kind of livers mainly related to the overall increase of obesity and 
alcohol consumption in all industrialized countries (Feldstein, 2010).
 We propose that the impairment in SIRT3 activity in fatty livers 
and its ability to suppress MPT formation increases the sensitivity of fatty 
livers to I/R injury. The consequent mitochondrial damage will lead to 
accumulation of dysfunctional mitochondria inducing further cellular injury 
due to mitochondrial ROS formation, calcium overload and futile ATP 
consumption. Treatment of fatty livers with NAD+ before I/R, is expected 
to increase sirtuin activity, decrease CypD acetylation and its association 
with the MPT, therefore preventing I/R damage.
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3.3.2 Results 
3.3.2.1 Plasma markers of liver injury:
 To determine if NAD+ given before ischemia protects liver from IR 
injury, serum levels of LDH, AST and ALT were evaluated. As shown in 
Figure 3.3.1, warm I/R significantly increased plasma LDH, AST and ALT 
levels relative to the control group. NAD+ administration before ischemia 
was effective in reducing plasma levels of LDH, AST and ALT. 
 
Figure 3.3.1 The effects of NAD+ administered before ischemia 
on plasma levels of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and lactate dehydrogenase (LDH). Plasma 
samples were collected and enzimatic determinations of ALT (A), AST (B) and LDH (C) 
performed using commercial kits. Data are means ± S.E.M of experiments performed with 
four animals/group. Statistically significant difference:  *Ctl versus I/R; # I/R versus NAD+; 
& Ctl versus NAD+(P<0.05).
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 As shown in Figure 3.3.2, I/R induced an increase in hepatic HIF-
1α (a master regulator of cell response to hypoxia), comparatively to Ctl 
and NAD+ livers. The hypoxia inducible factor-1α (HIF-1α) mediate the 
expression of cytokines, for example tumor necrosis factor-α (TNF-α). 
TNF-α plasmatic concentration was also significantly higher in the I/R 
group than in the Ctl and NAD+ groups (Figure 3.3.3 A ). 
                 
Figure 3.3.2 HIF-1α  content in liver homogenates was evaluated by 
western blotting. A representative blot from four independent experiments is shown.
TNF-α release leads to neutrophil activation and accumulation. In animals 
that just underwent hepatic I/R, MPO activity was significantly increased, 
indicating the presence of relevant neutrophil migration into liver tissue 
(Figure 3.3.3 B). This was prevented by NAD+ treatment.
        
Figure 3.3.3 The effects of NAD+ administered before ischemia 
on TNF-α levels (A) and MPO activity (B).  TNF-α levels in plasma were 
measure using commercial kits. MPO activity was evaluated in tissue homogenates by 
spectrophotometrically at 655 nm. Data are means ± S.E.M of experiments performed with 
four animals/group. Statistically significant difference:  *Ctl versus I/R; # I/R versus NAD+; 
& Ctl versus NAD+(P<0.05).
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3.3.2.3 Mitochondrial membrane potential (ΨΔ) and oxygen 
consumption:
 
 To address if protection afforded by NAD+ involved mitochondria, 
we evaluated several functional mitochondrial parameters.  
                       A  
 
                                       
 
Figure 3.3.4- The effects of NAD+ administered before ischemia on 
mitochondrial membrane potential (A,B) and lag phase (A,C). ΔΨ was 
measured with a TPP+-selective electrode. Reactions were carried out in 1 ml of reaction 
medium, supplemented with 3 μM rotenone and 1 mg of freshly isolated mitochondria, 
as described in materials and methods. Energization was achieved with 5 mM succinate 
and phosphorylation induced by 200 nmol ADP. Data are means ± S.E.M of experiments 
performed with four animals/group. Statistically significant difference:  *Ctl versus I/R; # I/R 
versus NAD+; & Ctl versus NAD+(P<0.05).
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 Mitochondria isolated from livers subjected to I/R exhibited 
decreased mitochondrial membrane potential (Figure 3.3.4 A,B), state 3 
respiration and RCR (Figure 3.3.5 A,B) , when compared to mitochondria 
from both control and NAD animals.
 The lag phase (time necessary for ADP phosphorylation) was 
significantly increased in animals subjected to I/R, comparatively to control. 
Treatment with NAD+ before ischemia markedly reduced the lag phase to 
a level compared with control animals, showing that NAD+ administration 
is able to preserve the efficiency of mitochondrial phosphorylation. 
 Figure 3.3.5 The effects of NAD + administered before ischemia on 
state 3 (A) respiration and respiratory control ratio (RCR) (B). Oxygen 
consumption of isolated mitochondria was polarographically determined with a Clark 
oxygen electrode. Mitochondria (1mg) were suspended under constant stirring, at 25ºC, 
in 1.4 ml of standard respiratory medium and energized by adding succinate to a final 
concentration of 5mM, 2 µM rotenone were previously added. State 3 respiration was 
induced by adding 200 nmol ADP. The oxygen consumption was also measured in the 
presence of oligomycin (0.5 µg/mg protein) and 1 µM FCCP. Data are means ± S.E.M of 
experiments performed with four animals/group. Statistically significant difference:  *Ctl 
versus I/R; # I/R versus NAD+; & Ctl versus NAD+(P<0.05).
3.3.2.4 Adenine nucleotides content
 To further determine whether NAD+ treatment is able to preserve 
mitochondrial ATP production upon I/R, endogenous ATP content was 
evaluated in tissue and in isolated mitochondria. As shown in Figure 
3.3.6, ATP content decreased in I/R animals associated with the observed 
decreased phosphorylation efficiency. NAD+ administration before 
ischemia was able to significantly preserve mitochondrial energy level.
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Figure 3.3.6 The effects of NAD+ administered before ischemia on 
ATP content tissue (A) and mitochondria (B). ATP content was evaluated by 
a bioluminescent assay kit. Data are means ± S.E.M of experiments performed with four 
animals/group. Statistically significant difference:  *Ctl versus I/R; # I/R versus NAD+; & Ctl 
versus NAD+(P<0.05).
3.3.2.5  ATPase activity
 The decreased performance of phosphorylation in I/R fatty livers, 
suggested alterations in the F1F0-ATPsynthase, a key component of the 
phosphorylative system. ATPase activity was decreased in mitochondria 
from I/R animals, comparatively to control. NAD+ preserved ATPase 
activity similarly to the observed in control group (Figure 3.3.7). 
Figure 3.3.7 The effects of NAD+ administered before ischemia on 
ATPase activity. ATPase activity was determined spectrophotometrically at 660 nm and 
was calculated as the difference in total activity and activity in the presence of oligomycin. 
Data are means ± S.E.M of experiments performed with four animals/group. Statistically 
significant difference:  *Ctl versus I/R; # I/R versus NAD+; & Ctl versus NAD+(P<0.05).
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3.3.2.6 Generation of reactive oxygen species (ROS)
 A pathological increase on the endogenous production of ROS 
after I/R has been associated with decreased capacity for cell survival. 
NAD+-treatment prevented the damage to the electron transport chain 
induced by I/R, as shown by the decrease in ROS generation in NAD+ 
animals (Figure 3.3.8). 
                            
                        
Figure 3.3.8 The effects of NAD+ administered before ischemia 
on reactive oxygen species (ROS) generation. ROS were estimated 
fluorometrically using the probe CM-H2DFDA (485 nm, 538 nm). After basal fluorescence 
(white) measurement, antimycin A was added to all preparation (black) to block complex III 
of the mitochondrial chain, to induce maximal ROS generation. Data are means ± S.E.M 
of experiments performed with four animals/group. Statistically significant difference:  *Ctl 
versus I/R; # I/R versus NAD+; & Ctl versus NAD+(P<0.05).
3.3.2.7 Mitochondrial permeability transition:
 Since induction of the MPT is a critical determinant of mitochondrial 
performance and I/R injury, we evaluated whether treatment of livers 
submitted to I/R with NAD+, protects from MPT induction. Prior to Ca2+ 
addition, mitochondria isolated from I/R animals exhibited decreased 
absorbance at 540 nm compared with control and treated group, indicating 
swelling of the mitochondrial population. Additionally, mitochondria from 
I/R animals were more susceptible to Ca2+-induced mitochondrial swelling, 
comparatively to both control and NAD+ treatment. In vitro pre-treatment of 
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mitochondria isolated from I/R livers with the MPT inhibitor CyA, prevented 
mitochondrial swelling induced by calcium, demonstrating that the swelling 
was due to MPT induction (Figure 3.3.8). 
                     
Figure 3.3.8  The effects of NAD+ administered before ischemia on the 
susceptibility to the induction of mitochondrial permeability transition 
(MPT). Mitochondrial swelling was spectrophotometrically monitored at 540 nm. Experiments 
were started by the addition of mitochondria (1 mg) to 2 ml of reaction medium supplemented 
with 3 μM rotenone and 5 mM succinate. MPT was induced with 15 nmol CaCl2. Cyclosporin 
A (CyA) (1 μM) was added to the reaction medium prior to calcium addition. The traces are 
representative of experiments performed with four independent mitochondrial preparations. 
3.3.2.8 Mitochondrial calcium fluxes
 As mitochondria isolated from I/R livers pre-treated with NAD+ 
decreased the susceptibility to calcium-induced swelling, mitochondrial 
calcium fluxes were evaluated. Mitochondria isolated from control animals 
were able to accumulate the added calcium after energization with succinate 
and retained it during the entire time of the assay (Figure 3.3.9). On the 
contrary, mitochondria isolated from animals subjected to I/R, displayed 
an immediate release of calcium into the media assay before the calcium 
challenge. Mitochondria isolated from I/R livers showed no alterations in 
the ability for calcium uptake from the medium. However, the accumulated 
calcium was early released, demonstrating the increased susceptibility to 
a calcium challenge. Pre-treatment with CyA prevented calcium release, 
implying that increased calcium efflux from mitochondrial isolated from I/R 
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ischemia prevented mitochondrial calcium efflux before and after a calcium 
challenge. 
 
Figure 3.3.9 The effects of NAD+ administered before ischemia on 
mitochondrial calcium fluxes. Calcium fluxes were fluorometrically monitored 
using the probe Calcium Green (485 nm, 535 nm). Mitochondria (1mg) were incubated in 
2 ml of standard incubation medium prior to calcium addition (15 nmol). Energization was 
achieved with succinate 5 mM. Calcium fluxes, expressed as relative fluorescence units 
(RFU) ,were recorded for an additional 25min. Cyclosporin A (CyA) 1µM was added to the 
reaction prior to calcium addition. The traces are representative of experiments performed 
with four independent mitochondrial preparations.
3.3.2.9 Sirtuin-3 content and activity and their relationship with 
acetylation and binding of CypD to ANT:
 Since the MPT is induced by I/R, and NAD+ treatment decreases 
the susceptibility to MPT, acetylation and binding of CypD to ANT were 
evaluated. As shown in Figure 3.3.10 A, in I/R, mitochondria displayed 
increased levels of acetylated CypD. When acetylated in Lys residue, 
CypD is active, causing its association to the ANT. As so, NAD+ addition 
before I/R reduced CypD co-immunoprecipitated with the ANT (Figure 
3.3.10 B), probably due to increased deacetylation of CypD by SIRT3. 
 Although SIRT3 content was unchanged (Figure 3.3.11 A), SIRT3 
activity was decreased in liver samples from I/R and increased in the NAD+ 
group (Figure 3.3.11 B).
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Figure 3.3.10  Acetylated CypD causing its association to the ANT 
in mitochondria isolated from I/R livers. CypD was immunoprecipitated 
from isolated mitochondria. The immunoprecipitates were separated by SDS-PAGE and 
electroblotted onto PVDF membranes. Western blots were then probed with antibodies 
against Ac-Lys, to access CypD acetylation. The blots were stripped and then re-probed 
with antibody against CypD (A).
ANT was immunoprecipitated from isolated mitochondria. The immunoprecipitates were 
separated by SDS-PAGE and electroblotted onto PVDF membranes. Western blots were 
then probed with antibodies against CypD or ANT (B).
 
Figure 3.3.11 The effects of NAD+ administered before ischemia on 
SIRT3 content and activity. A representative blot from four independent experiments 
is shown. SIRT3 activity was measure using commercial kit. Data are means ± S.E.M of 
experiments performed with four animals/group. Statistically significant difference:  *Ctl 
versus I/R; # I/R versus NAD+; & Ctl versus NAD+(P<0.05).
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S 3.3.2.10 Cytochrome c, caspase-3 and Bcl-2 content :
 The release of cytochrome c due to MPT induction, leads to 
caspase activation and development of the apoptotic process. As shown 
in Figure 3.3.12, NAD+ preserved mitochondrial cytochrome c content to 
a level compared to the control. Additionally, I/R animals, exhibited higher 
content in cleaved caspase-3 comparatively to control and NAD+ treatment 
(Figure 3.3.12). Additionally, due to the survival function of Bcl-2, by 
preventing apoptosis induction, we also evaluated Bcl-2 content. Livers 
injected with NAD+ also showed a higher content in anti-apoptotic Bcl-2, 
in contrast to I/R animals  (Figure 3.3.12). 
                  
Figure 3.3.12 Bcl-2, cleaved caspase-3 and cyt c content were 
evaluated by western blotting. A representative blot from four independent 
experiments is shown.
3.3.2.11 LC3 content
 Since MPT induction triggers autophagy, the levels of an autophagy 
marker, microtubule- associated protein 1 light chain 3 (LC3), were 
determined. LC3-I conversion to LC3-II was increased in I/R indicating 
autophagy induction. NAD+ treatment prevented the increase in the 
LC3-II levels, suggesting that NAD+ administration prevents I/R-induced 
autophagy (Figure 3.3.13).
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Figure 3.3.13 LC3 content was evaluated by western blotting. A 
representative blot from four independent experiments is shown.
3.3. Discussion
 This study shows that treatment of fatty livers with NAD+ is a strategy 
with therapeutic potential in the clinical setting of I/R. We demonstrated 
for the first time that adding NAD+ to fatty livers prior to I/R significantly 
increases SIRT3 activity, leading to decreased CypD acetylation and 
association with the ANT. This increases the resistance to the MPT and 
prevents I/R injury. 
 Hepatic I/R is an important cause of organ damage. It triggers a 
series of adverse events that culminate in cell death. There are currently no 
drugs for clinical use to reduce reperfusion injury, although the pathways 
implicated in I/R injury are subject of intense research. I/R in fatty livers 
was associated with increased hepatocellular injury characterized by 
an increase in serum transaminase levels and markers of apoptotic cell 
death. Activation of inflammatory pathways during I/R is due to increased 
production of cytokines, such as TNF-α, a cell death activator and MPT 
inducer (Tafani et al., 2000). Both TNF-α and MPO activity, a marker of 
neutrophil infiltration, as well as HIF-1α, were increased in I/R conditions. 
Administration of NAD+ 30 min prior to ischemia was effective in decreasing 
plasmatic ALT, AST and LDH activities, indicating a clear hepatoprotective 
effect in a situation of warm I/R injury. NAD+ treatment also inhibited the 
release of TNF-α and the increase in MPO activity.
 The pathogenesis of I/R injury involves numerous mechanisms, 
including alterations in mitochondrial performance. Associated with 
alterations in pH, Na+, and oxidative phosphorylation, I/R triggers a 
cascade of events that involve increased ROS generation and loss of Ca2+ 
homeostasis. This culminates in MPT induction and cell death. Therefore, 
modulation of mitochondria has emerged as a critical survival strategy in 
the prevention against I/R injury. In fact, protection against I/R injury by 
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of which converge at the mitochondrion (Varela et al., 2011; Banga et al., 
2005; Juhaszova et al., 2008; Halestrap et al.,2004; Hausenloy et al., 
2004; Park et al., 2006; Lemasters, 2007; Murphy et al., 2007; Rolo et al., 
2009; Varela et al., 2010).
 Fatty livers display a defective oxidative phosphorylation system 
and decreased capacity to accumulate and retain Ca2+, resulting in a 
decreased tolerance to Ca2+ insult (Teodoro et al., 2006). 
This inability to handle a pathological Ca2+ insult may predispose fatty 
livers to I/R injury. In the present study, fatty livers subjected to warm I/R 
exhibited marked biochemical changes in mitochondrial performance, 
including increasing ROS generation, defective oxidative phosphorylation 
and increased susceptibility to MPT induction. Mitochondrial swelling 
caused loss of the integrity of the mitochondrial outer membrane that lead 
to cytochrome c release into the cytosol, which is a cause for apoptotic cell 
death after I/R (Halestrap et al., 2004; Murphy et al., 2007). Treatment with 
NAD+ was able to prevent MPT induction and thus maintain cytochrome 
c content and prevent caspase-3 activation after warm hepatic I/R. The 
preservation of cytochrome c within mitochondria by NAD+ was associated 
with increased content of Bcl-2. Bcl-2 has been shown to prevent 
mitochondrial dysfunction associated with apoptosis by preventing the 
decrease in mitochondrial membrane potential observed in conditions 
of hypoxia (Shimizu et al., 1998). MPT mediates not only apoptosis but 
also, under certain conditions, autophagy (Lemasters, 2007). Autophagy 
is a catabolic process for degradation of cytoplasmic contents by using 
lysosomal machinery. Recently, Zhenga and colleagues suggested an 
important link between NAD+ and autophagy in ischemic brains of rodents 
(Zhenga et al., 2012). Our data shows that NAD+ administration can 
attenuate autophagy induction in the ischemic livers.
 The essential role of the MPT in mediating protection against I/R 
injury has been demonstrated in hearts deficient in CypD, where ischemic 
and pharmacological preconditioning and postconditioning do not have 
any protective action against I/R (Baines et al., 2005; Zorov et al., 2009; 
Schinzel et al., 2005). The mechanism by which CypD promotes induction 
of the MPT is probably related with mediated alterations in the conformation 
of mitochondrial inner membrane proteins, thus promoting formation and 
MPT induction (Hafner et al., 2010). In this work, treatment with NAD+ 
inhibited ROS formation and decreased the association between CypD 
and the ANT. Interactions between MPT-regulatory factors are under 
strict regulation. When acetylated in the Lys residue, CypD is active and 
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facilitates a conformational change in the ANT, promoting the MPT (Hafner 
et al., 2010). CypD deacetylation is mediated by SIRT3. SIRT3 localized 
to the mitochondria plays a role in various mitochondrial functions, such 
as regulation of energy homeostasis and apoptosis (Hirschey et al., 2010; 
Kendrick et al., 2011). Recent studies have suggested the protective role 
of SIRT3 in cells under stress condition, involving the MPT (Hafner et al., 
2010; Shulga et al., 2010). In this study, we demonstrated SIRT3-CypD-
MPT as a preventive axis in fatty livers against I/R injury. 
 We observed that the increase in CypD acetylation in I/R group 
was accompanied by an inhibition of SIRT3 activity. Conversely, NAD+ 
treatment increased SIRT3 activity and decreased CypD acetylation. This 
may be explained by the fact that obesity is associated with increased 
acetylation of mitochondrial proteins (Kendrick et al., 2011; Choudhury 
et al., 2010), caused by a decrease in SIRT3 activity (Dahl et al., 2010). 
Adding NAD+ before ischemia increases SIRT3 activity and thereby 
prevents against I/R injury.
 Besides its involvement in MPT regulation, SIRT3 has been 
reported as regulatory of electron transfer chain components: complex I, 
II, III (Cimen et al., 2010; Kim et al., 2006; Bao et al., 2010). In studies with 
SIRT3 deficiency or knockdown there is increased complex acetylation 
and consequent decreased activity, suggesting that SIRT3 regulates 
many aspects of mitochondrial oxidative phosphorylation. Several groups 
have also reported that SIRT3 plays a major role in the suppression of 
intracellular ROS generation (Bao et al., 2010; Kong et al., 2010; Qiu et al., 
2010; Someya et al., 2010), which justifies the decreased ROS generation 
in NAD+-treated animals. As so, our data demonstrating that oxidative 
phosphorylation efficiency was impaired in mitochondria isolated from I/R 
livers comes as no surprise, as is the fact that administration of NAD+ 
was able to recover state 3 respiration and RCR to control levels. The 
decrease in ATPase activity in I/R livers reveals the loss of mitochondrial 
phosphorylative efficiency.
 In conclusion, treatment with NAD+ before ischemia is protective 
against injury in a model of hepatic warm I/R. NAD+ modulates mitochondrial 
function, preserves oxidative phosphorylation and decreases the 
probability of MPT induction. Obesity decreases the cellular NAD+/NADH 
ratio, thereby contributing to a decrease in SIRT3 activity that increases the 
acetylation of mitochondrial activities, decreasing mitochondrial efficiency. 
NAD+ increases SIRT3 activity and decreases CypD acetylation, activity 
and binding of CypD to ANT, increasing the threshold to MPT induction. 
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Figure 3.3.14 – Mitochondrial dysfunction increases the susceptibility 
of fatty livers to I/R injury. NAD + administration increase SIRT3 activity , leading 
to decreased binding of CypD to the ANT, preventing MPT induction.
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 Non-alcoholic fatty liver disease (NAFLD) is a common clinical 
condition with histological features that resemble those of alcohol-induced 
liver injury, but occurs in patients who do not drink an excessive amount 
of alcohol. It is now considered to be the hepatic representation of the 
metabolic syndrome, since it is often associated with obesity, insulin 
resistance, dyslipidemia and hypertension (Levene et al., 2012). The 
increased incidence of NAFLD and the shortage of liver donors, has 
led to the acceptance of steatotic livers for transplantation, although 
steatosis is an important risk factor, associated with decreased recovery 
of function (McCormack et al., 2011). Similarly, liver resection in patients 
with steatosis is associated with higher risk of postoperative mortality 
when compared with patients with non-fatty livers. Such low tolerance to 
acute injury is probably related with an underlying state of mitochondrial 
dysfunction induced by fat accumulation (Teodoro et al., 2006; Teodoro et 
al., 2008). Dysfunctional mitochondria exhibit impaired OXPHOS capacity 
and increased rates of ROS generation that enhance the susceptibility of 
hepatocytes to cell death by necrosis, via ATP depletion, or by apoptosis, 
via release of cytochrome c after mitochondrial swelling. Therefore, in the 
context of organ transplantation or hepatic surgery, patients with fatty livers 
are at a higher risk of diminished liver function caused by I/R, a major and 
unavoidable clinical problem, whether donor livers are lean or steatotic. 
Fatty hepatocytes have reduced tolerance to ischemic injury with a 
predominant necrotic form of cell death (Selzner et al., 2000). In particular, 
I/R injury induces a dramatic increase in mitochondrial permeability, thereby 
instigating a chain of events that leads to both apoptotic and necrotic death 
(Varela et al., 2011). The increase in ROS generation induced by I/R further 
damages lipids, proteins and nucleic acids, perpetuating mitochondrial 
dysfunction and decreasing hepatocyte viability, which is aggravated by 
increased release of pro-inflammatory cytokines .Induction of the MPT 
is now known to mediate the lethal permeability changes that initiate 
mitochondrial-driven death in I/R injury.In fact, one of the major differences 
between fatty and lean livers is the higher susceptibility to the MPT following 
I/R (Rolo et al., 2009). I/R injury is associated with increases in MPT pore 
activators (calcium, ROS, Pi) and reductions in MPT pore inhibitors (ATP/
ADP). While the MPT pore is believed to be quiescent during ischemia, 
inhibited by low pH, the restoration of pH coupled with the rapid elevation in 
mitochondrial calcium and ROS leads to MPT induction upon reperfusion. 
This causes cell death by uncoupling oxidative phosphorylation, inducing 
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thus blocking cellular ATP formation. Such impaired mitochondria have 
the potential to further damage the population of healthy mitochondria, 
by exposure to accelerated ROS generation and increased calcium 
concentrations, creating an environment of dysfunctional mitochondria 
that decreases the possibility of recovering organ function following I/R. 
Therefore, the MPT represents an obvious therapeutic target for inhibition 
of hepatocyte mortality and treatment of ischemia-reperfusion.
 Over the past decade, intensive mitochondrial research has shown 
that mitochondria are not only the major suppliers of energy to a cell, but 
are also pivotal in the cell’s decision to live or die.  Maintaining a healthy 
population of mitochondria is essential to the well being of cells. Indeed, it 
is now well recognized that besides its crucial role in the pathogenesis of 
several diseases including I/R injury, protective pathways converging on 
mitochondria may preserve their function and drastically reduce the lethal 
I/R injury .This type of protection can be obtained with brief intermittent 
ischemia (IPC) or with pharmacological agents such as adenosine 
receptors, kinases and MPT modulation. In this regard, this work aimed to 
ameliorate the fatty condition to produce better outcomes following I/R, by 
identification of mitochondrial-dependent protective mechanisms. 
 First, it was crucial to define the functional mitochondrial 
mechanisms of IPC to allow drug targeting in a pharmacological treatment 
in fatty livers as a strategy to reduce I/R injury. By comparing IPC and 
pharmacological PC (modulation of A1R), (chapter 3.1) we observed that 
both strategies improved OXPHOS capacity, maintaining ATP content, 
decreasing ROS generation and caspase-3 activation, as well as the 
release of markers of hepatocellular damage into the plasma. Selective 
blocking of A1R with DPCPX abolished the protection achieved by 
IPC, while the A1R agonist CCPA reproduced its beneficial effects. The 
preservation of phosphorylative efficiency by PC was associated with an 
increased concentration dependence of the effect of CAT on ADP-induced 
depolarization in energized mitochondria, comparatively to the I/R condition. 
This indicates inhibition of ADP transport by I/R that is prevented by PC. 
It has been previously shown that PC also preserves the ATPsynthase 
activity, which further contributes to an improved phosphorylative system 
(Rolo et al., 2009). CAT induces MPT induction by facilitating changes in 
the conformational state of the ANT, stabilizing the “c” conformation where 
the nucleotide binding site faces the cytoplasmic side of the membrane 
(Zoratti and Szabó, 1995). The calcium-dependency of the MPT suggested 
that there might be a calcium trigger site exposed on the ANT associated 
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with the “c” conformation (Halestrap and Brenner, 2003). The requirement 
for the ANT in MPT induction was questioned when liver mitochondria of 
mice genetically modified to lack the two major isoforms of ANT (ANT1 and 
ANT2) still exhibited CyA-sensitive MPT (Kokoszka et al, 2004). However, 
ANT-deficient mitochondria require much higher calcium concentrations 
to induce MPT, suggesting a regulatory role for the ANT in MPT induction, 
sensitizing to adenine nucleotides and ANT ligands (Kokoszka et al., 2004; 
Baines and Molkentin, 2009). Both ischemic and pharmacological PC 
increased the threshold for MPT induction, suggesting that the observed 
inhibition of the ANT could be somehow related with prevention of the 
MPT by PC. In view of this, upstream players, activated by PC that could 
be related with MPT modulation were studied. Heat shock proteins (HSP) 
are a family of chaperone proteins induced by hyperthermia, oxidative 
stress, I/R that inhibit cell death and prevent cytochrome c release by 
mitochondria, and preserve its integrity and function (Kregel, 2002; 
Polla et al., 1996). HSP upregulation has been proposed as a mediator 
of preconditioning beneficial action (Kim et al., 2006). Direct regulation 
of pore conductance has been proposed for HSP modulation of MPT 
induction (He and Lemasters, 2002). This model proposed that stress 
induces misfolding of mitochondrial membrane proteins that cluster to 
form aqueous pores that are permeable to ions and molecules up to a 
molecular mass of about 1500 Da. Chaperone proteins and CypD bind 
to the pore complex to shut off conductance. However, increased Ca2+ 
causes CypD to perturb the MPT pore complex to an open conductance 
state, an effect that is antagonized by CyA. As the number of misfolded 
protein clusters exceeds the number of chaperones available to block 
MPT conductance, unregulated MPT induction occurs. IPC induced the 
increase of HSP70 that could explain the resistance to MPT induction. 
However, pharmacological preconditioning by CCPA, although preventing 
calcium-induced MPT did not upregulate HSP70, suggesting that other 
mechanisms of regulation of the MPT were associated with PC. 
 In the setting of cardiac I/R, inhibition of GSK-3β through a PI3-
kinase–Akt dependent pathway has been shown to be cardioprotective 
(Tong et al., 2002; Gross et al., 2004; Xi et al, 2009). Activation of the 
PI3K/Akt mediates PC-induced phosphorylation of GSK-3β on serine 
9 and inactives it; an increase in the inactivated form of GSK-3β in 
mitochondria mediates convergence of protection signaling to inhibit 
the MPT (Juhaszova et al., 2004), by interaction of translocated GSK-
3β with putative MPT components. Evaluation of GSK-3β and Akt status 
after I/R or PC showed that both pharmacological and IPC induced an 
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that modulation of MPT is critical in PC (ischemic and pharmacological) 
protective signaling during hepatic I/R, and that it can be achieved by a 
GSK-3β-dependent manner. 
 With the goal of identifying successful therapeutic strategies to 
prevent hepatic I/R injury, we evaluated the effect of treatment of lean 
livers, before I/R, with indirubin-3’-oxime, an inhibitor of GSK-3β (chapter 
3.2). This was based on the fact that pharmacological inhibitors of 
GSK-3β also increase phospho-GSK-3β (Zhang et al., 2003). Indirubin-
3’-oxime was shown to protect the liver by maintaining mitochondrial 
calcium homeostasis, thus preserving mitochondrial function and hepatic 
energetic balance. I/R induced translocation of GSK-3β from the cytosol 
to the mitochondria, increasing mitochondrial GSK-3β activity. On the 
other hand, indirubin-3’-oxime preserved the level of inhibition of GSK-3β 
activity on mitochondria, by preserving the mitochondrial pool of phospho-
Ser9-GSK-3β. Therefore, GSK-3β inactivation by indirubin-3’-oxime acts 
as pharmacological preconditioning, modulating the susceptibility to the 
MPT and preserving mitochondrial function after I/R. Although fatty livers 
exhibit mitochondrial dysfunction that enhances I/R injury, treatment 
with indirubin-3’-oxime was also a protective strategy in fatty livers, thus 
improving the efficiency of mitochondrial function.
 We then sought to identify which type of interaction between 
translocated GSK-3β and the MPT would mediate the protective action of 
PC. Although it has been proposed that GSK-3β could interact with VDAC, 
VDAC does not appear to be necessary for MPT induction (Krauskopf et 
al., 2006; Baines et al., 2007), ruling out this type of interaction as MPT 
modulator. However, it has been shown that GSK-3β regulates VDAC and 
modulates transport through the outer membrane of the mitochondria, 
suggest that VDAC may be an important regulator in I/R injury (Das et al., 
2008). Physical interaction of phospho-Ser9-GSK-3β with the ANT has 
been proposed to increase the MPT threshold by reducing ANT affinity 
to CypD (Nishiara et al.,2007; Terashima et al., 2010). Early on, it was 
demonstrated that ANT binds CypD in a CyA-sensitive manner and that 
role of CypD in MPTP formation is to induce a conformational change 
in the ANT (Crompton et al.,1998; Woodfiels et al., 1998). Furthermore, 
the proposed association between the mitochondrial phosphate carrier 
(PiC) and the ANT2 (liver mitochondria), than ANT1 (heart mitochondria) 
was proposed as the explanation for the increased sensitivity of liver 
mitochondria to the MPT, highlighting the importance of MPT targeting in 
the setting of I/R (Basso et al., 2008).
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 Based on the fact that CypD activity is modulated by phosphorylation 
via ERK/GSK-3β pathway, with Ser/Thr phosphorylation of CypD induced 
by GSK-3β favoring the MPT pore opening (Rasola et al., 2010), CypD 
status was evaluated after I/R in fatty livers. Active GSK-3β (in I/R 
situation) promoted an enhancement of CypD phosphorylation, resulting 
in increased CypD immunoprecipitated with the ANT and consequently 
MPT induction. Pharmacological preconditioning with indirubin-3’-oxime, 
maintained the levels of inhibited mitochondrial GSK-3β, inhibited the 
interaction CypD–ANT and preserved energetic balance in I/R fatty livers. 
 Dissociation of CypD from the ANT is also induced when SIRT3 
in a NAD+-dependent-manner deacetylates CypD (Shulga et al., 2010a; 
Shulga et al., 2010b; Hafner et al., 2010). Obesity decreases the cellular 
NAD+/NADH ratio, thereby contributing to a decrease in SIRT3 activity 
that increases the acetylation of mitochondrial proteins, and decreases 
mitochondrial efficiency. By exploring the role of the SIRT3-CypD-MPT 
axis in the protection against I/R injury in fatty livers, we observed that 
the increase in CypD acetylation in I/R group was accompanied by an 
inhibition of SIRT3 activity. (chapter 3.3) Conversely, adding NAD+ to fatty 
livers prior to I/R significantly increases SIRT3 activity and decreases 
CypD acetylation, activity and binding of CypD to ANT, increasing the 
threshold to MPT induction. NAD+ modulates mitochondrial function and 
preserves oxidative phosphorylation being protective against injury in a 
model of hepatic warm I/R. 
 In conclusion, modulation of CypD activity is a clear preventive 
strategy against I/R damage in fatty livers. Decreasing CypD 
phosphorylation (by inhibition of GSK-3β with indirubin-3’-oxime) or 
acetylation (by increasing SIRT3 deacetylase activity), increases the 
resistance to MPT induction. Since I/R injury is associated with increases 
in MPT pore activators (calcium, ROS, Pi) and reductions in MPT pore 
inhibitors, aggravated by fatty liver induced-mitochondrial dysfunction, 
CypD modulation has great therapeutic potential in the clinical setting of 
hepatic ischemia/reperfusion, acting as pharmacological preconditioning 
in lean and fatty livers.
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Figure 4.1 – Preconditioning (ischemic and pharmacological) protects 
from I/R injury via activation of signaling cascades that converge to 
the mitochondria. This increase the resistence to MPT induction, 
thereby preventing cell death.
161
162
163
164
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY
5
165
Acín-Pérez R.; Fernández-Silva P.; Peleato M.L.; Pérez-Martos A.; Enriquez J.A. 
Respiratory active mitochon-drial supercomplexes. Molecular Cell, 2008, 32(4), 
529– 539. 
Aggarwal B.B. Tumour necrosis factors receptor associated signaling molecules 
and their role in activation of apoptosis, JNK and NF-kappaB. Annals of the 
Rheumatic Diseases, 2000, 59 (Suppl 1), i6–i16.
Akao M.; O’Rourke B.; Kusuoka H.; Teshima Y.; Jones S.P.; Marbán E. Differential 
actions of cardioprotective agents on the mitochondrial death pathway. Circ Res, 
2003, 92, 195–202. 
Anderson C.D.; Belous A.; Pierce J.; Nicoud I.B.; Knox C.; Wakata A.; Pinson 
C.W.; Chari R.S. Mitochondrial calcium uptake regulates cold preservation- 
induced Bax translocation and early reperfusion apoptosis. American Journal of 
Transplantation, 2004, 4, 52-362. 
Anderson C.D.; Pierce J.; Nicoud I.; Belous A.; Knox C.D.; Chari R.S. Modulation 
of mitochondrial calcium management attenuates hepatic warm ischemia-
reperfusion injury. Liver Transpl., 2005, 11(6), 663-8.
Anderson L. Identification of mitochondrial proteins and some of their precursors 
in two-dimensional electrophoretic maps of human cells. Proc. Natl. Acad. Sci. 
USA, 1981, 78, 2407-2411.
Andraus W.; de Souza G.F.; de Oliveira M.G.; Haddad L.B.; Coelho A.M.; Galvão 
F.H.; Leitão R.M.; D’Albuquerque L.A.; Machado M.C. S-nitroso-N-acetylcysteine 
ameliorates ischemia-reperfusion injury in the steatotic liver. Clinics, 2010, 65(7), 
715-721.
Arai M.; Thurman R.G.; Lemasters J.J. Involvement of Kupffer cells and sinusoidal 
endothelial cells in ischemic preconditioning to rat livers stored for transplantation. 
Transplant Proc. 1999, 31, 425–427. 
Arkadopoulos N.; Kostopanagiotou G.; Theodoraki K.; Farantos C.; 
Theodosopoulos T.; Stafyla V.; et al. Ischemic preconditioning confers antiapoptotic 
protection during major hepatectomies performed under combined inflow and 
outflow exclusion of the liver. World J. Surg., 2009, 33, 1909-1915.
166
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY Badiola N.; Malagelada C.; Llecha N.; Hidalgo J.; Comella J.X.; Sabriá J.; 
Rodríguez-Alvarez J. Activation of caspase-8 by tumour necrosis factor receptor 
1 is necessary for caspase-3 activation and apoptosis in oxygen-glucose deprived 
cultured cortical cells. Neurobiol Dis., 2009, 35(3), 438-47.
Baines C.P.; Kaiser R.A.; Purcell N.H.; Blair N.S.; Osinska H.; Hambleton M.A.; 
Brunskill E.W.; Sayen M.R.; Gottlieb R.A.; Dorn G.W.; Robbins J.; Molkentin J.D. 
Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition 
in cell death. Nature, 2005, 434, 658–662.
Baines C.P.; Kaiser R.A.; Sheiko T.; Craigen W.J; Molkentin J.D. Voltage-
dependent anion channels are dispensable for mitochondrial-dependent cell 
death. Nat. Cell Biol., 2007, 9, 550–555.
Balaban R.S. The role of Ca(2+) signaling in the coordination of mitochondrial 
atp production with cardiac work. Biochim Biophys Acta, 2009, 1787, 1334–1341.
Banga N.R.; Homer-Vanniasinkam S.; Graham A.; Al-Mukhtar A.; White S.A.; 
Prasad K.R. Ischaemic preconditioning in transplantation and major resection of 
the liver. British Journal of Surgery, 2005, 92 (5), 528–538.
Banga N.R.; Homer-Vanniasinkam S.; Graham A.; Al-Mukhtar A.; White S.A.; 
Prasad K.R. Ischaemic preconditioning in transplantation and major resection of 
the liver. British Journal of Surgery, 2005, 92 (5), 528–538.
Bao H.; Ge Y.; Zhuang S.; Dworkin L.D.; Liu Z. et al. Inhibition of glycogen synthase 
kinase-3β prevents NSAID-induced acute kidney injury. Kidney International, 
2012, 81, 662-673.
Bao J.; Scott Lu Z.; Pang L.; Dimond C.C.; Gius D.; Sack M.N. SIRT3 is regulated 
by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Free Radic. 
Biol. Med., 2010, 49(7), 1230-1237.
Barillas R.; Friehs I.; Cao-Danh H.; Martinez J.F.; Del Nido P.J. Inhibition of 
glycogen synthase kinase-3beta improves tolerance to ischemia in hypertrophied 
hearts. The Annals of Thoracic Surgery, 2007, 84, 126-133.
Basso E.; Fante L.; Fowlkes J.; Petronilli V.; Forte M.A.; Bernardi P. Properties of 
the permeability transition pore in mitochondria devoid of cyclophilin D. J. Biol. 
Chem., 2005, 280,18558-18561.
167
Basso E.; Petronilli V.; Forte M.A.; Bernardi P. Phosphate is essential for inhibition 
of the mitochondrial permeability transition pore by cyclosporin A and by cyclophilin 
D ablation. J. Biol. Chem., 2008, 283(39), 26307–11.
Becker L.B. New concepts in reactive oxygen species and cardiovascular 
reperfusion  physiology. Cardiovasc. Res., 2004, 61, 461-470.
Behrns K.E.; Tsiotos G.G.; DeSouza N.F.; Krishna M.K.; Ludwig J.; Nagorney 
D.M. Hepatic steatosis as a potential risk factor for major hepatic resection. J. 
Gastrointest Surg., 1998, 2, 292-298.
Bernardi P. Mitochondrial transport of cations: Channels, exchangers, and 
permeability transition. Physiol Rev, 1999, 79, 1127–1155. 
Bernardi P. Modulation of the mitochondrial cyclosporin A-sensitive permeability 
transition pore by the proton electrochemical gradient. Evidence that the pore 
can  be opened by membrane depolarization. J. Biol. Chem., 1992, 267(13), 
8834–9. 
Bernardi P.; Krauskopf A.; Basso E.; Petronilli V.; BlalchyDyson E.; DiLisa F.; Forte 
M.A. The mitochondrial permeability transition from in vitro artifact to disease 
target. FEBS J., 2006, 273, 2077-2099.
Beutner G.; Sharma V.K.; Giovannucci D.R.; et al. Identification of a ryanodine 
receptor in rat heart mitochondria. J. Biol. Chem., 2001, 276, 21482–21488.
Bijur G.N.; Jope R.S. Glycogen synthase kinase-3 beta is highly activated in 
nuclei and mitochondria. NeuroReport, 2003, 278, 2415-2419.
Bijur G.N.; Jope R.S. Rapid accumulation of Akt in mitochondria following 
phosphatidyl-inositol 3-kinase activation. J. Neurochem, 2003, 87,1427-1435.
Blachly-Dyson E.; Forte M. VDAC channels. IUBMB Life, 2001, 52, 113–118.
Bolli R. The late phase of preconditioning. Circ. Res., 2000, 87, 972-983. 
Borutaite V. ; Brown G.C. Mitochondria in apoptosis of ischemic heart. FEBS 
Letters, 2003, 541, 1-5. 
Boveris A.; Cadenas E.; Stoppani A.O. Role of ubiquinone in the mitochondrial 
168
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY generation of hydrogen peroxide. Biochem. J., 1976, 156, 435-444. 
Boyer P.D. ATP-synthase – past and future. Biochim. Biophys. Acta, 1998, 1365, 
3-9.
Boyer P.D. The ATP synthase – a splendid molecular machine. Ann. Rev. 
Biochem., 1997, 66, 717-749.
Bradham C.A.; Plumpe J.; Manns M.P.; Brenner D.A.; Trautwein C. Mechanisms 
of hepatic toxicity. I. TNF-induced liver injury. American Journal of Physiology, 
1998, 275 (3 Pt 1), G387-G392.
Bradham C.A.; Schemmer P.; Stachlewitz R.F.; Thurman R.G.; Brenner D.A. 
Activation of nuclear factor-kappaB during orthotopic liver transplantation in rats is 
protective and does not require Kupffer cells. Liver Transplantation and Surgery, 
1999, 5 (4), 282-293.
Browning J.D. & Horton J.D. Molecular mediators of hepatic steatosis and liver 
injury. J. Clin. Invest., 2004, 114, 147-152.
Brunt E.M.; Tiniakos D.G. Histopathology of nonalcoholic fatty liver disease. World 
J. Gastroenterol., 2010, 16(42), 5286-5296.
Caldwell S.H.; Chang C.Y.; Nakamoto R.K.; Krugner-Higby L. Mitochondria in 
nonalcoholic fatty liver disease. Clin. Liver Dis., 2004, 8, 595-617.
Caldwell-Kenkel J.C.; Currin R.T.; Tanaka Y.; Thurman R.G.; Lemasters J.J. 
Kupffer cell activation and endothelial cell damage after storage of rat livers: 
effects of reperfusion. Hepatology, 1991, 13 (1), 83-95.
Canelo R.; Braun F.; Sattler B.; Klinge B.; Lorf T.; Ramadori G.; et al. Is a fatty liver 
dangerous for transplantation? Transplant Proc., 1999, 31, 414–415.
Caraceni P.; Bianchi C.; Domenicali M.; Maria Pertosa A.; Maiolini E.; Parenti 
Castelli G.; et al. Impairement of mitochondrial oxidative phosphorylation in rat 
fatty liver exposed to preservation-reperfusion injury. J. Hepatol., 2004, 41, 82-88.
Caraceni P.; Domenicali M.; Vendemiale G.; Grattagliano I.; Pertosa A.; Nardo B.; 
et al. The reduced tolerance of rat fatty liver to ischemia reperfusion is associated 
with mitochondrial oxidative injury. J Surg Res., 2005, 124, 160-168.
169
Caraceni P.; Nardo B.; Domenicali M.; Turi P.; Vici M.; Simoncini M.; De Maria 
N.; Trevisani F.; Van Thiel D.H.; Derenzini M.; Cavallari A.; Bernardi.  Ischemia-
reperfusion injury in rat fatty liver: role of nutritional status. Hepatology, 1999, 
29(4), 1139.
Carini R.; Grazia De Cesaris M.; Splendore R.; Domenicotti C.; Nitti M.P.; Pronzato 
M.A.; Albano E. Signal pathway responsible for hepatocyte preconditioning by 
nitric oxide. Free Radic. Biol. Med., 2003, 34, 1047-1055. 
Cesura A.M.; Pinard E.; Schubenel R.; Goetschy V.; Friedlein A.; Langen H.; et 
al. The voltage-dependent anion channel is the target for a new class of inhibitors 
of the mitochondrial permeability transition pore. J. Biol. Chem., 2003, 278(50), 
49812–8.
Chance B.; Williams G.R. Respiratory enzymes in oxidative phosphorylation. 
VI. The effects of adenosine diphosphate on azide-treated mitochondria. J. Biol. 
Chem., 1956, 221, 477-489.
Chappell J.B.; Crofts A.R. Calcium ion accumulation and volume changes of 
isolated liver mitochondria: calcium ion-induced swelling. Biochem J., 1965, 95, 
378–86.
Chavin K.D.; Yang S.; Lin H.Z.; Chatham J.; Chacko V.P.; Hoek J.B.; Walajtys-
Rode E.; Rashid A.; Chen C.H.; Huang C.C.; Wu T.C.; Lane M.D.; Diehl A.M. 
Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes 
liver ATP depletion. J. Biol. Chem., 1999, 274, 5692-5700.
Chen  H.;  Xing  B.;  Liu  X.;  Zhan  B.; Zhou  J.;  Zhu H.; Chen Z. Ischemic 
postconditioning inhibits apoptosis after renal  ischemia/reperfusion  injury  in rat. 
Transpl. Int., 2008, 21, 364-371.
Chen D.H.; Xie J.X. Chinese Trad. Herb. Drugs, 1984, 15, 6.
Chen Q.; Moghaddas S.; Hoppel C.L.; Lesnefsky E.J. Ischemic defects in the 
electron transport chain increase the production of reactive oxygen species from 
isolated rat heart mitochondria. American Journal of Physiology Cell Physiology, 
2008, 294, C460-C466.
Choi C.H; Jung Y.K.; Oh S.H. Autophagy induction by capsaicin in malignant 
human breast cells is modulated by p38 and extracellular signal-regulated mitogen-
170
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY activated protein kinases and retards cell death by suppressing endoplasmic 
reticulum stress-mediated apoptosis. Mol. Pharmacol., 2010, 78, 114-125.
Choudhury M.; Jonscher K.R.; Friedman J.E. Reduced mitochondrial function in 
obesity-associated fatty liver: SIRT3 takes on the fat. Aging, 2011, 3, 175-178.
Choudhury S.; Bae S.; Ke Q.; Lee J.Y.; Kim J.; Kang P.M. Mitochondria to nucleus 
translocation of AIF in mice lacking Hsp70 during ischemia/reperfusion. Basic 
Res. Cardiol., 2011, 106(3), 397-407.
Chung H.T.; Pae H.O.; Choi B.M.; Billiar T.R., Kim Y.M. Nitric oxide as a bioregulator 
of apoptosis. Biochemical and Biophysical Research Communications, 2001, 282 
(5), 1075-1079.
Cimen H.; Han M.J.; Yang Y.; Tong Q.; Koc H.; Koc E.C. Regulation of succinate 
dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry, 
2010, 49, 304-311. 
Clarke S.J.; McStay G.P.; Halestrap A.P. Sanglifehrin A acts as a potent inhibitor 
of the mitochondrial permeability transition and reperfusion injury of the heart by 
binding to cyclophilin-D at a different site from cyclosporin A. J. Biol. Chem., 2002, 
277(38), 34793–9. 
Clavien P.A.; Yadav S.; Sindram D.; Bentley R.C. Protective effects of ischemic 
preconditioning for liver resection performed under inflow occlusion in humans. 
Ann. Surg., 2000, 232, 155-162. 
Clemens M.G.; Zhang J.X. Regulation of sinusoidal perfusion: in vivo methodology 
and control by endothelins. Semin. Liver Dis., 1999, 19, 383-396.
Cohen M.V.; Downey J.M. Adenosine: trigger and mediator of cardioprotection. 
Basic Res. Cardiol. 2008, 103, 203-215.
Cohen M.V; Baines C.P; Downey J.M. Ischemic precondi-tioning: from adenosine 
receptor to KATP channel. Annu. Ver. Physiol, 2000, 62, 79-109.
Coito A.J.; Buelow R.; Shen X.D.; Amersi F.; Moore C.; Volk H.D.; Busuttil R.W.; 
Kupiec-Weglinski J.W. Heme oxygenase-1 gene transfer inhibits inducible nitric 
oxide synthase expression and protects genetically fat Zucker rat livers from 
ischemia-reperfusion injury. Transplantation, 2002, 74 (1), 96-102.
171
Connern C.P.; Halestrap A.P. Purification and N-terminal sequencing of peptidyl-
prolyl cis-trans-isomerase from rat liver mitochondrial matrix reveals the existence 
of a distinct mitochondrial cyclophilin. Biochem. J., 1992, 284, 381-385.
Cortez-Pinto H.; Chatham J.; Chacko V.P.; Arnold C.; Rashid A.; Diehl A.M. 
Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot 
study. JAMA., 1999, 282, 1659-1664.
Crisostomo P.R.; Wairiuko G.M.; Wang M.; Tsai B.M.; Morrell E.D.; Meldrum D.R. 
Preconditioning versus postconditioning: mechanismsand therapeutic potentials. 
J. Am. Coll. Surg., 2006, 202, 797-812.
Crompton M.; McGuinness O.; Nazareth W. The Involvement of cyclosporin A 
binging proteins in regulating and uncoupling mitochondrial energy transduction. 
Biochim. Biophys. Acta, 1992, 1101, 214-217.
Crompton M.; Virji S.; Doyle V.; Johnson N.; Ward J.M. The mitochondrial 
permeability transition pore. Biochem. Soc. Symp., 1999, 66, 167-179.
Crompton M.; Virji S.; Ward J.M. Cyclophilin-D binds strongly to complexes of the 
voltage-dependent anion channel and the adenine nucleotide translocase to form 
the permeability transition pore. Eur. J. Biochem., 1998, 1, 258(2), 729-735. 
Cutrin J.C.; Perrelli M.G.; Cavalieri B.; Peralta C.; Rosello-Catafau J.; Poli G. 
Microvascular dysfunction induced by reperfusion injury and protective effect 
of ischemic preconditioning. Free Radical Biology and Medicine., 2002, 33 (9), 
1200-1208.
D’Alessandro A.M.; Kalayoglu M.; Sollinger H.W.; Hoffmann R.M.; Reed A.; 
Knechtle S.J.; et al.The predictive value of donor liver biopsies for the development 
of primary nonfunction after orthotopic liver transplantation. Transplantation, 
1991, 51, 157-163.
Dahl T.B.; Haukeland J.W.; Yndestad A.; Ranheim T.; Gladhaug I.P.; Damås J.K.; 
Haaland T. et al. Intracellular nicotinamide phosphoribosyltransferase protects 
against hepatocyte apoptosis and is down-regulted in non-alcoholic fatty liver 
disease. J. Clin. Endocrinol Metab., 2010, 95, 3039-3047. 
Dajani R.; Fraser E.; Roe S.M.; Young N.; Good V.; Dale T.C.; Pearl L.H. Crystal 
structure of glycogen synthase kinase 3beta: structural basis for phosphate-
172
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY primed substrate specificity and autoinhibition. Cell, 2001, 105, 721–732.
Das S.; Wong R.; Rajapakse N.; Murphy E.; Steenbergen C. Glycogen synthase 
kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates 
voltage-dependent anion channel phosphorylation. Circ. Res., 2009, 103, 983-
991.
D’Autréaux B.; Toledano M. B. ROS as signalling molecules: mechanisms that 
generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol., 2007, 8, 813–
824. 
Degle Esposti D.; Sebagh M.; Pham P.; Reffas M.; Pous C.; Azzoulay D.; Lemoine 
A. Ischemic preconditioning induces autophagy and limits necrosis in human 
recipients of fatty liver grafts,decreasing the incidence of rejection episodes. Cell 
Death Dis., 2011.
Demetris A.J.; Adeyi O.; Bellamy C.O.; Clouston A.; Charlotte F.; et al. Liver biopsy 
interpretation for causes of late liver allograft dysfunction. Hepatology, 2006, 44, 
489–501.
Denton R.M. Regulation of mitochondrial dehydrogenases by calcium ions. 
Biochim Biophys Acta, 2009, 1787, 1309–1316.
Dhalla N.S.; Elmoselhi A.B.; Hata T.; Makino N. Status of myocardial antioxidants 
in ischemia–reperfusioninjury. Cardiovascular Research, 2000, 47, 446-456.
Di Lisa F.; Canton M.; Menabo R.; Kaludercic N.; Bernardi P. Mitochondria 
and  cardioprotection. Heart Fail Rev, 2007, 12(3–4), 249–60.
Diehl, A.M. Cytokine regulation of liver injury and repair. Immunological Reviews, 
2000, 174, 160-171.
Doble B.W.; Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. 
Cell Sci., 2003, 116, 1175-1186.
Downey J.M. The cellular mechanisms of ischaemic and pharmacological 
precon-  ditioning. Cardiovasc. J. S. Afr., 2004, 15, S3.
 
Dudkina N. V.; Sunderhaus S.; Boekema E.J.; Braun H.P. The higher level 
of organization of the oxidative phosphorylation system: mitochondrial 
173
supercomplexes. Journal of Bioenergetics and Biomembranes, 2008, 40(5), 
419–424.
Echtay K.S.; Esteves T.C.; Pakay J.L.; Jekabsons M.B.; Lambert A.J.; Portero 
Otin M.; Pamplona R.; Vidal Puig A.J.; Wang S.; Roebuck S.J.; Brand M.D. A 
signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. 
EMBO J., 2003, 22, 4103-4110.
Estabrook R.W. Mitochondrial respiratory control and the polarographic 
measurements of ADP/O ratios. Methods Enzymol, 1967, 10, 41-47.
Fan C.; Zwacka R.M.; Engelhardt J.F. Therapeutic approaches for ischemia/
reperfusion injury in the liver. Journal of Molecular Medicine, 1999, 77(8), 577-
592.
Farber J.L. Membrane injury and calcium homeostasis in the pathogenesis of 
coagulative necrosis. Lab. Invest., 1982, 47, 114-123.
Feldstein A.E. Novel insights into pathophysiology of nonalcoholic fatty liver 
disease. Semin. Liver Dis., 2010, 30, 391-401.
Fernandez L.; Heredia N.; Grande L.; Gomez G.; Rimola A.; Marco A.; Gelpi E.; 
Rosello-Catafau J.; Peralta C. Preconditioning protects liver and lung damage in 
rat liver transplantation: role of xanthine/xanthine oxidase. Hepatology, 2002, 36 
(3), 562–572.
Fiore C.; Trézéguet V.; Le Saux A.; Roux P.; Schwimmer C.; Dianoux A.C.; Noel 
F.; Lauquin G.J.; Brandolin G.; Vignais P.V. The mitochondrial ADP/ATP carrier: 
structural, physiological and pathological aspects. Biochimie, 1998, 80, 137–150. 
Fontaine E.; Ichas F.; Bernardi P. A ubiquinone-binding site regulates the 
mitochondrial permeability transition pore. J. Biol. Chem., 1998, 273(40), 25734–
40. 
Forbes R.A.; Steenbergen C.; Murphy E. Diazoxide-induced cardioprotection 
requires signaling through a redox-sensitive mechanism. Circ. Res., 2001, 88, 
802-809.
Frey T.G.; Mannella C. A. The internal structure of mitochondria. Trends Biochem. 
Sci., 2000, 25, 319-324.
174
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY Fukumori T.; Ohkohchi N.; Tsukamoto S.; Satomi S. Why is a liver with steatosis 
susceptible to cold ischemic injury? Transplant Proc., 1999, 31(1-2), 548-549.
Fukumori T.; Ohkohchi N.; Tsukamoto S.; Satomi S. Why is fatty liver unsuitable 
for transplantation? Disorientation of mitochondrial ATP synthesis and sinusoidal 
structure during cold preservation of a liver with steatosis. Transpl Proc, 1997, 
29, 412-415.
Furukawa H.; Todo S.; Imventarza O.; Casavilla A.; Wu Y.M.; Scotti-Foglieni 
C.; Broznick B.; Bryant J.; Day R. and Starzl T.E. Effect of cold ischemia time 
on the early outcome of human hepatic allografts preserved with UW solution. 
Transplantation, 1991, 51, 1000-1004. 
Gao W.; Bentley R.C.; Madden J.F.; et al. Apoptosis of sinusoidal endothelial 
cells is a critical mechanism of preservation injury in rat liver transplantation. 
Hepatology, 1998, 27(6), 1652-1660.
Garcia-Dorado D.; Rodriguez-Sinovas A.; Ruiz-Meana M.; Inserte J.; Agullo L.; 
Cabestrero A. The end-effectors of preconditioning protectionagainst myocardial 
cell death secondary to ischemia–reperfusion. Cardiovasc. Res., 2006, 70, 274-
285.
Garrido C.; Schmitt E.; Cande C.; Vahsen N.; Parcellier A.; Kroemer G. HSP27 
and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle, 2003, 2, 579-
584.
Gazotti P, Malmstron K, Crompton M. A Laboratory Manual on Transport and 
Bioenergetics. New York, NY:Springer Verlag, 1979. Falta Páginas
Gomez L.; Paillard M.; Thibault H.; Derumeauz G.; Ovize M. Inhibition of GSK3-
beta by postconditioning is required to prevent opening of the mitochondrial 
permeability transition pore during reperfusion. Circulation., 2008, 117, 2761-
2768. 
Gornall A.G.; Bardawill C.J.; David M.M. Determination of serum proteins by 
means of the biuret reaction. J. Biol. Chem., 1949, 177, 751-766.
Gosh S.; May M.J.; Koop E.B. NF-Kb and Rel proteins: evolucionary conserved 
mediators of immune responses. Annu Rev Imunol., 1998, 16, 225-260.  
175
Grattagliano I.; Vendemiale G.; Lauterburg B.H. Reperfusion injury of the liver: 
role of mitochondria and protection by glutathione ester. Journal of Surgical 
Research, 1999, 86 (1), 2-8.
Green D.R.; Reed J.C. Mitochondria and apoptosis. Science., 1998, 28, 
281(5381), 1309-1312.
Griffiths E.J.; Halestrap A.P. Further evidence that cyclosporin-A protects 
mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-
trans isomerase - Implications for the immunosuppressive and toxic effects of 
cyclosporine. Biochem. J., 1991, 274, 611-614.
Griffiths E.J.; Halestrap A.P. Mitochondrial non-specific pores remain closedduring 
cardiac ischaemia, but open upon reperfusion. Biochemical Journal, 1995, 
307,93–98.
Griffiths E.J.; Halestrap A.P. Protection by cyclosporin A of ischemia/reperfusion-
induced damage in isolated rat hearts. J. Mol. Cell Cardiol., 1993, 25(12), 1461–9.
Gross E.R.; Hsu A.K.; Fross G.J. Opioid-induced cardioprotection occurs via 
glycogen synthase kinase beta during reperfusion in intact rat hearts. Circ. Res., 
2004, 94, 960–966. 
Hafez T.S.; Glantzounis G.K.; Fusai G.; Taanman J.W.; Wignarajah P.; Parkes H.; 
Fuller B.; Davidson B.R.; Seifalian A.M. Intracellular oxygenation and cytochrome 
oxidase C activity in ischemic preconditioning of steatotic rabbit liver. Am. J. 
Surg., 2010, 4, 507-518. 
Hafner A.V.; Dai J.; Gomes A.P.; Xiao C.Y.; Palmeira C.M.; Rosenzweig A.; 
Sinclair D.A. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD 
at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY), 
2010, 2(12), 914-923.
Hakamada K.; Sasaki M.; Takahashi K.; Umehara Y.; Konn M. Sinusoidal flow 
block after warm ischemia in rats with diet-induced fatty liver. Journal of Surgical 
Research, 1997, 70 (1), 12–20.
Halestrap A. A pore way to die. Nature, 2005, 434, 578-579.
Halestrap A.P. What is the mitochondrial permeability transition pore? J. Mol. Cell 
176
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY Cardiol., 2009, 46, 821-831.
Halestrap A.P.; Clarke S.J.; Javadov S.A. Mitochondrial permeability transition 
pore opening during myocardial reperfusion--a target for cardioprotection. 
Cardiovascular Research, 2004, 61, 372-385. 
Halestrap A.P.; Davidson A.M. Inhibition of Ca2(+)-induced large amplitude 
swelling of liver and heart mitochondria by Cyclosporin A is probably caused by 
the inhibitor binding to mitochondrial matrix peptidyl-prolyl cis-trans isomerase 
and preventing it interacting with the adenine nucleotide translocase. Biochem. 
J., 1990, 268, 153-160.
Halestrap A.P.; McStay G.P.; Clarke S.J. The permeability transition pore complex: 
another view. Biochimie., 2002, 84,153-166.
Haque M.; Sanyal A. The metabolic abnormalities associated with non alcoholic 
fatty liver disease. Best Pract. Res. Clin. Gastroenlogy., 2002, 16, 709-731.
Harada H.; Wakabayashi G.; Takayanagi A.; Shimazu M.; Matsumoto K.; Obara 
H.; Shimizu N.; Kitajima M. Transfer of the interleukin-1 receptor antagonist gene 
into rat liver abrogates hepatic ischemia-reperfusion injury. Transplantation, 2002, 
74 (10), 1434–1441.
Hatano E. Tumor necrosis factor signaling in hepatocyte apoptosis. J. Gastroenterol 
Hepatol., 2007, 22 Suppl 1, S43-44.
Hatefi Y. The mitochondrial electron transport and oxidative phosphorilation 
system. Ann. Rev. Biochem., 1985, 54, 1015-1069.
Hausenloy D.J.; Yellon D.M.; Mani-Babu S.; Duchen M.R. Preconditioning 
protects by inhibiting the mitochondrial permeability transition. American Journal 
of Physiology, 2004, 287, H841-H849.
Haworth R.A.; Hunter D.R. Control of the mitochondrial permeability transition 
pore by high-affinity ADP binding at the ADP/ATP translocase in permeabilized 
mitochondria. J. Bioenerg. Biomembr., 2000, 32, 91–96. 
Haworth R.A.; Hunter D.R. The Ca2+-induced membrane transition in mitochon- 
dria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys, 1979, 195, 460–7.
He L.; Lemasters J.J. Heat shock suppresses the permeability transition in rat 
177
liver mitochondria. J. Biol. Chem., 2003, 278, 16755.
He L.; Lemasters J.J. Regulated and unregulated mitochondrial permeability 
transition pores: A new paradigm of pore structure and function? FEBS Lett., 
2002, 13, 512.
He S.; Atkinson C.; Evans Z.; Ellett J.D.; Southwood M.; Elvington A.; Chavin K.D.; 
Tomlinson S..A role for complement in the enhanced susceptibility of steatotic 
livers to ischemia and reperfusion injury.  J. Immunol., 2009, 183(7), 4764-4772.
Hensley K.; Robinson K.A.; Gabbita S.P.; Salsman S.; Floyd R.A. Reactive 
oxygen species, cell signaling, and cell injury. Free Radic. Biol. Med., 2000, 28, 
1456-1462.
Hirschey M.D.; Shimazu T.; Goetzman E.; Jing E.; Schwer B.; Lombard D.B.; 
Grueter C.A.; et al. SIRT3 regulates mitochondrial fatty–acid oxidation by 
reversiblr enzyme deacetylation. Nature, 2010, 464, 121-125.
Hoch F.L. Cardiolipins and biomembrane function. Biochim. Biophys. Acta, 1992, 
1113, 71-133.
Honda H.M.; Korge P.; Weiss J.N. Mitochondria and ischemia/reperfusion njury. 
Annals of the New York Academy of Sciences, 2005, 1047, 248-258. 
Hool L.C. Reactive oxygen species in cardiac signalling: from mitochondria to 
plasma membrane ion channels. Clin. Exp. Pharmacol. Physiol., 2006, 33, 146-
151.
Hu K.; Zhan E.; McIntosh V.J.; Lasley R.D. Adenosine A2A and A2B receptors 
are both  required for adenosine A1 receptor-mediated cardioprotection. Am. J. 
Physiol., 2011, 301, H1183-1189. 
Huang J.; Klionsky D.J. Autophagy and human disease. Cell Cycle, 2007, 6, 
1837-1849.
Iimuro Y.; Nishiura T.; Hellerbrand C.; Behrns K.E.; Schoonhoven R.; Grisham 
J.W.; Brenner D.A. NFkappaB prevents apoptosis and liver dysfunction during 
liver regeneration. Journal of Clinical Investigation, 1998, 101 (4), 802-811.
Imahashi K.; Schneider M.D.; Steenbergen C.; Murphy E. Transgenic expression 
178
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during 
ischemia, and reduces ischemia/reperfusion injury. Circ. Res., 2004, 95, 734-741.
Inagaki K.; Churchill E.; Mochly Rosen D. Epsilon protein kinase C as a potential 
therapeutic target for the ischemic heart. Cardiovasc. Res., 2006, 70, 222-230.
Inserte J.; Gacrcia-Dorado D.; Hernando V.; Barba I.; Soler-Soler J. Ischemic 
preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity 
during early reperfusion. Cardiovasc. Res., 2006, 70, 364-373.
Inserte J.; Garcia-Dorado D.; Ruiz-Meana M.; Padilla F.; Barrabes J.A.; Pina P.; et 
al. Effect of inhibition of Na+/Ca2+ exchanger at the time of myocardial reperfusion 
on hypercontracture and cell death. Cardiovasc. Res., 2002, 55, 739-748.
Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and 
preconditioning. American Journal of Physiology: Gastrointestinal and Liver 
Physiology, 2003, 284 (1), G15-G26.
Jaeschke H. Reactive oxygen and ischemia/reperfusion injury of the liver. 
Chemico–Biological Interactions, 1991, 79 (2), 115-136. 
Jaeschke H.; Farhood A.; Smith C.W. Neutrophils contribute to ischemia/
reperfusion injury in rat liver in vivo. FASEB J., 1990, 4(15), 3355-3359.
Jaeschke H.; Mitchell J.R. Mitochondria and xanthine oxidase both generate 
reactive oxygen species in isolated perfused rat liver after hypoxic injury. 
Biochemical and Biophysical Research Communications, 1989, 160 (1), 140-147.
Jaeschke H.; Smith C.V.; Mitchell J.R. Hypoxic damage generates reactive oxygen 
species in isolated perfused rat liver. Biochem. Biophys. Res. Commun., 1988, 
150(2), 568-574.
Jassem W.; Fuggle S.V.; Rela M.; Koo D.D.; Heaton N.D. The role of mitochondria 
in ischemia/reperfusion injury. Transplantation, 2002, 27, 73(4), 493-499.
Javadov S.A.; Clarke S.; Das M.; Griffiths E.J.; Lim K.H.; Halestrap A.P. Ischaemic 
preconditioning inhibits opening of mitochondrial permeability transition pores in 
the reperfused rat heart. J. Physiol, 2003, 549(Pt 2), 513–24.
Jennings R.B.; Reimer K.A. The cell biology of acute myocardial ischemia. Annu. 
179
Rev. Med., 1991, 42, 225-246.
Jeon B.R.; Yeom D.H.; Lee S.M. Protective effect of allopurinol on hepatic energy 
metabolism in ischemic and reperfused rat liver. Shock, 2001, 15 (2), 112-117. 
Johnson E.F.; Palmer C.N.; Griffin K.J.; Hsu M.H. Role of the peroxisome 
proliferator activated receptor in cytochrome P450 4A gene regulation. FASEB J., 
1996, 10, 1241-1248.
Jope R.S.; Yuskaitis C.J.; Beurel E. Glycogen synthase kinase-3 (GSK3): 
inflammation, diseases, and therapeutics. Neurochem. Res., 2007, 32, 577-595
Jope R.S; Jonhson, G.V.M. The glamour and gloom of glycogen synthase 
kinase-3. Trends Biochem. Sci., 2004, 29, 95-102.
Juhaszova M.; Wang S.; Zorov D.B.; Nuss H.B.; Gleichmann M.; Mattson M.P.; 
Sollott S.J. The identity and regulation of the mitochondrial permeability transition 
pore: where the known meets the unknown. Ann. N. Y. Acad. Sci., 2008, 1123, 
197-212.
Juhaszova M.; Wang S.; Zorov D.B.; Nuss H.B.; Gleichmann M.; Mattson M.P.; 
Sollott S.J. The identity and regulation of the mitochondrial permeability transition 
pore: where the known meets the unknown. Ann. N. Y. Acad. Sci., 2008, 1123, 
197-212.
Juhaszova M.; Zorov D.B.; Kim S.H.; Pepe S.; Fu Q.; Fishbein K.W.; Ziman B.D.; 
Wang S.; Ytrehus K.; Antos C.L.; Olson E.N.; Sollott S.J. Glycogen synthase 
kinase-3 beta mediates convergence of protection signaling to inhibit the 
mitochondrial permeability transition pore. J. Clin. Invest., 2004, 113, 1535-1549.
Kamo N.; Muratsugu M.; Hongoh R.; Kobatake V. Membrane potential of 
mitochondria measured with an electrode sensitive to tetraphenyl phosphonium 
and relationship between proton electrochemical potential and phosphorylation 
potential in steady state. J. Membr. Biol., 1979, 49, 105-121.
Ke B.; Lipshutz G.S.; Kupiec-Weglinski J.W. Gene therapy in liver ischemia and 
reperfusion injury. Curr. Pharm. Des., 2006, 12, 2969-2975.
Kendrick A.A.; Choudhury M.; Rahman S.M.; McCurdy C.E.; Friederich M.; Van 
Hove J.L.; Watson P.A.; Birdsey N.; Bao J.; Gius D.; Sack M.N.; Jing E.; Kahn 
180
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY C.R.; Friedman J.E.; Jonscher K.R. Fatty liver is associated with reduced SIRT3 
activity and mitochondrial protein hyperacetylation. Biochem. J., 2011, 433 (3), 
505-514.
Kim H.P.; Morse D.; Choi A.M. Heat-shock proteins: new keys to the development 
of cytoprotective therapies. Expert Opin Ther Targets, 2006, 10(5), 759-769.
Kim S.C.; Sprung R.; Chen Y.; Xu Y.; Ball H.; Pei J.; Cheng T.; Kho Y.; Xiao H.; Xiao 
L.; Grishin N.V.; White M.; Yang X.J.; Zhao Y. Substrate and functional diversity of 
lysine acetylation revealed by a proteomics survey. Mol. Cell., 2006, 23, 607-618.
Kleiner D.E.; Brunt E.M.; Van Natta M.; Behling C.; Contos M.J.; Cummings O.W.; 
Ferrell L.D.; Liu Y.C.; Torbenson M.S.; Unalp-Arida A.; Yeh M.; McCullough A.J.; 
Sanyal A.J. Design and validation of a histological scoring system  for nonalcoholic 
fatty liver disease. Hepatology, 2005, 41, 1313-1321.
Kockeritz L.; Doble B.; Patel S.; Woodgett J.R. Glycogen Synthase Kinase-3 – An 
overview of an over-achieving protein kinase. Curr. Drug Targets, 2006, 7, 1377-
1388. 
Kodavanti P.; Mehendale H. Biochemical methods of studying hepatotoxicity. 
Hepatology, 1991, 241-326.
Kokoszka J.E.; Waymire K.G.; Levy S.E.; Sligh J.E.; Cai J.; Jones D.P.; MacGregor 
G.R.; Wallace D.C. The ADP/ATP translocator is not essential for the mitochondrial 
permeability transition pore. Nature, 2004, 427, 461-465.
Kong X.; Wang R.; Xue Y.; Liu X.; Zhang H.; Chen Y.; Fang F.; Chang Y. Sirtuin 3, 
a new target of PGC-1alpha, plays an important role in the suppression of ROS 
and mitochondrial biogenesis. PLoS ONE, 2010, 5, e11707. 
Koolman J.; Röhm K.H. Color Atlas of Biochemistry. Thieme Medical Publishers 
Inc., 1996, 130-131, 278-279.
Kostyak J.C.; Hunter J.C.; Korzick D.H. Acute PKCdelta inhibition limits ischaemia-
reperfusion injury in the aged rat heart: role of GSK-3beta. Cardiovascular 
Research, 2006, 70, 325-334.
Koti R.S.; Seifalian A.M.; Davidson B.R. Protection of the liver by ischemic 
preconditioning: a review of mechanisms and clinical applications. Dig. Surg., 
181
2003, 20, 383–396.
Kuno A.; Critz S.D.; Cui L.; Solodushko V.; Yang X.M.; Krahn T.; Albrecht B.; 
Philipp S.; Cohen M.V.; Downey J.M. Protein kinase C protects preconditioned 
rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling 
during early reperfusion. J. Mol. Cell. Cardiol., 2007, 43, 262-271.
Lambert A. J.; Brand M. D. Inhibitors of the quinone binding site allow rapid 
superoxide production from mitochondrial NADH:ubiquinone oxidoreductase 
(complex I). J. Biol. Chem., 2004, 279, 39414–39420. 
Lanir A.; Jenkins R.L.; Caldwell C.; Lee R.G.; Khettry U.; Clouse M.E. Hepatic 
transplantation survival: correlation with adenine nucleotide level in donor liver. 
Hepatology, 1988, 8, 471-475.
Leclerc S.; Garnier M.; Hoessel R.; Marko D.; Bibb J.A.; Snyder G.L.; Greengard 
P.; Biernat J.; Wu Y.Z.; Mandelkow E.M.; Eisenbrand G.; Meijer L. Indirubins inhibit 
glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in 
abnormal tau phosphorylation in Alzheimer’s disease. A property common to most 
cyclin-dependent kinase inhibitors? J. Biol. Chem., 2001, 276, 251-260.
Lee J.S.; Lee J.J.; Seo J.S. HSP70 deficiency results in activation of c-Jun 
N-terminal Kinase, extracellular signal-regulated kinase, and caspase-3 in 
hyperosmolarity-induced apoptosis. J. Biol. Chem., 2005, 280, 6634-6641.
Lemasters J.J. Modulation of mitochondrial membrane permeability in 
pathogenesis, autophagy and control of metabolism. J. Gastroenterol Hepatol, 
2007, 22, S31-S37.
Lemasters J.J.; Thurman R.G. The many facets of reperfusion injury. 
Gastroenterology, 1995, 108, 1317-1320.
Lemasters, J.J. Necrapoptosis and the mitochondrial permeability transition: 
shared pathways to necrosis and apoptosis. American Journal of Physiology, 
1999, 276 (1 Pt 1), G1-G6.
Lentsch A.B.; Kato A.; Yoshidome H.; McMasters K.M.; Edwards M.J. Inflammatory 
mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion 
injury. Hepatology, 2000, 32 (2), 169-173. 
182
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY Lentsch A.B.; Yoshidome H.; Cheadle W.G.; et al. Chemokine involvement in 
hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory 
protein-2 and KC. Hepatology, 1998, 27(4), 1172-1177.
Lentsch A.B.; Yoshidome H.; Kato A.; et al. Requirement for interleukin-12 in the 
pathogenesis of warm hepatic ischemia/reperfusion injury in mice. Hepatology, 
1999, 30(6), 1448-1453.
Leung A.W.C.; Varanyuwatana P.; Halestrap A.P. The mitochondrial phosphate 
carrier interacts with cyclophilin D and my play a key role in the permeability 
transition. J. Biol. Chem., 2008, 283, 26312-26323.
Levene A.P.; Goldin R.D. The epidemiology, pathogenesis and histopathology of 
fatty liver disease. Histopathology, 2012, 156(9),A4568
Li X.; Zhang J.F.; Lu M.Q.; Yang Y.; Xu C.; Li H.; Wang G.S.; Cai C.J.; Chen G.H. 
Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction 
of small interference RNA targeting Fas. Langenbecks Arch Surg., 2007, 392(3), 
345-351
Lieber A.; He C.Y.; Meuse L.; Schowalter D.; Kirillova I.; Winther B.; Kay M.A. The 
role of Kupffer cell activation and viral gene expression inearly liver toxicity after 
infusion of recombinant adenovirus vectors. Journal of Virology, 1997, 71 (11), 
8798-8807
Lim S.Y.; Davidson S.M.; Hausenloy D.J.; Yellon D.M. Preconditioning and 
postconditioning: the essential role of the mitochondrial permeability transition 
pore. Cardiovascular Research, 2007, 75, 530-535.
Lin K.M.; Lin B.; Lian I.Y.; et al. Combined and individual mitochondrial HSP60 
and HSP10 expression in cardiac myocytes protects mitochondrial function and 
prevents apoptotic cell deaths induced by simulated ischemia – reoxygenation. 
Circulation, 2001, 103, 1787-1792.
Ma Y.; Chen H.; He X.; Nie H.; Hong Y.; Sheng C.; Wang Q.; Xia W.; Ying W. NAD+ 
Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for 
Neurological Diseases. Curr. Drug Targets, 2012, 13, 222-229.
Mari M.; Bai J.; Cederbaum A.I. Adenovirus-mediated overexpression of 
catalase in the cytosolic or mitochondrial compartment protects against toxicity 
183
caused by glutathione depletion in HepG2 cells expressing CYP2E1. Journal of 
Pharmacology and Experimental Therapeutics, 2002, 301(1), 111-118.
Marni A.; Ferrero M.E.; Gaja G. Metabolic function of grafted liver in rats. 
Transplantation, 1988, 46, 830-835.
Massip-Salcedo M.; Casillas-Ramirez A.; Franco-Gou R.; Bartrons R.; Ben 
Mosbah I.; Serafin A.; Rosello-Catafau J.; Peralta C. Heat shock proteins and 
mitogen-activated protein kinases in steatotic livers undergoing ischemia-
reperfusion: some answers. Am. J. Pathol., 2006, 168, 1474–1485.
Matsui T.; Rosenzweig A. Convergent signal transduction pathways controlling 
cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J. Mol. Cell 
Cardiol., 2005, 38, 63-71.
McCormack L.; Dutkowski P.; El-Badry A.M.; Clavien P.A. Liver transplantation 
using fatty livers: always feasible? J. Hepatol., 2011, 54, 1055–1062.
McCuskey R.S.; Urbaschek R.; Urbaschek B. The microcirculation during 
endotoxemia. Cardiovascular Research, 1996, 32 (4), 752-763.
Metzger J.; Dore S.P.; Lauterburg B.H. Oxidant stress during reperfusion of 
ischemic liver: no evidence for a role of xanthine oxidase. Hepatology, 1988, 8 
(3), 580-584.
Michels G.; Khan I.F.; Endres-Becker J.; et al. Regulation of the human cardiac 
mitochondrial Ca2+ uptake by 2 different voltage-gated Ca2+ channels. 
Circulation, 2009, 119, 2435–2443. 
Mitchell P. Coupling of phosphorilation to electron and hydrogen transfer by a 
chemi-osmotic type mechanism. Nature, 1961, 191, 144-145.
Mittler R.; Vanderauwera S.; Suzuki N.; Miller G.; Tognetti V. B.; Vandepoele 
K.; Gollery M.; Skulachev V.; Van Breusegem F. ROS signaling: the new wave? 
Trends Plant Sci., 2011, 16, 300–309. 
Miura T.; Nishihara M.; Miki T. Drug development targeting the glycogen synthase 
kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-
3beta in myocardial protection against ischemia/reperfusion injury. J. Pharmacol 
Sci., 2009, 109(2), 162-167. 
184
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY Miyamoto S.; Murphy A.N.; Brown J.H. Akt mediates mitochondrial protection 
in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II, Cell 
Death Differ., 2008, 15, 521-529.
Mochida S.; Arai M.; Ohno A.; Masaka N.; Ogata I.; Fujiwara K. Oxidative stress in 
hepatocytes and stimulatory state of Kupffer cells after reperfusion differ between 
warm and cold ischemia in rats. Liver., 1994, 14 (5), 234-240.
Moreau B.; Nelson C.; Parekh A.B. Biphasic regulation of mitochondrial ca2+ 
uptake by cytosolic Ca2+ concentration. Curr. Biol., 2006, 16, 1672–1677. 
Morihira M.; Hasebe N.; Baljinnyam E.; Sumitomo K.; Matsusaka T.; Izawa K.; 
Fujino T.; Fukuzawa J.; Kikuchi K. Ischemic preconditioning enhances scavenging 
activity of reactive oxygen species and diminishes transmural difference of infarct 
size. Am. J. Physiol., 2006, 290, H577-H583.
Mosbah I.B.; Alfany-Fernandez I.; Martel C.; Zaouali M.A.; Bintanel-Morcillo M.; 
Rimola A.; et al. Endoplasmic reticulum stress inhibition protects steatotic and 
non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death 
and Dis., 2010, 1 (e52), 1-12.
Mosher B.; Dean R.; Harkema J.; Remick D.; Palma J.; Crockett E. Inhibition of 
Kupffer cells reduced CXC chemokine production and liver injury. J. Surg. Res., 
2001, 99(2), 201-10.
Murata M.; Akao M.; O’Rourke B.; Marban E. Mitochondrial ATP-sensitive 
potassium channels attenuate matrix Ca2+ overload during simulated ischemia 
and reperfusion: possible mechanism of cardioprotection. Circ. Res., 2001, 89, 
891-898.
Murphy E.; Steenbergen C. Ion transport and energetics during cell death and 
protection. Physiology (Bethesda), 2008, 2, 115-123.
 Murphy E.; Steenbergen C. Preconditioning: the mitochondrial connection. Annu. 
Ver. Physiol., 2007, 69, 51-67.
Murphy M. P. How mitochondria produce reactive oxygen species. Biochem. J., 
2009, 417, 1–13. 
Nakagawa T.; Shimizu S.; Watanabe T.; Yamaguchi O.; Otsu K.; Yamagata 
185
H.; Inohara H.; Kubo T.; Tsujimoto Y. Cyclophilin D-dependent mitochondrial 
permeability transition regulates some necrotic but not apoptotic cell death. 
Nature, 2005, 434, 652-658.
Nakayama H.; Yamamoto Y.; Kume M.; Yamagami K.; Yamamoto H.; Kimoto S.; 
et al. Pharmacologic stimulation of adenosine A2 receptor supplants ischemic 
preconditioning in providing ischemic tolerance in rat livers. Surgery, 1999, 126, 
945-954.
Nicchitta C.V.; Williamson J.R. Spermine. A regulator of mitochondrial calcium 
cycling. J. Biol. Chem., 1984, 259, 12978–12983.
Ning X.H.; Xu C.S.; Song Y.; Xiao Y.; Hu Y.J.; Lupinetti F.; Portman M. Hypothermia 
preserves function and signaling for mitochondrial biogenesis during subsequent 
ischemia. Am. J. Physiol., 1998, 274 (Heart Circ. Physiol. 43), H786-H793.
Nishihara M.; Miura T.; Miki T.; Tanno M.; Yano T.; Naitoh K.; et al. Modulation 
of the mitochondrial permeability transition pore complex in GSK-3 β -mediated 
myocardial protection. J Mol. Cell Cardiol., 2007, 43, 564 – 570.
Noack E.; Greeff K. Inhibition of calcium transport in mitochondria by -receptor 
blocking substances and its reactivation by phospholipids. Experientia, 1971, 27, 
810–811. 
Nussler A.K.; Di S.M.; Billiar T.R.; et al. Stimulation of the nitric oxide synthase 
pathway in human hepatocytes by cytokines and endotoxin. J. Exp. Med., 1992, 
176 (1), 261-4.
Nylandsted J.; Rohde M.; Brand K.; Bastholm L.; Elling F.; Jaattela M. Selective 
depletion of HSP70 activates a tumor-specific death program that is independent 
of caspases and bypasses Bcl-2. Proc. Natl. Acad. Sci., 2000, 97, 7871-7876.
Orrenius S.; McConkey D.J.; Bellomo G.; Nicotera P. Role of Ca in toxic cell 
injury. TIPS, 1989,10, 281-285.
Pachori A.S.; Melo L.G.; Hart M.L.; Noiseux N.; Zhang L.; Morello F.; Solomon 
S.D.; Stahl G.L.; Pratt R.E.; Dzau V.J. Hypoxia-regulated therapeutic gene as 
a preemptive treatment strategy against ischemia/reperfusion tissue injury. 
Proceedings of the National Academy of Sciencesof the United States of America., 
2004, 101 (33), 12282-12287.
186
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY
Pagel P.S.; Krolikowski J.G.; Neff D.A.; Weihrauch D.; Bienengraeber M.; Kersten 
J.R.; Wartlier D.C. Inhibition of glycogen synthase kinases enhances isoflurane-
induced protetion against myocardial infarction during early reperfusion in vivo. 
Anesth. Analg., 2006, 102,1348-1354. 
Palmeira C.M.; Moreno A.J.; Madeira V.M.C. Interactions of herbicides 2,4-D and 
dinoseb with liver mitochondrial bioenergetics. Toxicol. Appl. Pharmacol., 1994, 127, 
50-57.
Palmeira C.M.; Rolo A.P. Mitochondrial membrane potential (ΔΨ) fluctuations 
associated with the metabolic states of mitochondria. Methods Mol. Biol., 2012, 810, 
89-101. 
Palmeira C.M; Wallace K.B. Benzoquinone inhibits the voltage-dependent induction 
of the mitochondrial permeability transition caused by redox-cycling naphtoquinones. 
Toxicol. Appl. Pharmacol., 1997, 143, 338-347. 
Paradies G.; Petrosillo G.; Pistolese M.; Di Venosa N.; Federici A.; Ruggiero F.M. 
Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart-
Involvement of reactive oxygen species and cardiolipin. Circ. Res., 2004, 94, 53-59.
Paradies G.; Ruggier F.M.; Petrosillo G.; Quagliariello E. Peroxidative damage to 
cardiac mitochondria: cytochrome oxidase and cardiolipin alterations. FEBS Lett., 
1998, 424, 155-158.
Parekh A.B. Mitochondrial regulation of intracellular Ca2+ signaling: More than just 
simple Ca2+ buffers. News Physiol Sci, 2003, 18, 252–256. 
Park S.S; Zhao H.; Mueller R.A.; Xu Z. Bradykinin prevents reperfusion injury by 
targeting mitochondrial permeability transition pore through glycogen synthase 
kinase 3beta. J. Mol. Cell Cardiol., 2006, 40, 708-716.
Park S.W.; Chen S.W.C.; Kim M.; Brown K.M.; D.D’Agati V.; Lee H. T. Protection 
against Acute Kidney Injury via A1 Adenosine Receptor-Mediated Akt Activation 
Reduces Liver Injury after Liver Ischemia and Reperfusion in Mice. J. Pharmacol. 
Exp. Ther., 2010, JPET 333, 736-747.
Paschen S.A.; Neupert W. Protein import into mitochondria. IUBMB Life, 2001, 52, 
101-112.
187
Pastorino J.G.; Hoek J.B.; Shulga N. Activation of glycogen synthase kinase 3beta 
disrupts  the binding of hexokinase  II  to mitochondria by phosphorylating voltage-
dependent anion channel and potentiates chemotherapy-induced cytotoxicity. 
Cancer Res., 2005, 65, 10545-10554.
Penzo D.; Petronilli V.; Angelin A.; Cusan C.; Colonna R.; Scorrano L.; et al. 
Arachidonic acid released by phospholipase A(2) activation triggers Ca(2+)-
dependent apoptosis through the mitochondrial pathway. J. Biol. Chem., 2004, 
279(24), 25219–25. 
Peralta C.; Fernandez L.; Panes J.; Prats N.; Sans M.; Pique J.M.; Gelpi E.; Rosello-
Catafau J. Preconditioning protects against systemic disorders associated with 
hepatic ischemia-reperfusion through blockade of tumor necrosis factor-induced 
P-selectin up-regulation in the rat. Hepatology, 2001, 33, (1), 100-113.
Peralta C.; Hotter G.; Closa D.; Prats N.; Xaus C.; Gelpí E.; Roselló-Catafau 
J. The protective role of adenosine in inducing nitric oxide synthesis in rat liver 
ischemia preconditioning is mediated by activation of adenosine A2 receptors. 
Hepatology, 1999, 29, 126-132. 
Peralta C.; Prats N.; Xaus C.; Gelpi E.; Rosello-Catafau J. Protective effect of liver 
ischemic preconditioning on liver and lung injury induced by hepatic ischemia-
reperfusion in the rat. Hepatology, 1999, 30 (6), 1481-1489. 
Peralta C.; Rull R.; Rimola A.; Deulofeu R.; Rosello-Catafau J.; Gelpi E.; Rodes J. 
Endogenous nitric oxide and exogenous nitric oxide supplementation in hepatic 
ischemia-reperfusion injury in the rat. Transplantation,  2001,  71 (4), 529-536.
Pérez-Carreras M.; Del Hoyo P.; Martín M.A.; Rubio J.C.; Martín A.; Castellano 
G.; Colina F.; Arenas J.; Solis-Herruzo J.A. Defective hepatic mitochondrial 
respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology., 2003, 
38, 999-1007.
Petronilli V.; Costantini P.; Scorrano L.; Colonna R.; Passamonti S.; Bernardi 
P. The voltage sensor of the mitochondrial permeability transition pore is tuned 
by the oxidation-reduction state of vicinal thiols. Increase of the gating potential 
by oxidants and its reversal by reducing agents. J. Biol. Chem., 1994, 269(24), 
16638–42.
188
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY Petrosillo G.; Portincasa P.; Grattagliano I.; Casanova G.; Matera M.; Ruggiero 
F.M.; Ferri D.; Paradies G. Mitochondrial dysfunction in rat with nonalcoholic fatty 
liver. Involvemnt of complex I, reactive oxygen species and cardiolipin. Biochimica 
et Biophysica., 2007, Acta 1767, 1260-1267.
Petrosillo G.; Ruggiero F.M.; Di Venosa N.; Paradies G. Decreased complex 
III activity in mitochondria isolated from rat heart subjected to ischemia and 
reperfusion: role of reactive oxygen species and cardiolipin. FASEB J., 2003, 17, 
U395-U413.
Philipp S.; Yang X.M.; Cui L.; Davis A.M.; Downey J.M.; Cohen M.V. 
Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b 
receptor cascade, Cardiovasc. Res., 2006, 70 308-314.
Pillai V.B.; Sundaresan N.R.; Kim G.; Gupta M.; Rajamohan S.B.; Pillai J.B; 
Samant S.; et al. Exogenous NAD blocks cardiac hypertrophic response via 
activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem., 
2010, 285, 3133-3144.
Ploeg R.J.; D’Alessandro A.M.; Hoffmann R.M.; Eckhoff D.; Isaacs R.; Knechtle 
S.J.; Pirsch J.D.; Stegall M.D.; Kalayoglu M.; Belzer F.O. Impact of donor factors 
and preservation on function and survival after liver transplantation. Transplant 
Proc., 1993, 25, 3031-3033. 
Polster B.M.; Basanez G.; Etxebarria A.; Hardwick J.M.; Nicholls D.G. Calpain 
I induces cleavage and release of apoptosis-inducing factor from isolated 
mitochondria.  J. Biol. Chem., 2005, 280(8), 6447–54. 
Porte R.J.; Ploeg R.J.; Hansen B.; van Bockel J.H.; Thorogood J.; Persijn G.G.; 
Hermans J.; Terpstra O.T. Long-term graft survival after liver transplantation in the 
UW era: late effects of cold ischemia and primary dysfunction. Transpl. Int., 1998, 
11, Suppl. 1, S164-S167. 
Preiss D.; Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, 
diagnosis, pathogenesis and treatment considerations. Clinical Science, 2008, 
115, 141-150.
Putney J.W. Jr; Thomas A.P. Calcium signaling: Double duty for calcium at the 
mitochondrial uniporter. Curr. Biol., 2006, 16, R812–815. 
189
Qiu X.; Brown K.; Hirschey M.D.; Verdin E.; Chen D. Calorie restriction reduces 
oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab., 2010, 12, 662-
667. 
Rachek L.I.; Yuzefovych L.V.; Ledoux S.P.; Julie N.L.; Wilson G.L. Troglitazone, 
but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial 
dysfunction and cell death in human hepatocytes. Toxicol. Appl. Pharmacol., 
2009, 240, 348-354.
Rajdev S.; Reynolds I.J. Calcium green-5N, a novel fluorescent probe for 
monitoring high intracellular free Ca2+ concentrations associated with glutamate 
excitotoxicity in cultured rat brain neurons. Neuroscience Letters, 1993, 162, 149-
152.
Rasola A.; Sciacovellia M.; Chiara F.; Pantica B.; Brusilown W.S.; et al. Activation 
of mitochondrial ERK protects cancer cells from death through inhibition of the 
permeability transition. PNAS, 2010, 11, 727-731.
Reddy J.K.; Mannaerts G.P. Peroxisomal lipid metabolism. Annu. Rev. Nutr., 
1994, 114, 343-370.
Rehman H.; Connor H.D.; Ramshesh V.K.; Theruvath T.P.; Mason R.P.; Wright 
G. L.; Lemasters J.J.; Zhong Z. Ischemic Preconditioning Prevents Free Radical 
Production and Mitochondrial Depolarization in Small-for-Size Rat Liver Grafts. 
Transplantation, 2008, 85, 1322-1331.
Ren F.; Duan Z.; Cheng Q.; Shen X.; Gao F.; et al. Inhibition of glycogen synthase 
kinase 3 beta ameliorates liver ischemia reperfusion injury by way of an interleukin-
10-mediated immune regulatory mechanisms. Hepatology, 2011, 54 (2), 687-696.
Ricci C.; Pastukh V.; Leonard J.; Turrens J.; Wilson G.; Schaffer D.; Schaffer 
S.W. Mitochondrial DNA damage triggers mitochondrial-superoxide generation 
and apoptosis. Am. J. Physiol. Cell Physiol., 2008, 294, C413-C422.
Rizzuto R.; Brini M.; Murgia M.; et al. Microdomains with high Ca2+ close to ip3-
sensitive channels that are sensed by neighboring mitochondria. Science, 1993, 
262, 744–747. 
Rizzuto R.; Simpson A.W.; Brini M.; et al. Rapid changes of mitochondrial Ca2+ 
revealed by specifically targeted recombinant aequorin. Nature, 1992, 358, 325–
190
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY 327. 
Rolo A.P.; Teodoro J.S.; Peralta C.; Rosello-Catafau J.; Palmeira C.M. Prevention 
of I/R injury in fatty livers by ischemic preconditioning is associated with increased 
mitochondrial tolerance: the key role of ATPsynthase and mitochondrial 
permeability transition. Transpl Int., 2009, 22(11), 1081-1090. 
Rossi C.S.; Vasington F.D.; Carafoli E. The effect of ruthenium red on the uptake 
and release of Ca2+ by mitochondria. Biochem Biophys Res Commun, 1973, 50, 
846–852.
Rostovtseva T.K.; Tan W.; Colombini M. On the role of VDAC in apoptosis: fact 
and fiction. J. Bioenerg Biomembr, 2005, 37, 129–142. 
Ryu S.Y.; Beutner G.; Dirksen R.T.; et al. Mitochondrial ryanodine receptors and 
other mitochondrial Ca2+ permeable channels. FEBS Lett., 2010, 584, 1948–
1955.
Ryu S.Y.; Beutner G.; Kinnally K.; et al. Single channel characterization of the 
mitochondrial ryanodine receptor in heart mitoplasts. J Biol Chem, 2011.
Saito T.; Ishii S.; Abe T.; Tsuchiya T.; Kanno H.; Miyazawa M.; Suzuki M.; Gotoh 
M. Effect of preconditioning in the liver against alterations of gene transcription. 
Transplant. Proc., 2001, 33, 849.
Sastrasinh M.; Weinberg J.M.; Humes H.D. The effect of gentamicin on calcium 
uptake by renal mitochondria. Life Sci., 1982, 30, 2309–2315. 
Schanne F.A.X.; Kane A.B.; Young E.A.; Farber J.L.; Calcium dependence of 
toxic cell death, a final common pathway. Science, 1979, 206, 700-702.
Schellenberg G.D.; Anderson L.; Cragoe E.J. Jr; et al. Inhibition of brain 
mitochondrial Ca2+ transport by amiloride analogues. Cell Calcium, 1985, 6, 
431–447. 
Scherz-Shouval R.; Shvets E.; Fass E.; Shorer H.; Gil L.; Elazar Z. Reactive 
oxygen species are essential for autophagy and specifically regulate the activity 
of Atg4. EMBO J., 2007, 26, 1749-1760.
Schinzel A.; Takeuchi O.; Huang Z.; Fisher J.K.; Zhou Z.; Rubens J.; et al. 
191
Cyclophilin D is a component of mitochondrial permeability transition and 
mediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad. Sci., 
2005, 102, 12005-12010.
Schon E.A.; Dencher N.A. Heavy breathing: energy conversion by mitochondrial 
respiratory supercomplexes. Cell Metabolism, 2009, 9(1), 1–3. 
Schulz R.; Cohen M.V.; Behrends M.; Downey J.M.; Heusch G. Signal transduction 
of ischemic preconditioning. Cardiovasc. Res., 2001, 52, 181–198.
Schwarz E.R.; Whyte W.S.; Kloner R.A. Ischemic preconditioning. Curr.Opin. 
Cardiol., 1997, 12, 475-481.
Schwer B.; Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell 
Metab., 2008, 7, 104-112. 
Selzner  M.;  Rüdiger  H.;  Sindram  D.;  Maddan  J.;  Clavien  P. A.  Mechanisms 
of ischemic injury are different in the steatotic and normal rat liver. Hepatology, 
2000, 32, 1280-1288.
Selzner M.; Clavien P.A. Fatty liver in liver transplantation and surgery. Semin. 
Liver. Sis., 2001, 21, 105-113.
Selzner N.; Rudiger H.; Graf R.; Clavien P.A. Protective strategies against 
ischemic injury of the liver. Gastroenterology, 2003, 125 (3), 917-936.
Selzner N.; Selzner M.; Jochum W.; Amann-Vesti B.; Graf R.; et al. Mouse livers 
with macrosteatosis are more susceptible to normothermic ischemic injury than 
those with microsteatosis. J. Hepatol., 2006, 44, 694.
Serafín A.; Fernández-Zabalegui L.; Prats N.; Wu Z.Y.; Roselló-Catafau J.; 
Peralta C. Ischemic preconditioning: tolerance to hepatic ischemia-reperfusion 
injury. Histol Histopathol, 2004, 19(1), 281-289.
Shimizu S.; Eguchi Y.; Kamiike W.; Funahashi Y.; Mignon A.; Lacronique V.; 
Matsuda H.; Tsujimoto Y. Bcl-2 prevents apoptotic mitochondrial dysfunction by 
regulating proton flux. Proceedings of the National Academy of Sciences USA, 
1998, 95, 1455-1459.
Shulga N.; Pastorino J.G. Acyl coenzyme A-binding protein augments bid-
192
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY induced  mitochondrial damage and cell death by activating mu-calpain. J. Biol. 
Chem.,  2006, 281(41), 30824–33. 
Shulga N.; Pastorino J.G. Ethanol sensitizes mitochondria to the permeability 
transition by inhibiting deacetylation of cyclophilin-D mediated by sirtuin-3. J. Cell 
Sci., 2010, 123, 4117-4127. 
Shulga N.; Wilson-Smith R.; Pastorino J.G. Sirtuin-3 deacetylation of cyclophilin 
D induces dissociation of hexokinase II from the mitochondria. J. Cell. Sci., 2010, 
123(Pt 6), 894-902. 
Sinay L.; Kurthy M.; Horvath S.; Arato E.; Shafei M.; Lantos J.; Ferencz S.; Bator 
A.; Balatonyi B.; Verzar Z.; Suto B.; Kollar L.; Weber G.; Roth E.; Jancso G. 
Ischaemic postconditioning reduces peroxide formation, cytokine expression and 
leukocyte activation in reperfusion injury after abdominal aortic surgery  in rat 
model. Clin. Hemorheol. Microcirc., 2008, 40,133-142.
Skulachev V. P. Role of uncoupled and non-coupled oxidations in maintenance 
of safely low levels of oxygen and its one-electron reductants. Q. Rev. Biophys., 
1996, 29, 169–202. 
Skulachev V. P. Uncoupling: new approaches to an old problem of bioenergetics. 
Biochim. Biophys. Acta, 1998, 1363, 100–124.
Skulachev V.P. Uncoupling: new approaches to an old problem of bioenergetics. 
Biochim. Biophys. Acta, 1998, 1363, 100-124.
Smeitink J.; Van Den Heuvel L.; Di Mauro S. The genetics and pathology of 
oxidative phosphorylation. Nature Rev. Genet., 2001, 2(5), 342-352. 
Someya S.; Yu W.; Hallows W.C.; Xu J.; Vann J.; Leeuwenburgh C.; Tanokura 
M.; Denu J.M.; Prolla T.A. SIRT3 mediates reduction of oxidative damage and 
prevention of age-related hearing loss under caloric restriction. Cell, 2010, 143, 
802-812. 
Sparagna G.C.; Gunter K.K.; Sheu S.S.; et al. Mitochondrial calcium uptake from 
physiological-type pulses of calcium. A description of the rapid uptake mode. J. 
Biol. Chem., 1995, 270, 27510–27515. 
Stankiewicz A.R.; Lachapelle G.; Foo C.P.; Radicioni S.M.; Mosser D.D. HSP70 
193
inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax 
translocation. J. Biol. Chem., 2005, 280, 38729-38739.
Stocchi V.; Cucchiarini L.; Magnani M.; Chiarantini L.; Palma P.; Crescentini 
G. Simultaneous extraction and reverse-phase highperformance liquid 
chromatographic determination of adenine and pyridine nucleotides in human red 
blood cells. Analytical Biochemistry, 1985, 146, 118-124.
Stryer, L. Biochemistry (3rd Edition). W.H. Freeman Company, 1988, 529-556. 
Suleiman M.S.; Halestrap A.P.; Griffiths E.J. Mitochondria: a target for myocardial 
protection. Pharmacol. Ther., 2001, 89, 29-46.
Sun C.K.; Zhang X.Y.; Zimmermann A.; Davis G.; Wheatley A.M. Effect of 
ischemia-reperfusion injury on the microcirculation of the steatotic liver of the 
Zucker rat. Transplantation, 2001, 27, 72(10), 1625-1631.
Tafani M.; Schneider T.G.; Pastorino J.G.; Farber J.L. Cytochrome c-dependent 
activation of caspase-3 by tumor necrosis factor requires induction of the 
mitochondrial permeability transition. Am. J. Pathol., 2000, 156, 2111-2121.
Takano H.; Manchikalapudi S.; Tang X.L.; Qiu Y.; Rizvi A.; Jadoon A.K.; Zhang 
Q.; Bolli R. Nitric oxide synthase is the mediator of late preconditioning against 
myocardial infarction in conscious rabbits. Circulation, 1998, 98, 441–449.
Takeshige K.; Minakami S. NADH and NADPH dependent formation of superoxide 
anions by bovine heart submitochondrial particles and NADH-ubiquinone 
reductase preparation. Biochem. J., 1979, 180, 129-135.
Teodoro J.; Rolo A.P.; Oliveira P.J.; Palmeira C.M. Decreased ANT content in 
Zucker fatty rats: relevance for altered hepatic mitochondrial bioenergetics in 
steatosis. FEBS Lett., 2006, 580, 2153-2157.
Teodoro J.S.; Rolo A.P.; Duarte F.V.; Simões A.M.; Palmeira C.M. Differential 
alterations in mitochondrial function induced by a choline-deficient diet: 
understanding fatty liver disease progression. Mitochondrion., 2008, 8, 367-376.
Teoh N.; Leclercq I.; Pena A.D.; Farell G. Low-dose TNF-alpha protects against 
hepatic ischemia-reperfusion injury in mice: implications for preconditioning. 
Hepatology, 2003, 37 (1), 118-128.
194
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY Teoh N.C.; Farrel G.C. Hepatic ischemia reperfusion injury: pathogenic 
mechanisms and basis for hepatoprotection. Journal of Gastroenterology and 
Hepatology, 2003, 18 (8), 891-902.
Teramoto K.; Bowers  J.; Kruskal  J.; Clouse M. Hepatic microcirculatory 
changes after  reperfusion  in  fatty and normal  liver  transplantation  in  the  rat. 
Transplantation, 1993, 56, 1076-1082.
Terashima Y.; Sato T.; Yano T.; Maas O.; Itoh T.; Miki T.; Tanno M.; Kuno A.; 
Shimamoto K.; Miura T. Roles of phospho-GSK-3β in myocardial protection 
afforded by activation of the mitochondrial K ATP channel. J. Mol. Cell Cardiol., 
2010, 49(5), 762-770.
Tong H.; Imahashi K.; Steenbergen C.; Murphy E. Phosphorylation of glycogen 
synthase kinase-3b beta during preconditionoing through a phosphatidylinositol-
3-kinase dependent pathway is cardioprotective. Circ. Res., 2002, 90, 377-379. 
Toth A.; Jeffers J.R.; Nickson P.; Min J.Y.; Morgan J.P.; Zambetti G.P.; Erhardt P. 
Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac 
function during ischemia-reperfusion. Am. J. Physiol., 2006, 291, H52–H60.
Trenker M.; Malli R.; Fertschai I.; et al. Uncoupling proteins 2 and 3 are fundamental 
for mitochondrial Ca2+ uniport. Nat. Cell Biol., 2007, 9, 445–452.
Tsuchiya D.; Hong S.; Matsumori Y. Overexpression of rat heat shock protein 
70 is associated with reduction of early mitochondrial cytochrome c release and 
subsequent DNA fragmentation after permanent focal ischemia. J. Cereb. Blood 
Flow Metab., 2003, 23, 718-727.
Tsung A.; Sahai R.; Tanaka H.; Nakao A.; Fink M.P.; Lotze M.T.; Yang H.; Li J.; 
Tracey K.J.; Geller D.A.; Billiar T.R. The nuclear factor HMGB1 mediates hepatic 
injury after murine liver ischemia–reperfusion. J. Exp. Med., 2005, 201, 1135-1143. 
Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol., 2003, 
552, 335-344.
Turrens J.F.; Alexandre A.; Lehninger A.L. Ubisemiquinone is the electron donor 
for superoxide formation by complex III of heart mitochondria. Arch. Biochem. 
Biophys., 1985, 237, 408-414.
195
Varela A.T.; Gomes A.P.; Simões A.M.; Teodoro J.S.; Duarte F.V.; Rolo A.P.; 
Palmeira C.M. Indirubin-30-oxime impairs mitochondrial oxidative phosphorylation 
and prevents mitochondrial permeability transition induction. Toxicology and 
Applied Pharmacology, 2008, 233, 179-185.
Varela A.T.; Rolo A.P.; Palmeira C.M. Fatty liver and ischemia/reperfusion: are 
there drugs able to mitigate injury? Curr. Med. Chem., 2011, 18, 4987-5002.
Varela A.T.; Simões A.M.; Teodoro J.S.; Duarte F.V.; Gomes A.P.; Palmeira C.M.; 
Rolo A.P. Indirubin-3’-oxime prevents hepatic I/R damage by inhibiting GSK-3beta 
and mitochondrial permeability transition. Mitochondrion., 2010, 10(5), 456-463.
Vendemiale G.; Grattagliano I.; Caraceni P.; Caraccio G.; Domenicali M.; Dall’Agata 
M.; et al. Mitochondrial oxidative injury and energy metabolism alteration in rat 
fatty liver: Effect of the nutritional status. Hepatology, 2001, 33, 808-815.
Waldmeier P.C.; Zimmermann K.; Qian T.; TintelnotBlomley M.; Lemasters J.J. 
Cyclophilin D as a drug target. Curr. Med. Chem., 2003, 10, 1485-1506.
Wallace D.C. Mitochondrial DNA mutations in diseases of energy metabolism. J. 
Bioenerg. Biomemb., 1994, 26, 241-250.
Wang J.Y.; Shen J.; Gao Q.; Ye Z.G.; Yang S.Y.; Liang H.W.; Bruce  I.C.;  Luo 
B.Y.;  Xia Q. Ischemic postconditioning protects against global cerebral ischemia/
reperfusion-induced injury in rats. Stroke, 2008, 39, 983-990.
Wang L.; Du F.; Wang X. TNF-alpha induces two distinct caspase-8 activation 
pathways. Cell, 2008, 16, 133(4), 693-703.
Wanner G.A.; Ertel W.; Muller P.; et al. Liver ischemia and reperfusion induces 
a systemic inflammatory response through Kupffer cell activation. Shock., 1996, 
5(1), 34-40.
Woodfield K.; Ruck A.; Brdiczka D.; Halestrap A.P. Direct demonstration of a 
specific interaction between cyclophilin-D and the adenine nucleotide translocase 
confirms their role in the mitochondrial permeability transition. Biochem. J., 1998, 
336, 287–290.
Woodfield K.Y.; Price N.T.; Halestrap A.P. cDNA cloning of rat mitochondrial 
cyclophilin. Biochim. Biophys. Acta, 1997, 1351, 27-30.
196
5
Re
gu
lat
ion
 o
f m
ito
ch
on
dr
ial
 fu
nc
tio
n 
in 
isc
he
m
ia/
re
pe
rfu
sio
n:
 lo
ok
ing
 fo
r t
he
ra
pe
ut
ic 
str
at
eg
ies
 in
 fa
tty
 liv
er
s
BI
BL
IO
GR
AP
HY
Xi J.; Wang H.; Mueller R.A.; Norfleet E.A.; Xu Z. Mechanism for resveratrol-
induced cardioprotection against reperfusion injury involves glycogen synthase 
kinase 3beta and mitochondrial permeability transition pore. Eur. J. Pharmacol., 
2009, 604(1-3), 111-116.
Xing B.; Chen H.; Zhang M.; Zhao D.; Jiang R.; Liu X.; Zhang S. Ischemic 
postconditioning  inhibits apoptosis after focal cerebral ischemia/reperfusion 
injury in the rat. Stroke, 2008, 39, 2362-2369. 
Yang Z.; Sun W.; Hu K. Molecular mechanism underlying adenosine receptor-
mediated mitochondrial targeting of protein kinase C. Biochim. Biophys. Acta, 
2012, 1823(4), 950-958.
Ye S.Y.; Wu J.; Zhang J.; Zheng S.S. Locally synthesized HSP27 in hepatocytes: 
Is it possibly a novel strategy against human liver ischemia/reperfusion injury? 
Med. Hypotheses, 2011, 76(2), 296-298.
Yin D.P.; Sankary H.N.; Chong A.S.; Ma L.L.; Shen J.; Foster P.; Williams J.W. 
Protective effect of ischemic preconditioning on liver preservation-reperfusion 
injury in rats. Transplantation, 1998, 66, 152-157. 
Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: 
regulation and biological consequences. Antioxid. Red. Signal, 2008, 337, 179-
206.
Ying W.; Wei G.; Wang D.; Wang Q.; Tang X.; Shi J.; Zhang P.; Lu H. Intranasal 
administration with NAD+ profoundly decreases brain injury in a rat model of 
transient focal ischemia. Front. Biosci., 2007, 12, 2728-2234. 
Yoshidome, H.; Kato, A.; Edwards, M.J.; Lentsch, A.B. Interleukin-10 suppresses 
hepatic ischemia/reperfusion injury in mice: implications of a central role for 
nuclear factor kappa B. Hepatology, 1999, 30 (1), 203-208.
Yoshizumi T.; Yanaga K.; Soejima Y.; Maeda T.; Uchiyama H.; Sugimachi K. 
Amelioration of liver injury by ischaemic preconditioning. Br. J. Surg., 1998, 85, 
1636-1640. 
Zeng Z.; Huang H.F.; Chen M.Q.; Song F.; Zhang Y.J. Postconditioning Prevents 
Ischemia/Reperfusion Injury in Rat Liver Transplantation. Hepatogastroenterology, 
2010, 57 (101), 875-881
197
